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The following thesis contains information from many
patients collected over a period of years. It represents
the combined efforts of a dedicated team of doctors,
nurses and other colleagues who have contributed to the
care of the patients and without whom this thesis would
not have been possible.
I was appointed as Senior Registrar in Haematology, in
May 1980, and I have been closely involved with the
autologous bone marrow transplant programme at University
College Hospital, London, since then. I was a member of
the original group who following lengthy discussions
proposed the early treatment protocols.
I have been a member of the team looking after the
day to day care of the autograft patients, particularly
the early patients. I have reviewed the notes of all
patients whom I was not personally involved in the care
of. I have acted as transplant co-ordinator throughout
this period.
I have been solely responsible for collecting and
tabulating the data. Where patients were treated outside
of University College Hospital, I have visited to collect
data or discuss the patients with their supervising
clinician.
It is because of my familiarity with the patients and
their data, that I have been able to make various
observations, identifying for example, the differences in
infective morbidity between patients with AML and ALL,
and the likely importance of the time to achieve CR1 as a
prognostic indicator in patients with AML treated during
first remission and finally to suggest future treatment
protocols based on the present results.
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ABSTRACT
The aim of this thesis is to assess the feasibility of
using autologous bone marrow transplantation (ABMT), to
allow escalation of the dose of cytotoxic agents which
may successfully be employed to increase the response
rate and prolong the disease free survival in patients
with acute leukaemia or relapsed lymphoma.
A total of 78 patients have been treated with a variety
of intensive chemoradiotherapy regimens followed by ABMT.
There have been 12 (15%) procedure related deaths.
Acute Myeloid Leukaemia (AML) - Patients treated in first
remission: 10 (62.5%) of 16 patients remain in 1st
remission with a median follow-up of 24 months (range
1 6-61) post ABMT. The six relapses that occurred were
between 1-15 months post ABMT.
Acute Lymphoblastic Leukaemia (ALL) - Patients treated in
first remission: Only one of eight patients treated
(12.5%) remains in remission 34 months post ABMT. Three
patients died during the procedure. Four patients
relapsed; 2, 11, 32 and 33 months post ABMT.
AML & ALL - Patients treated at a later stage: 18
patients were treated either at relapse or during a later
remission, only 2 patients, both with ALL, remain alive
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in remission, 22 and 48 months post ABMT. Two patients
died procedural deaths. Fourteen patients relapsed and
died, 2-13 months post ABMT.
Non-Hodgkin's Lymphoma: 21 patients have been treated, 8
achieved a complete remission (CR), 3 a partial remission
(PR), 6 had no response and four were not evaluable
because of early deaths. Only 3 patients remain in
remission at 7, 6, and 6 months post ABMT without further
treatment. Three further patients have received
additional radiotherapy since their ABMT and one
chemotherapy as well, they are now in remission 42, 32
and 29 months post ABMT.
Hodgkin's Disease: 15 patients were treated, 11 achieved
a CR, 3 a PR but only 4 remain in CCR 29, 17, 8, and 7
months post ABMT. One patient died an early death and was
not evaluable.
CONCLUSIONS:
(1) The use of intensive chemoradiotherapy followed by
ABMT is feasible in these groups of patients, even though
many have received extensive prior therapy and some have
been in poor clinical condition at the time of ABMT.
(2) The response rate has been high, even where disease
was thought to be resistant to conventional doses of
cytotoxic agents. Some -of these responses have been well
maintained.
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(3) Intensive chemoradiotherapy with ABMT should now be
considered earlier in the course of most of these
diseases when treatment related complications should be
less.
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CHAPTER 1
INTRODUCTION
The aim of this thesis is: 1) to assess the feasibility
of using high dose chemoradiotherapy regimes followed by
autologous bone marrow transplantation (ABMT) to amelior¬
ate the severe marrow toxicity thus produced, in patients
with leukaemia and lymphoma, 2) to evaluate the results
in terms of response rate and long-term disease free
survival (DFS) in these patients and finally 3) to
consider the results in the context of other currently
employed regimens with a view to suggesting future
protocols.
WHY USE BONE MARROW TRANSPLANTATION ?
The haematological malignancies were once a group of
incurable diseases. Over recent years treatment regimens
have been increasingly successful at producing complete
remissions (CR), extended disease free survival (DFS) and
even cure in some patients with these diseases.
The early use of cytotoxic drugs was with single
agents and as the diseases were regarded as incurable,
most were used only in an attempt at palliation. It was
1 0
however, soon noted that a better response was often
produced by a higher dose of the agent employed (eg
24
nitrogen mustard, Brindley et al, 1964) . This was in
keeping with the evidence that there was a definite
dose-response curve in the use of radiotherapy to treat
9 9
localized Hodgkin's Disease (HD) (Kaplan HS, 1962)
The awareness of a relationship between dose and
response resulted in escalation of the doses of cytotoxic
agents employed but this also led to increased toxicity.
Drug combinations were a way of attempting additive
antitumour effect whilst minimising the toxicity to the
patient. The improved results in patients with HD as
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reported by DeVita et al, 1965 , with MOPP, demonstrated
the effectiveness of this approach. In sensitive tumours
there is a steep dose-response curve for radiotherapy,
however, the amount of total body irradiation (TBI) which
can be tolerated by the patient is limited by
myelosuppression. If myelosuppression can be circum¬
vented, then the amount of TBI is limited by toxicity to
other organs.
In an attempt to increase the tumoricidal effect,
supra-lethal doses of TBI have been given successfully to
patients, by using syngeneic, allogeneic or rarely
autologous bone marrow transplantation to rescue them
from the otherwise fatal myelosuppression.
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The rationale for this form of dose escalation
supposes that there is a steep dose-response curve for
the therapeutic modality employed. Animal experiments
have demonstrated that such dose-response curves do exist
(Bruce et al, 1 966 ; Frei & Canellos, 1 980 )^'^. In
humans the best demonstration of a dose-response curve is
the eradication of leukaemia by TBI and cyclophosphamide
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(Thomas et al, 1979) . The major dose limiting factor
for an agent or combination of agents, is the toxicity
produced. Where the major toxicity is myelosuppression,
then the use of allogeneic, syngeneic or autologous bone
marrow transplantation (ABMT) will allow dose escalation
and thereby an improved response rate.
There will be few patients who have an identical twin,
therefore syngeneic transplantation is not an available
alternative for most patients. If the use of allogeneic
and autologous marrow was associated with the same
toxicities then allografting might be considered
preferable to autografting as there would be no risk of
contamination of the marrow with clonogenic tumour cells.
WHAT LIMITS ALLOGENEIC BONE MARROW TRANSPLANTATION ?
Allogeneic transplantation was first employed in




In 1963 Mathe et al , were the first to report long-
term survival and evidence of engraftment in a 26 year
old patient who was given an allogeneic graft after
conditioning with methyl-nitro-imidazolyl-mercaptopurine
and TBI for the treatment of resistant relapsed
leukaemia. He suffered acute graft-versus-host disease
(GVHD) and later chronic GVHD and died leukaemia free at
20 months of varicella encephalitis.
Since that time allogeneic transplantation techniques
have continued to develop and at the present time
allogeneic transplantation is the recommended treatment
for young patients with acute leukaemia who have relapsed
and is possibly also the treatment of choice for young
patients with acute myeloid leukaemia (AML) in first CR
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(Gale & Champlin 1986) . Patients must usually be under
40 years of age and have an HLA (Human Leucocyte Antigen)
identical sibling for the marrow donor. Younger patients
do best with a 75% long-term survival for those patients
less than 20 years of age and only 25% for those over 30
years old. This is due to an increase in deaths from
pneumonitis and GVHD in the older age group and not to
1 6 ft
relapse of their disease (Thomas ED, 1983)
Current research is directed to trying to eliminate
these treatment related complications. A variety of
radiation schedules have been used to try and reduce the
O O
radiation induced pneumonitis (Buckner at al, 1982) .
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GVHD is often found in association with pneumonitis. Its
onset in a particular patient is unpredictable but acute
GVHD is more common in the older patient.
During the early years of experimental marrow trans¬
plantation, the ultimate fate of animals surviving
received little attention. The first report of secondary
1 2
mortality was made by Barnes & Loutit, 1955 . The
authors reported that lethally irradiated CBA mice that
received syngeneic spleen cells were all afforded
long-lasting protection but that nine out of 16 lethally
irradiated CBA mice that received spleen cells of strain
A mice although surviving for 30 days, died before 100
days after transplantation. These observations were soon
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confirmed by many other workers. Cohen et al, 1957 ,
drew attention to the severe diarrhoea, weight loss and
skin lesions that occur in animals during the period of
delayed mortality. Over the next few years observations
of a number of laboratories suggested that 'secondary
disease' was in fact graft-versus-host disease (GVHD)(van
178
Bekkum & de Vries, 1967) . This concept was further
strengthened by the observations of Billingham & Brent,
1 7
1957 , who observed a runting syndrome in newborn mice
that had been transplanted with allogeneic spleen cells.
The main observations in 'runt disease' were retarded
growth and development, diarrhoea, varying degrees of
hypoplasia of the lymphatic system, skin lesions and
focal necrosis of the liver cells. Every one of these
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observations was also made in animals given allogeneic
marrow transplants following lethal TBI. Perhaps the most
convincing pieces of evidence that supported a graft-
versus-host mechanism in radiation chimeras was the
observation that on increasing the number of lymphoid
cells injected together with the marrow, the severity of
the secondary disease could be increased and the delay
between transplantation and appearance of signs of the
disease could be reduced (Santos & Cole, 1958; van Bekkum
153 178
& de Vries, 1967) ' . It soon became apparent to most
workers that the cell initiating GVHD was a lymphocyte
O O
(Grebe & Streilein, 1976)
Billingham (1966-67)^ stated that the essential
requirements for GVHD were: "(1) The graft must contain
immunologically competent cells; (2) The host must
possess important transplantation isoantigens that are
lacking in the graft donor, so that the host appears
foreign to it, and is therefore, capable of stimulating
it antigenically; (3) The host itself must be incapable
of mounting an effective immunological reaction against
the graft, at least for sufficient time for the latter to
manifest its immunological capabilities i.e., must have
security of tenure." The three important target organs in
man are skin, gut and liver (van Bekkum & de Vries,
1967)118.
The Seattle group demonstrated that the prophylactic
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use of methotrexate could markedly reduce GVHD in
lethally irradiated dogs given allogeneic but major
histocompatibility complex (MHC) - matched bone marrow
(Thomas et al, 1 963; Storb et al, 1 970)^^'^^. They
adopted the use of methotrexate for prevention of GVHD in
clinical studies in man and, except for the Baltimore
group who demonstrated a similar effect for the use of
cyclophosphamide in rodents and primates (Santos & Owens,
1966; Owens & Santos, 1971)^^^methotrexate was the
standard agent initially adopted for the prevention of
GVHD in all centres.
It was hoped that the introduction of cyclosporin A, a
cyclic polypeptide with immunosuppressive properties,
would prevent or reduce acute GVHD. Animal studies
suggest that cyclosporin A inhibits the development of
cell-mediated reactions by blocking resting lymphocytes.
It also inhibits production of lymphokines. It would
appear that cyclosporin A will reduce the severity of
acute GVHD but not its incidence or its influence on
overall survival (Powles et al, 1980; Deeg et al,
1 32 47
1985) ' . Seattle have now reported a study comparing
the use of a combination of both methotrexate and
cyclosporin with cyclosporin alone to prevent acute GVHD.
The combination appears to be better than cyclosporin
164
alone and may improve survival (Storb et al, 1986)
Current attempts to reduce acute GVHD by eliminating T
1 6
cells from the donor marrow and thereby extending the use
of allogeneic marrow, are undergoing clinical trials
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(Prentice et al, 1984) . Whilst this technique appears
useful at reducing the incidence of acute GVHD it does
not eliminate it completely and whether it improves
overall survival remains to be seen.
The conditioning regimen used for allogeneic bone
marrow transplantation in acute leukaemia has two
functions: firstly to serve as immunosuppressive therapy
to prevent rejection of the allogeneic marrow and
secondly to eradicate host disease. The conditioning
regimen most commonly used is TBI given as a single dose
or in fractions to a total dose of 9-12 Grays together
with cyclophosphamide 60 mg/kg on two consecutive days,
as pioneered by the Seattle transplant team (Thomas et
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al, 1975) . Rejecton of a marrow graft following this
regimen in patients allografted for acute leukaemia is
rare.
Relapse still remains a problem. In patients with AML
treated by allograftiing in first CR the incidence of
relapse is reported to be between 10 and 25% (O'Reilly
1 24 46
RJ, 1983; Deeg et al, 1984) ' . The majority of
relapses occurring in the first two years post graft,
although relapse has been reported even six years later
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(Deeg et al, 1984) . Fewer patients with acute
lymphoblastic leukaemia (ALL) have been allografted in
1 7
first CR but relapse appears more frequent than in
patients with AML. In patients with AML and ALL
allografted after first CR the relapse rate is higher
(Appelbaum et al, 1983; Deeg et al, 1 984)®'^ with five
year survival of less than 27% in ALL with leukaemic
relapse being the commonest cause of death (Thomas et al,
1 983 )1 75.
In the first 100 patients transplanted in Seattle for
acute leukaemia in relapse, a time at which the leukaemic
burden would be high and the disease is more likely to be
resistant than early in first CR, the majority of
patients surviving the procedure relapsed (Thomas et al,
1 72
1977) . Twelve patients not only achieved a CR but
remain in remission many years later (Thomas ED,
168
1983) . This approach is therefore capable of
eradicating disease in a small proportion of patients
with relapse but there is no way of knowing in advance




Thomas et al, 1975 , reported the use of syngeneic
or monozygotic twin marrow to rescue leukaemic patients
with advanced disease following lethal doses of TBI.
There is no risk of GVHD following syngeneic grafts and
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therefore no immunosuppressive therapy is required to
prevent rejection of the graft. This study demonstrated a
definite antileukaemic effect of the TBI, however, all
patients relapsed again within 12 weeks, demonstrating
the need for a more powerful antileukaemic conditioning
regimen.
Syngeneic grafts treated with the same conditioning
regimen as allografts have no GVHD and immediate survival
is greater, but leukaemic relapse is also greater (Fefer
6 2
et al, 1981) . There is some evidence that a graft-
versus-leukaemia (GVL) effect may operate when GVHD is
present (Weiden et al, 1 979, 1 981 ,182,183^ However^
other observations do not support the existence of an
allogeneic GVL effect. There is no difference in the
relapse rate after allogeneic BMT for chronic granulo¬
cytic leukaemia (CGL) in chronic phase, compared to that
after syngeneic BMT (Fefer et al, 1985; Thomas et al,
64 176
1985) ' neither is there any correlation between GVHD
and post transplant relapse rate for patients with AML
transplanted with allogeneic marrow in CR1 or for chronic
61
phase CGL (Fefer 1986) . Furthermore, attempts to
manipulate GVHD to increase its incidence and severity
has not improved leukaemic relapse rate (Sullivan et al,
166
1984) . The strongest circumstantial evidence cor¬
relating GVHD and a GVL effect is restricted to children
transplanted with allogeneic marrow for ALL in relapse
(Sanders et al, 1 985)^®.
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AUTOLOGOUS BMT
Autologous marrow has been used since the 1950's to
allow dose escalation above the accepted maximum dose of
the agent employed (whether chemotherapy or irradiation)
in an effort to obtain better responses in solid tumours.
The intention was not to rescue the patient from marrow
ablation but rather to speed haematological recovery.
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Clifford et al, 1961 , gave autologous marrow in¬
fusions to 3 patients following high doses of nitrogen
mustard used in the treatment of head and neck tumours. 6
patients received the highest dose, 3 of these were
followed by an infusion of autologous marrow. The 3
patients who received autologous marrow survived, whilst
the remaining 3 died before regeneration. The authors
concluded patients could survive high dose nitrogen
mustard therapy if accompanied by an infusion of
autologous marrow.
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Pegg et al, 1962 , used autologous marrow infusions
after varying amounts of wide-field or total body
irradiation and also differing chemotherapeutic agents,
in 23 patients with a variety of advanced malignant
diseases. They concluded that the rapidity of
haematological recovery was increased after some of the
agents but not others.
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Although these and other studies demonstrated the
feasibility of using autologous marrow in humans, the
neoplastic disorders treated were generally only
palliated and overall survival was not improved.
It is only since allogeneic transplantation following
TBI and cyclophosphamide has been demonstrated to produce
cures in some patients with end-stage leukaemia (Thomas
1 72
et al, 1977) that there has been revived interest in
the use of autologous transplantation in the haemato-
logical malignancies.
Autografts are similar to syngeneic grafts in that
they do not cause GVHD, autografting can therefore, be
safely used in older patients and an HLA identical
sibling is not required. It is therefore, a technique
which is likely to be applicable to a much wider group of
patients. It is unlikely, as there is no GVHD, that there
will be a GVL effect. Fefer, has suggested however, that
ABMT may be preferable to syngeneic grafting as the
autologous marrow having been exposed to the tumour,
might have become primed to putative tumour associated
antigens, and might therefore, exert an anti-tumour
61
effect when reinfused (Fefer 1986) . Many murine models
have been established in which disseminated leukaemia or
lymphoma can be cured by a combination of non-curative
chemotherapy and infusion of syngeneic T cells immune to
the tumour (Fefer et al, 1982)®^.
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It would seem reasonable to assume that as with
syngeneic grafts there may be a need for a greater anti-
leukaemic effect from the conditioning regimen pre-ABMT.
Autologous or syngeneic bone marrow grafting has the
advantage that immune mediated graft rejection does not
occur. The autologous bone marrow must however, be
assumed to be contaminated with residual leukaemia in
view of the relapsing nature of the disease.
With the successful use of intensive chemoradiotherapy
followed by allografting in patients with acute leukaemia
consideration of intensifying the treatment of patients
with poor prognosis lymphomas by allografting has also
received attention. The difficulty is to decide which
patients are likely to benefit from transplantation at an
early stage of their disease. Poor prognostic indicators
are becoming increasingly recognised but most of the
patients with non-Hodgkin1s lymphoma (NHL) will be more
than 40 years of age. The patients with HD who are going
to do badly may not be recognised until they have had
many prior treatment regimens when their disease is
unlikely to be cured by any currently employed
conditioning regimens.
There would appear to be two main problems to consider
when deciding on a suitable conditioning regimen for ABMT
in the haematological malignancies: the eradication of
22
disease in the patient as in the allograft situation and
the eradication of potential residual disease in the
autologous marrow. This is discussed in the following





All adult patients with acute leukaemia or advanced
relapsed lymphoma were considered eligible for intensive
chemoradiotherapy regimens with ABMT rescue. Other
significant medical conditions were regarded as a
relative contraindication and patients were rejected only
if it was thought likely it would affect the safe outcome
of the procedure. The criteria for each condition are
discussed later.
BONE MARROW HARVESTING
Bone marrow was harvested if judged clear of disease
by morphological examination under the light microscope,
of aspirates in all patients, and trephine biopsies as
well in lymphoma patients.
Bone marrow was harvested by aspiration from the
posterior and anterior iliac crests and where necessary
from the sternum during a general anaesthetic. Klima bone
marrow needles were used. Initially 2-4 ml aliquots only
were aspirated from each site. However, in a local study
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where one operator aspirated 2-4 ml aliquots and the
other operator 5-12 ml aliquots, we were unable to
demonstrate a significant difference in the nucleated
cell count thus obtained and we now aspirate up to 12 mis
from each site. The needles and syringes are flushed out
before each aspiration with preservative free heparin.
Each aliquot is then transferred by injecting directly,
without filtering, into a two-litre transfer pack
containing 200 mis of tissue culture medium (TC 199 Gibco
Europe) with 8000 units of preservative free heparin.
g
The aim was to harvest a minimum of 2x10 cells/kg
body weight. It was found, however, that any gain in
nucleated cells obtained in a volume exceeding 1,000 mis
was lost during later processing and that the optimum
volume of marrow to be harvested was around 800 mis. If
g
<1.0x10 cells/kg is now obtained after final processing
a second harvest is planned before proceeding to ABMT.
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MARROW HARVEST
CONCENTRATION (Removal of RBC's)
MIX WITH CRYOPROTECTANT (DMSO)
FREEZING
STORAGE IN LIQUID NITROGEN
THAWING (37°C water bath)
REINFUSION
Figure 1. Schematic representation of 'ex vivo'
autologous marrow processing.
MARROW PROCESSING
To concentrate the marrow we use a Hemonetics model 30
cell separator. This is set up using a paediatric
pheresis pack as for a conventional leucopheresis. As the
marrow is already anticoagulated with heparin the
anticoagulant line on the harness is clipped off. The
draw needle adaptor is also clipped off and the marrow
enters the system through the saline reinfusion female
connector via a conventional drip set. The filter in this
26
drip set prevents small clots frequently present in the
harvested marrow from entering the system. The bowl is
then filled at a rate of approximately 100 ml/min. When
the buffy coat reaches the top of the bowl the filling
rate is reduced to 20 ml/min and the buffy coat
redirected through the white cell collection port into a
600 ml transfer pack. Collection is usually continued
for two minutes. The aim of processing is to end with a
predetermined volume of buffy coat (250 ml) in the
transfer bag for freezing. Once all the marrow has been
processed the drip set is transferred to the reinfusion
bag port allowing the red cell and plasma discard to be
reprocessed, extracting the last vestiges of buffy coat
until the desired volume is obtained. For efficient
processing of marrow using the intermittent flow cell
separator the total volume of red cell discard must fill
the bowl (i.e. 100 ml) as this is used to displace the
buffy coat. This method of marrow processing removes most
of the red cells prior to freezing and thawing.
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MARROW FREEZING
The volume of the processed marrow is determined by
weight and an equal volume of precooled 20% (vol/vol)
dimethyl sulphoxide (DMSO Analar grade) in TC 199 is
added via a transfer set and three-way tap using a 50 ml
disposable syringe. This addition is performed in a ten
minute period with good mixing to minimise osmotic shock.
This procedure is performed on ice in a laminar flow
sterile hood. Equal volumes (100-150 ml) of the processed
marrow and cryopreservative are then transferred via a
second transfer set attached to the three-way tap into
four 700 ml Gambro Hemofreeze bags (DF-700-3). Ten to
twenty millilitres are also placed in 2 ml freezing vials
to enable repeated evaluation of the freezing and
storage. Previous studies with peripheral blood
leucocytes from patients with chronic granulocytic
leukaemia showed that the progenitor cell recovery from
both the 2 ml vial and the 120 ml bag were very similar
when both were frozen at the same time. The four
Hemofreeze bags are sandwiched between aluminium plates
and placed with the vials in a Cryoson BV-4 biological
freezer (Cryotech Ltd. UK). A thermocouple placed against
one of the bags gives a continuous reading of the bag
temperature and another thermocouple within the freezing
cabinet gives a continuous reading of the cabinet
temperature. The samples are allowed to equilibrate at
0°c for approximately 1 0 min and the cabinet is then
28
cooled at 1. 2°C per minute until the liquid to solid
phase change. This is indicated by the rise in the bag
temperature due to the release of the latent heat of
fusion. At this stage the cabinet temperature is dropped
rapidly by a manual override to -60°C to minimise the
post-freezing plateau (Figure 2). When the latent heat
release is over, the cabinet temperature is allowed to
rise to -35°C and the cabinet is then cooled 2.0°C per
minute, during which time the freezing bag cools at about
1.25°C per minute. This cooling rate is then maintained
to -60°C at which stage the bags and vials are
transferred immediately into liquid nitrogen where they
are stored until used. Similar freezing regimes have been
used by others (Lewis et al, 1967; Wells et al,
1979)105'186.
The 2 ml vials containing aliquots of every marrow
harvested are stored separately to allow 'in vitro'
assessment of Gm CFC as part of the routine evaluation of
our cryopreservation technique.
Further discussion of the technique for harvesting and
cryopreservation has already been published (Linch et al,
1982)107.
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Representative cabinet and freezing bag temperature
recordings are shown.
A = freezing bags and 2 ml vials placed in precooled
freezing cabinet.
B = phase change with latent heat release.
Figure 2. Cryopreservation of bone marrow: freezing
curves.
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MARROW THAWING AND REINFUSION
The bags of frozen marrow are transported to the
bedside in a portable liquid nitrogen container. The bags
are then rapidly thawed, one at a time, by immersion in a
water bath (37°C). The marrow is then infused without
washing through a blood giving set into a central line,
each bag being infused over about 10 minutes. Each
patient is given 10 mg of chlorpheniramine intravenously,
immediately prior to marrow infusion. The only problems
attributable to the DMSO infused have been that of its
unsavoury taste and smell and minor febrile reactions.
One patient collapsed at the time of marrow infusion with
rapid recovery. The cause was never ascertained.
The amount of free haemoglobin transfused is small,
but patients and staff are warned to expect apparent
haematuria and a high fluid input is maintained
immediately post marrow infusion.
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ASSESSMENT OF HAEMATOLOGICAL RECOVERY
Blood samples from all patients were evaluated for
haematological recovery on a Coulter S Plus. Automated
cytochemistry was also performed on a Hemalog D90.
Patients included early in the study had fewer Hemalog D
counts but efforts were made to obtain daily counts in
the later patients during the early regenerative period.
The principles of the Hemalog D90 have been previously
described (Ansley & Orstein, 1970; Mansberg et al,
4 112
1974) ' . One component of this automated differential
white cell count is an electronic threshold area into
which large cells having no cytochemical staining are
counted. This group of large unstained cells (LUC's) is
usually considered to be part of the lymphocyte
population if it falls within the normal range
(0.8-3.1%). However, when this cell component is elevated
immature cell types and atypical lymphoid cells must be
considered and a May-Grunwald Giemsa stained blood film
examined.
The high level of precision of the differential white
cell count in leucopenic patients using this technique
1 47
has previously been reported (Ross & Bardwell, 1982)
In leucopenic patients with an absolute neutrophil count
of 0.5x10 /L the co-efficient of variation is 8% compared
to a 20% co-efficient of variation using manual methods
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of differential white cell counting.
During the course of this study it was observed that
blood samples run on the Hemalog D90 often had a high
percentage of LUC's in the period immediately prior to a
detectable return of the total WBC count on a Coulter
counter. This is discussed further in Chapter 7:
Haematological Recovery.
NURSING PRECAUTIONS
All patients receiving very high dose chemoradio-
therapy regimens were nursed in single rooms without
filtered air precautions. The patients were reverse
barrier nursed while their neutrophil count was below
0.5x109/L.
VENOUS ACCESS
All had Hickman central catheters inserted by the





Each patient had a full physical examination by myself
or another member of the transplant team, a chest X-ray
(CXR) and electro-cardiograph (ECG). In the latter part
of the study a radionuclide ventriculogram was also
performed if substantial amounts of cardiotoxic drugs,
particularly anthracyclines had already been given. A
full blood count (FBC), biochemical screen* and a full
microbiological screen** were assessed prior to starting
the conditioning regimen.
* Biochemical screen: blood urea, electrolytes,
creatinine, uric acid and liver function tests.
** Microbiological screen: A skin swab taken from the
Hickman exit site, a throat swab, a mid stream urine
sample and faeces were cultured to obtain sensitivities
of any potential pathogen, together with a blood sample




Remission patients: Patients with acute leukaemia in
remission were treated with the high dose chemotherapy
regimen as an elective procedure. The treatment was
discussed with the patient and offered as an alternative
to conventional chemotherapy. At least two patients, one
with AML and one with ALL, chose to have conventional
treatment.
Patients in remission had to be physically fit with no
evidence of infection.
The CXR was required to show no active lesion. The ECG
was performed to identify patients with significant
cardiac ischaemia. No patient was rejected because of
either an abnormal CXR or ECG.
The radionuclide ventriculogram is a non-invasive
technique which has been reported to identify patients
with anthracycline induced cardiotoxicity before clinical
manifestations of cardiac failure develop (Alexander et
1 ft 1
al, 1979; Gottdiener et al, 1981) ' . Later reports
suggest that determinations during exercise may identify
patients at risk more effectively (Dresdale et al, 1982;
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Druck et al, 1983) ' . Radionuclide ventriculography
was not available to us at the start of our study, and
neither the patient (UPN B4) who developed left ven-
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tricular failure on day -3 of the protocol, during the
period of drug administration or the patient with
lymphoma (UPN 61) who died in CCR 8 months post ABMT had
had a radionuclide ventriculogram performed prior to
ABMT. Only one patient who had a low resting left
ventricular ejection fraction (LVEF) of 37% (normal LVEF
>45%) had ABMT II delayed. The scan was repeated 5 months
later when the LVEF had returned to 45%. The patient was
found to have relapsed within a week of this scan and
ABMT II was not therefore considered.
9
If a FBC demonstrated a thrombocytopenia of <100x10 /L
even though the marrow appeared to be in remission, then
the ABMT was delayed and the patient reassessed in one
month, having received no further chemotherapy in the
interval.
If the patient was anaemic but all other
haematological parameters were acceptable then the
harvest went ahead as planned and the patient was
transfused.
No patient in the series had sufficiently abnormal
renal function demonstrated on the biochemical screen to
require a reduction in any of the drug doses or to defer
the ABMT. One patient was found to have significantly
deranged LFT's following induction therapy. This appears
to have been due to nonA nonB post transfusion hepatitis.
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The patient was deferred until her LFT's should either
return to normal or stabilise when she might be
reconsidered. She relapsed before ABMT I.
If an unexpected infection was discovered on micro¬
biological screening eg. a urinary tract infection, then
the infection was treated before proceeding. If a
pathogenic bacteria was discovered eg Staph. aureus in
the nose, then the patients harvest was not delayed but
they were started on treatment with topical 'Naseptin'.
If screening the faeces revealed a potentially
pathogenic organism, its sensitivity to gentamicin was
recorded. In the event of gentamicin resistance the
patient would be treated with amikacin as an alternative
to gentamicin in the event of a pyrexia with no site of
origin developing during the pancytopenic phase; see
below.
No patient in this series was HBs antigen positive.
Relapsed Patients: The five patients treated as
reinduction therapy for their acute leukaemia were the
most seriously ill group. All were already pancytopenic
and on parenteral antibiotics when they were treated with
the chemotherapy of ABMT I. One patient (UPN 107) was
known to have leukaemic infiltration of the kidneys.
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LYMPHOMA
These patients were generally treated late in their
disease, the above criteria were therefore modified and
providing that the abnormalities discovered were
consistent with the state of their disease they proceeded
to ABMT as planned eg abnormal CXR, abnormal LFT's etc.
One patient who was thought to have pyrexia relating to
his disease was discovered to have a gram negative
septicaemia. This was therefore treated prior to
proceeding to ABMT.
During Admission For ABMT
Each patient was assessed daily by myself or another
senior member of the team. A full blood count and a
biochemical screen were performed at least on alternate
days. Calcium was monitored once weekly and if noted to
be low, a magnesium level was also obtained. A full
microbiological screen was carried out once weekly with
extra tests being performed as clinically indicated.
The haemoglobin level was maintained above 9 gm/dl by
transfusion of donor red cells. Random platelet
concentrates were transfused whenever the patients count
fell below 20x10 /L or there was evidence of bleeding.
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Donor granulocytes were only considered if the
g
patients granulocytes were <0.2x10 /L and they were
severly ill, with an infection which was not responding
to parenteral antibiotics.
Blood products were not irradiated prior to infusion
post ABMT.
The biochemistry screen was used to assess the
necessary electrolyte replacement. All patients on
parenteral antibiotics required potassium supplements,
some required calcium spplements and occasional patients
also required magnesium supplements. The blood urea and
creatinine allowed assessment of renal function and
assisted in determining the dose of nephrotoxic
antibiotics.
All significant positive microbiological isolates were
treated according to their sensitivities.
Follow-up After Discharge
Patients were discharged when their neutrophils had
9 9
risen above 0.5x10 /L and their platelets were >20x10 /L
unsupported. The neutrophil recovery generally lagged
behind the platelet recovery to these levels for all
patients recovering from ABMT I and for lymphoma patients
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recovering from ABMT II (Table 1). The neutrophils of
patients with acute leukaemia recovered more quickly than
the platelets in most patients post ABMT II. Therefore,
occasional patients who could attend easily on a daily
basis for platelet transfusions have been discharged
before their platelet count was sustained above
20x10 /L. After discharge patients were assessed twice
weekly until the platelet count had returned to normal or
until the patients count was stable with no bleeding
manifestations, in those patients with delayed platelet
recovery.
The UCH patients were followed up by myself or another
member of the transplant team. Patients who had been
referred from any distance were returned to the care of
the referring haematologist, who sent details of their
counts and progress to me for collection. Both the
patients and their consultants were encouraged to phone
and discuss any problems arising. Patients not returning
to UCH for their regular follow-up are invited for review
once a year.
I have reviewed all the temperature and drug charts,
and all the entries in the notes of any patient who I did
not personally supervise the care of.
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Table 1. Comparison of the time to achieve platelet
g
recovery of >20x10 /L with the time at which neutrophils
9
rose above 0.5x10 /L.






AML ABMT I (n = 22)
ABMT II (n = 8)
16 (76%) 5
1 (12.5%) 7
ALL ABMT I (n = 15) 13 (87%)
ABMT II (n = 9) 3 (43%)
2
4
NHL ABMT I (n = 21) 11 (69%)
ABMT II (n = 3) 3
HD ABMT I (n = 15) 10 (83%)
ABMT II (n = 2) 2
TOTALS 59 (70%) 25 (30%)
Antibiotic Policy
Prophylactic antibiotics: Routine antifungal pro¬
phylaxis with oral nystatin or amphotericin was given.
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Some patients also received antibacterial prophylaxis
with cotrimoxazole, but this was abandoned in December
1983 because of increasing resistance of intestinal
flora. No prophylactic antibacterial agents are given
after discharge.
Antibiotics for treating episodes of pyrexia: Antibiotics
were given for any infective episode and were started
empirically whenever the temperature rose to >38.5°C
unless transfusion of blood products was in progress. In
this instance, antibiotics were only started if the
patient appeared ill or if the fever persisted at the end
of the transfusion. High volume blood cultures (>15 mis)
were taken at the inception of any fever and prior to
instigating antibiotics.
If a focus of infection was identified then
antibiotics appropriate to the likely infecting organism
were initiated. If there was no obvious focus of
infection then broad spectrum antibiotics were started at
full dosage, as recommended for serious infections, after
a repeat microbiological screen as outlined below.
Initially, the unit policy agreed with microbiological
colleagues was to administer gentamicin and high dose
benzyl penicillin parenterally, unless the patient was
penicillin sensitive, when cefuroxime was substituted. If
positive microbiology became available then the anti-
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biotics were adjusted accordingly to any sensitivities
reported. If there was no helpful microbiology, but the
fever persisted after 48 hours, ceftazidime was
substituted for the benzyl penicillin and metronidazole
added. If fever still persisted, after a further 48
hours, then the addition of intravenous amphotericin was
considered.
We later decided to enter patients in the current
European Organisation for Research on Treatment of Cancer
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(EORTC) trial of antibiotic therapy in neutropenic
patients which meant patients received antibiotics
according to the trial protocol (Figure 3).
STATISTICAL METHODS
Statistical evaluation of results has been applied
where appropriate. This has been either by a students t
test, by the chi squared test or a Mantel test (Mantel N,
1 966 )1 1 3.
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CONTINUE FOR +VE MICROBIOLOGY NO MICROBIOLOGY
INSTITUTE
APPROPRIATE THERAPY
PMN>0 . 5X1 0 /L PMN< 0 . 5X1 0 /L
FAILURE'
CONTINUE FOR AT CONTINUE FOR AT
LEAST 9 DAYS LEAST 9 DAYS +
AMPHOTERICIN





In 1 957, Ronald Bodley Scott''^, the Queen's
physician, wrote: "Acute leukaemia remains stubbornly
fatal". Since then the application of, at first, single
agents and then combination chemotherapy, has produced an
ability to achieve a CR in most patients with acute
leukaemia. However, in spite of this capability, most
patients will relapse and ultimately die of their
disease. Present approaches are therefore, designed to
prolong DFS with the hope of possible cure.
If intensification of treatment for patients with AML
in 1st CR, by using ABMT to allow high dose chemoradio-
therapy, is to be successful, it must be demonstrated to
be better than conventional chemotherapy without ABMT
rescue, or if of similar efficacy, it must be
demonstrated to have additional advantages eg shorter
duration of chemotherapy.
If ABMT is to be used in preference to allografting
then it needs to be shown to produce better long-term
DFS. If results are similar, then ABMT may still be
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preferred as a normal donor is not required.
COMPARISON OF DIFFERENT THERAPEUTIC STRATEGIES
Comparison of the results of different treatment
regimens in patients with AML is difficult because many
of the reported regimens have excluded the older age
groups which have the worst CR rates, shortest length of
remission and survival (Keating et al, 1982; Beguin et
100 14
al,1985) ' . The exclusion of older patients also
limits the value of any treatment as the majority of
patients with AML present after 60 years of age. The
median age of patients entered in the MRC AML8 trial was
53 years, but the median age of those notified to the
trials office but not entered was 69 years (JKL Rees,
personal communication). The CR rate in AML depends on
the initial induction therapy and this has not been
standardised although most remission induction regimens
now employed include combinations of daunorubicin,
cytosine arabinoside and thioguanine. They have been
variously reported as achieving a 60-80% CR rate (Gale &
Cline, 1 977; Rees et al, 1 977)^'^^. The result of




Patients who are treated with a BMT have usually been
referred to a special centre from many other instituions
and have not had uniform induction therapy nor do the
transplant centres all use the same conditioning regimen.
Patient selection has already occurred resulting in a
better prognosis group because those who fail remission
induction or who relapse quickly, do not usually get
referred for BMT. Further selection of suitable
transplant recipients occurs as only one in four siblings
will be HLA identical, resulting in approximately 30-40%
of patients with siblings having an HLA identical donor.
Most centres do not consider patients above 40 years of
age for allografts and it has even been suggested that




In 1983, Weinstein et al , reported the updated
results of the VAPA protocol, which is a 14 month
intensive post induction chemotherapy protocol for use in
both children and adults up to the age of 50 years. 107
patients were entered in the study and 70% of these
achieved a CR. A Kaplan-Meier analysis of patients
entering remission predicts that 56% of patients less
than 18 years of age but only 45% of patients between 18
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and 50 years of age will remain in CR at 3 years, {ie 31%
of the original cohort).
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Rees et al, 1985 , published data from the Medical
Research Council's AML 8 trial, suggesting that late
intensification therapy was beneficial with a longer
period of DFS and overall survival. The principal results
of this trial have recently been published (Rees et al,
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1986) . A total of 1,127 patients were entered into
this trial. Patients less than 13 years of age were
originally excluded but then this restriction was lifted
so there was no age restriction, median age was 49 years.
CR rate varied depending upon age, but the overall CR
rate was 67%. The overall median survival from diagnosis
was just over 12 months, with a five year survival
projected at 18% of the original cohort. As well as a
beneficial effect from late intensification the study
also demonstrated a small benefit to the use of 6 courses
of consolidation rather than 2 but this did not achieve
statistical significance. The impression that intens¬
ification of post induction treatment is beneficial
argues in favour of more intensive regimens to improve
long-term DFS.
This study also demonstrates a statistical benefit in
relation to survival of the patients entered in the
latter half of this trial although no criteria for
admission eligibility or treatment were altered. This
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seems likely to be due to improvement in support
facilities, but demonstrates how the use of historical
controls might give a false impression of advantage.
BONE MARROW TRANSPLANTATION
Thomas ED, 1 983^®, reported an overall DFS of 50% for
patients with AML transplanted from an HLA identical
donor following TBI and cylophosphamide whilst in first
CR. If the patient population is divided by age then the
long-term survival of those <20 years of age is 75% and
and those >30 years of age 25% whilst those aged between
20 and 30 years of age have an intermediate survival.
Deaths in the older age group being due to a much higher
incidence of GVHD and pneumonitis with no increase in
the relapse rate. The same group have also reported the
results of a prospective comparison of BMT versus
chemotherapy in 111 adult patients with AML, who were
aged between 17-50 years. 81% acheived a CR. The patients
were then divided into 2 groups dependent on whether or
not they had a suitable donor. The chemotherapy and
transplant group were reported to be similar with respect
to age, white blood cell (WBC) count at diagnosis and FAB
(French-American-British) subtype (Bennett et al,
1 976)^. 17 of 33 (52%) of the BMT group are alive in CR
1.5-7 years post remission induction, whereas only 10 of
the 43 chemotherapy patients (23%) are alive in remission
49
9
(Appelbaum & Thomas, 1985) .
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The Royal Marsden (Powles et al, 1980) reported a
series of 50 patients, 22 treated by allogeneic BMT and
28 by chemotherapy. They found a significant reduction in
leukaemic relapse after transplantation but survival at 3
years was not significantly improved (67% vs. 35% p<0.1).
1 33
A subsequent update (Powles et al, 1982) on 103
patients did report a survival advantage (56% vs. 24%
p<0.005). The same difficulty, in relation to patient
selection, applied to the Marsden study as well as the
Seattle study, but the patients who received BMT in this
study had received their remission induction therapy at
other centres, whereas all the patients treated with
chemotherapy were induced at the Marsden.
Autografting does not have the severe age restriction
of allografting and an HLA identical sibling is not
required. Patient selection will still occur however, at
the referring institution or by early relapse of disease.
A further exclusion in either autologous or allogeneic
transplantation is patients who refuse this treatment
option.
CHOICE OF CONDITIONING REGIMEN FOR ABMT
The same pre-graft conditioning as for allogeneic
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transplants could be used for ABMT, but the relapse rate
after a syngeneic graft is high suggesting failure to
eradicate host disease (Fefer et al, 1981) . After ABMT
the relapse rate might be expected to be higher than
after a syngeneic graft in view of the theoretical
possibility of reinfusing residual disease with the
autologous marrow.
There are therefore, two important considerations in
the choice of a protocol for conditioning the patient
pre-ABMT, the eradication of disease in the patient and
the eradication of residual disease in the harvested
marrow.
When we first developed our cryopreservation technique
we ran a small pilot protocol in which bone marrow was
harvested during first remission (CR1) from patients with
acute leukaemia and upon relapse they were to be treated
with 10 gray TBI and 60 mg/kg cyclophosphamide given on
two consecutive days prior to the TBI, as used in
allografts by the Seattle group. The stored autologous
marrow from first remission was to be used to rescue the
patient from the aplasia thus produced. The plan was to
use this as their reinduction therapy. The allogeneic
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data from Thomas et al, 1977 did not lead us to expect
a prolonged remission without further therapy, but we
were concerned that further treatment immediately post
autograft might result in prolonged cytopenias. We
therefore postponed the possibility of further
consolidation or maintenance therapy.
Four patients were treated, 2 had relapsed AML and 2
relapsed ALL. One patient received only 8 gray TBI with
the cyclophosphamide and failed to attain a remission.
One patient appeared to be free of disease as assessed by
a bone marrow aspirate at day 28, but remained
hypoplastic until relapse at 44 days post ABMT. The other
2 patients achieved a complete remission with full
haematological recovery, but relapsed again at 5 and 6
months post ABMT. One of these patients had a second
remission lasting more than twice the period of time
between harvest of the marrow and relapse, suggesting
some reduction of the residual disease in the autologous
marrow from the procedure of harvesting, cryopreservation
and reinfusion alone, without any other purging manouvre.
Following this experience and in the light of early
reports in the literature (Dicke et al, 1979; Kaizer et
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al, 1981) ' we decided on a double autograft
technique. We felt this had several advantages:
Eradication of residual leukaemia in the host: If a
single dose of massive chemoradiotherapy may eradicate
disease in some but not all patients, then to repeat the
procedure should produce a greater tumour kill. TBI is an
unsuitable modality for a double protocol. It has
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occasionally been used at a much lower dose a second time
in patients who have relapsed post allogeneic graft (P
Stewart, personal communication), but its efficacy in
this situation is doubtful, and the toxicity,
particularly from interstitial pneumonitis, would be
expected to be high. We decided on a combination
chemotherapy protocol using the same drug regimen for the
first and second ABMT.
8 2
Graw et al, 1974 , reported the successful use of
BACT chemotherapy (Table 2) to condition patients with
acute leukaemia prior to allogeneic bone marrow trans¬
plantation. They also used the regimen in two patients
prior to autologous bone marrow transplantation, both of
whom died of sepsis, one at day 14 before any evidence of
engraftment and one at day 28 when the bone marrow was
hypocellular with 20% blasts. In 1 978, Appelbaum et al~",
reported the successful use of BACT chemotherapy (Table
2) followed by ABMT in patients with relapsed non-
Hodgkin's lymphoma. They demonstrated a definite
reduction in the time to haematological recovery for
patients who received autologous marrow post treatment
with BACT chemotherapy when compared with controls who
received no marrow.
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45 MG / KG
BCNU *
200 MG / M2
CYTOSINE ARABINOSIDE **
100 MG / M2
THIOGUANINE **
100 MG / M2
ABMT
regimen (Graw et al,
2 3 4 5 6 7
* * *
BACT chemotherapy regimen (Appelbaum et al,
1 978 )5.
DAY 1 234567
CYCLOPHOSPHAMIDE * * * *
45 MG / KG
BCNU *
200 MG / M2
CYTOSINE ARABINOSIDE ** ** ** **
100 MG / M2
THIOGUANINE ** ** ** **




Gorin et al, 1979 , used a modified BACT regimen -
TACC in which the BCNU was replaced by CCNU (Table 3),
followed by ABMT in 8 of 12 patients. 4 patients had
solid tumours and 8 acute leukaemia. They concluded that
the autologous marrow was beneficial and would reduce the
period of aplasia by approximately 50%, but that TACC
high dose combination chemotherapy did not produce
irreversible aplasia or eradicate the leukaemia.
Table 3. TACC chemotherapy regimen.
DAY 1234
CYCLOPHOSPHAMIDE * * * *
45 MG / KG
CCNU *
200 MG / M2
CYTOSINE ARABINOSIDE ** ** ** **
100 MG / M2
THIOGUANINE ** ** ** **
100 MG / M2
ABMT
We decided to adopt our
protocol as the basis of
dose of drugs used in both
marrow ablation as judged
own variation of the BACT
our chemotherapy regimen. The
BACT and TACC had not produced
by the successful haemato-
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logical recovery of patients who did not receive any
marrow rescue. We therefore decided to increase the dose
of BCNU to 300 mg/m^. We also felt the addition of an
anthracycline was important in the treatment of patients
with AML and as we assumed all patients would already
have received daunorubicin in their induction regimes we
chose to use adriamycin. High dose cyclophosphamide used
in combination chemotherapy, has been reported as
191
producing cardiotoxicity (Zeigler et al, 1976) , as we
did not wish to induce unacceptable cardiotoxicity by
adding adriamycin in a high dose we decided to add it at
a conventional dose of 50 mg/m . The same combination
chemotherapy protocol being used for ABMT I & II (Table
4).
The use of a second ABMT also removed the worry of
producing prolonged cytopenia if conventional chemo¬
therapy was to be used immediately post ABMT.
Eradication of residual leukaemia in the marrow: We
argued that a double protocol would effect a form of 1 in
vivo' purging. For example if the marrow at the time of
the first harvest contained X tumour cells then post
harvest the cryopreserved marrow would contain only 2% X
assuming a harvest of 2% of the total marrow content
(Faille et al, 1981 )^^ and no differential loss of
disease and normal stem cells during cryopreservation. If
leukaemic and normal marrow cells have the same regrowth
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potential then they will remain in the same proportions
post ABMT. However, the success of induction regimes
which render the patients marrow severely hypoplastic
relies on normal haemopoietic tissue having a
regenerative advantage to the leukaemic population.
After a second ABMT therefore, the residual population of
leukaemic cells should be considerably less than after a
single ABMT. This number might fall below the critical
level at which the body's own defences might be able to
eliminate or contain any residual disease, total
elimination being perhaps unnecessary.
Table 4. UCH double chemotherapy regimen.
DAY 1 234567
CYCLOPHOSPHAMIDE
1.5 G / M2
* *
BCNU
300 MG / M2
CYTOSINE ARABINOSIDE
100 MG / M2
THIOGUANINE
100 MG / M2
ADRIAMYCIN





24 adult patients with AML have been treated between
January 1981 and January 1985. The median age was 40
years (range 19-57 years). 16 patients were autografted
in first remission, 5 in second remission and 3 patients
who had marrow harvested during first remission were
reinduced with the regimen at relapse. Further details
are given in Table 5.
BONE MARROW HARVESTING, CRYOPRESERVATION AND REINFUSION
Bone marrow was harvested, cryopreserved and reinfused
as previously described (Chapter 2; Linch et al,
107
1982) . 19 patients were harvested in CR1 and 5 in
second remission (CR2). The mean number of nucleated
g
cells frozen was 1.9x10 cells/kg body weight (range
g
0.6-3.1x10 cells/kg). The time for which the marrow was
stored in liquid nitrogen before both ABMT I and II, is
shown in Table 6.
TREATMENT PLAN
This is outlined in Figure 4. The first bone marrow
harvest was performed where possible, following recovery
from consolidation therapy in first remission patients
and as soon as possible following reinduction therapy in
the 5 patients treated in second remission.
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TABLE 5. PATIENT CHARACTERISTICS: AML
PATIENTS TREATED WITH ABMT DURING 1ST REMISSION
UPN Sex Age FAB NO. OF DIAG CR-> DIAG- > STATUS DFS SURV. TOTAL CURRENT
CLASS. GRAFTS - > CR ABMT ABMT POST ABMT POST ABMT SURV. STATUS
19 M 25 M1 2 2 2 4 CR 61 + 65 + A S W
30 M 38 M3 1 1 7 8 CR 55 + 63 + A & W
105 F 43 M4 2 2 5 8 CR 31 + 39 + A S W
108 F 39 M1 2 2 7 9 CR 30 + 39 + A & W
128 F 32 M2 1 1 5 6 CR 25 + 31 + A & W
131 F 45 M4 1 3 5 8 CR 24 + 32+ A & W
132 M 47 M1 1 2 4 6 CR 1 1 25 DEAD
B3 M 42 M4 1 3 1 4 CR 2 7 DEAD
B4 F 55 M2 1 3 1 0 13 CR 6 21 DEAD
143 M 49 M1 2 1 3 4 CR 20 + 24+ A & W
147 M 35 M5 2 2 4 6 CR 19 + 25 + A & W
1 48 M 26 M1 2 1 6 7 CR 1 9 + 26 + A & W
156 F 1 9 M2 1 3 9 12 CR 15 29 DEAD
160 M 36 M1 1 2 7 9 CR 16 + 25+ A X W
163 F 36 M4 1 4 2 6 CR 7 1 3 DEAD
174 F 40 M2 1 3 4 7 REL *** 0 13 DEAD
PATIENTS TREATED WITH ABMT AS REINDUCTION THERAPY OR IN 2ND REMISSION
41*/** F 57 M2 1 2 20 22 CR 7 32 DEAD
55 F 31 M1 1 2 5 7 CR 2 15 DEAD
92*/** M 49 M1 1 3 22 25 NE Died 25 DEAD
day 1 2
98 M 44 M1 2 6 4 1 0 CR 8 19 DEAD
100*/** M 51 M5 1 2 6 8 CR 3 11 DEAD
122 F 34 M5 1 1 6 7 CR 2 14 DEAD
125* M 21 M1 2 2 35 37 CR 5 43 DEAD
129 M 51 M6 1 1 35 36 CR 13 50 DEAD
UPN = Unique Patient Number. All patients grafted in the Bloomsbury Transplant
Unit have been given consecutive numbers dependent only on the date of ABMT.
Where the UPN has been prefixed with a 'B' the patients were grafted at the
Queen Elizabeth Hospital, Birmingham; FAB CLASS. = French, American, British
classification; NO. = Number; DIAG = Diagnosis; CR = Complete remission; DFS
SURV. = Disease free survival; NE = Not Evaluable.
* Patients who were harvested in 1 st remission.
** Patients who were treated in 1st relapse.
*** Although performed in apparent remission this patient regenerated with
disease.
All time intervals are recorded as months: + indicates continuing survival.
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Table 6. Time for which the marrow was stored in days:AML
ABMT I ABMT II
Mean Range Pat Nos Mean Range Pat Nos
CR1 26 7-1 40 n = 16 11 8-16 n = 6
( Median 10 )
CR2 11 5-24 n = 5 10 8-12 n = 2
HARVEST IN CR1 TREATED
AFTER RELAPSE 158 22*-252 n = 3
* This patient was originally harvested when thought to
be in CR1 . On review of his pre-harvest marrow, it was
clear he was in early relapse. As he had already had a
lot of treatment it was decided to proceed to ABMT with
the minimally involved marrow already harvested. He
remained in good health post ABMT for 3 months without
further treatment. He has been included in the group of













HIGH DOSE CHEMOTHERAPY II
ABMT II
RELAPSE
C * RE INDUCTION
A All patients
B 20 patients harvested in 1 st remission
C 4 patients harvested in 2nd remission
D 4 patients harvested in 1st remission but not treated
E 3 patients treated in relapse
F 1 patient reinduced before treatment
G 8 patients who had ABMT II
See text for details of treatment regimens.
Figure 4. Treatment plan : AML
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All first remission patients were treated within 13
months of their diagnosis, mean 8 months (range 4-13
months).
8 patients have completed a second autograft. All had
their marrow reharvested as soon as possible after full
haematological recovery and proceeded directly to ABMT
II. The reasons for not proceeding to ABMT II are shown
in Table 7.
Table 7. Reasons for not proceeding to ABMT II: AML
AML
DEATH IN PART I 1
RELAPSE 4 (1 CNS)




* 1 Patient who had a reduced resting left ventricul¬
ar ejection fraction on radionuclide ventriculogram.





First remission AML: 16 patients have so far been
treated. Ten patients (62.5%) continue in unmaintained
remission 62, 55, 32, 28, 25, 24, 20, 19, 19 and 15
months post ABMT, with no procedural deaths. Six have
relapsed 1, 2, 6, 7, 11 and 15 months post ABMT (Figure
5).
Relapsed AML: Three patients with AML were treated with
this regime as reinduction therapy following relapse. Two
achieved a complete remission, one patient (UPN 92) died
during aplasia of an intra-cerebral haemorrhage. The two
surviving patients did not go on to receive ABMT II
because of delayed haematological recovery. Both have
relapsed and died, relapse occurring 3 and 7 months post
ABMT (Figure 5).
Second Remission AML: Five patients were treated in
second remission, two received both ABMT I & II, all have




Figure 5. DFS in patients with AML.
Patients treated in CR1 (n=16) *——o
Patients treated in CR2 or relapse (n=8)
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DISCUSSION
An increasing number of high dose chemotherapy-
regimens utilising autologous bone marrow transplant to
alleviate the severe haematological toxicity, are being
used for treating patients with acute leukaemia, lymphoma
and other solid tumours, in an attempt to prolong disease
free survival by allowing increases in the tumoricidal
doses of chemotherapy. In acute leukaemia, this technique
suffers from the disadvantage that residual leukaemic
cells are likely to be reinfused with the autologous
marrow. The autologous marrow has been used unpurged
7 q on
(Gorin et al, 1985; Burnett et al, 1984) ' or has been
purged 'in vitro' in an attempt to remove presumed
residual disease (Ritz & Schlossman, 1982; Laporte et al,
142 104
1984) ' , although the need for purging has not yet
been proven.
There is no convincing evidence of benefit from
purging the autologous marrow in any situation (Gorin et
79
al, 1985) and for AML in particular there is no
evidence of altered sensitivity of leukaemic cells from
normal progenitor cells when treated with cytotoxic drugs
55
'in vitro' (Douay et al, 1984) nor is there a suitable
monoclonal antibody available which can distinguish
between these cell types. We do not use 'in vitro'
purging but feel that repeating the procedure a second
time should reduce the leukaemic burden further and
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effect 'in vivo' purging.
Ten (62.5%) of our patients with AML treated with ABMT
as early intensification therapy in first remission
continue in unmaintained remission with a minimum follow
up time of 16 months, median 24 months, range 16-61
months (Figure 5). Our figures for first remission AML in
adults are highly encouraging compared to the results of
more conventional chemotherapy (Weinstein et al, 1983;
Rees et al, 1 985; Wolff et al, 1 985)^ 38,1 87
allogeneic BMT where the mortality rate in patients over
30 years of age is high (70-75%) with most deaths being
due to GVHD or interstitial pneumonitis (Thomas ED,
168
1983) . Thirteen of our patients are over 30 years of
age and their survival is still 62%, with a minimum
follow up of 1 6 months.
Massive chemotherapy with ABMT rescue appears
effective at inducing a CR in relapsed patients with AML
(two of three patients with one death occurring during
aplasia). Five of our patients were treated in second
remission. These seven patients have relapsed again
within 13 months (2, 2, 3, 5, 7, 8 and 13 months) and
have died (Figure 5).
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It has been suggested that patients undergoing either
allogeneic BMT or ABMT are a selected population with a
better prognosis, as pre-BMT delays tend to occur for
many reasons, thus the major threat of relapse has
31
passed. Burnett et al, 1986 , have reported improved
results following ABMT, when the procedure is delayed
until at least 4 months after CR1 is obtained.
In our own series of 16 patients with AML, where the
intention was to progress to ABMT as early as possible
following induction of CR1 and one course of con¬
solidation therapy, 5 patients were treated with ABMT
within 4 months of induction of CR1, 9 patients between
4-8 months and only 2 were treated after more than 8
months. Although the group transplanted early in CR1
fared worse than the 4-8 month group the 2 patients
receiving ABMT as late consolidation beyond one year have
both relapsed and died (Figure 6).
If BMT, either allografting or autografting is to be
beneficial, then the earlier it is applied to try and
prevent relapse in patients destined to relapse early,
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Figure 6. DFS post ABMT:
Patients treated <4/12 (n=5) # <#
4-8/12 (n=9 )
>8/12 (n=2 )
after achieving CR1 .
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The need for a double autograft is unproven.
1 1 4
Maraninchi et al, 1984 , have also advocated a double
protocol. Four of their long-terra survivors had ABMT I
and II {11+, 11+, 28+, 29+) and of ten relapses eight
patients received only ABMT I.
In our patients with AML, the six patients who
received a double autograft as consolidation therapy in
first remission remain well in unmaintained CR, between
19 and 61 months post ABMT. Ten patients had only ABMT I
and six have already relapsed between 1-15 months post
ABMT, median 6 months (Figure 7).
The four remaining patients in first unmaintained
remission are now 16, 24, 25 and 55 months post ABMT. The
relapse of six (60%) of patients with AML treated in
first CR who did not have ABMT II whilst there are no
relapses in the six patients who had ABMT I & II
encourages us to believe that the second ABMT has
resulted in a greater reduction of host disease, with the
possibility of cure. It could also mean that delay in
haematological recovery after ABMT I which is the main
reason for failing to proceed to ABMT II may be a
characteristic of more aggressive or resistant disease
and such patients may be a poor prognosis group,
irrespective of whether they receive ABMT II or not.
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Months
Figure 7. DFS in AML in CR1I ABMT I vs ABMT X & XX.
ABMT I (n=1 0 ) • •
ABMT I & II (n=6)
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The collective EBMTG data (Gorin et al, 1985) , which
includes our group of patients, showed a trend in favour
of double autografting when compared to single autografts
for DFS: 79% versus 48% at 640 days, (p<0.1). Numbers are
small and the differences do not achieve statistical
significance. If encouraging results are maintained it
will not be possible to determine if this is due to
improved leukaemic eradication or 'in vivo' purging. This
will depend on the development of sensitive assays for
minimal residual disease.
The best prognostic determinant in our series of
patients with AML treated in CR1 is the length of time
from diagnosis to achieve CR1 (Table 8). This appears a
better discriminator than whether or not the patient
receives both ABMT I and II (p<0.01 vs p<0.05).
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Table 8. The time taken to achieve CR1 as a prognostic
indicator in patients with AML treated in CR1
UPN TIME FROM DIAG CURRENT NO OF
TO CR IN DAYS STATUS GRAFTS
Patients who took >2/12
B3 132 REL 1
163 123 REL 1
174 108 REL 1
131 97 CR 1
156 90 REL 1
105 74 CR 2
132 72 REL 1
B4 71 REL 1
Patients who took <2/12
160 60 CR 1
19 55 CR 2
147 54 CR 2
108 43 CR 2
148 39 CR 2
128 35 CR 1
30 33 CR 1
143 20 CR 2
Minimum follow-up is 16 months




No patient who achieved a CR in less than 2 months (8
patients) has relapsed, whether or not they had ABMT I or
ABMT I & II, whereas 6 of the 8 patients who took more
than 2 months to achieve their 1st CR have already
relapsed (Figure 8). 5 of the 6 patients who had ABMT I &
II are in the group of patients who remitted quickly,
this is likely to be explained by less pre-ABMT
chemotherapy resulting in better marrow yields and faster
haematological recovery, such that patients were able to
tolerate two procedures better than extensively treated
patients. Patients who enter CR easily are likely to have
more sensitive disease and it may even be that a second
autograft is not required in this group.
It may become possible as further numbers of patients
are treated with this protocol to determine whether or
not a second ABMT is improving survival in either the
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Figure 8. DFS in AML in CR1:
Patients who achieved CR1 in <2/12 (n=8)
Patients who took >2/12 (n=8) ♦
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The optimum time to proceed to ABMT has yet to be
determined as well as what the best conditioning regimen
might be and whether a double protocol is necessary. The
use of the high dose chemotherapy regime employed here
with ABMT rescue appears to be a useful approach to in¬
tensify consolidation treatment of the adult patient with
AML in first remission and perhaps should already be con¬
sidered as the most appropriate therapy for patients over
30 years of age whether or not they have a suitable allo¬
geneic donor.
There is little clear benefit from this particular
intensive regime for patients with AML treated after
first remission.
1 89
Yeager et al, 1986 , have reported the use of ABMT
following conditioning with Busulphan/Cyclophosphamide in
relapsed patients. The autologous remission marrow was
incubated with 4 hydroperoxycyclophosphamide (4HC) before
cryopreservation and reinfusion. DFS for CR2 and CR3
patients is 50%, median duration 17 months.
The use of the time to acheive CR1 as a prognostic
indicator post ABMT needs to be confirmed in a larger
series of patients. If it remains significant it will be
valuable in comparing the different prognostic groups
when treated with different conditioning regimens and may
ultimately be able to predict which patients with AML
75






The use of ABMT in patients with ALL to be justified,
must, as in patients with AML, be shown to produce better
DFS than either chemotherapy regimens without ABMT or
allogeneic BMT. However, survival following treatment for
ALL is quite different to that of patients treated for
AML. The two most striking differences are the success of
induction consolidation maintenance chemotherapy regimens
in achieving a cure rate in children of >50% and the high
relapse rate post allogeneic transplant which limits its
1 50
success (Sanders et al, 1985)
CHILDHOOD ALL
Therapeutic results in childhood acute lymphoblastic
leukaemia have improved progressively with CR rates of
over 90% and 5 year disease free survival in more than
40-50% (Sallan et al, 1978; Haghbin et al, 1980; Riehm et
al, 1980)149'84'141.
Children with ALL are now able to be divided into good
77
and poor prognosis groups at presentation. The most
important prognostic indicator being the peripheral blast
cell count and the patients age and sex (Chessels JM,
41
1982) '.
Children, particularly girls, with a low peripheral
blast cell count at presentation, represent a group with
a good prognosis who should do well on conventional
chemotherapy regimes without ABMT.
Relapse
Once a patient has relapsed during initial therapy,
although a further CR may be achieved median duration of
remisson is only short eg. 13 weeks (Chessels &
42
Cornbleet, 1979) . The Childrens Cancer Study group
1 3
(Baum et al, 1983) have reported one of the most
successful regimens to date in maintaining a second or
subsequent remission using a modified Capizzi regimen
3 6
(Capizzi et al, 1974) which gives a predicted median
duration of remission of 57 weeks with 10 patients (33%)
remaining in CR at 1 year and 3 (10%) at 2 years. The
1 44
Paediatric Oncology Group Study (Rivera et al, 1986)
reports the results of an intensive reinduction and
continuation chemotherapy protocol, for children with
first bone marrow relapse of ALL, occurring whist still
on treatment or within 6/12 of cessation of treatment.
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They achieved an 80% induction of CR2. The best predictor
for the length of CR2 was the time for which the patient
had been in CR1. No patient who had an initial CR of
<18/12 remains in CR2 at 30 months, whereas more than 50%
of patients who had an initial CR of >18/12 remain in CR2
for more than 36 months. Patients who relapse after
treatment is stopped may have a second prolonged CR with
chemotherapy but not all results agree (Mauer AM, 1980;
Sallan & Hitchcock-Bryan, 1981)^^'^^.
Long-term remission is now the rule in most children
and so they would not normally be considered for bone
marrow transplantation (BMT) in first CR. After relapse
has occurred, although a further long remission may be
possible the patient will ultimately relapse again and
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die of their disease (Johnson et al, 1981) . Children
should therefore be considered for BMT during second CR.
ADULT ALL
In adults the results of remission induction therapy
are not as good as reported in children, with recent
multicentre trials reporting CR rates of 61-85% with
remission duration of 9-25 months (Lister et al, 1978;
Amadori et al, 1 980 ; Omura et al, 1 980)^^'^'^^.
In a recent review of therapy for adults with ALL,
79
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Jacobs & Gale, 1984 , report the results of several
trials of induction continuation therapy with CR rates of
72-92% and a median duration of survival of 62 months on
the L10 protocol (Schauer et al, 1 983)^^. The L1 0
protocol is a multi-drug induction regimen employing
vincristine, prednisolone and adriamycin, followed by an
intensive consolidation and maintenance chemotherapy
programme. These encouraging results are much more
similar to the results in children.
Prognostic indicators
The factors affecting prognosis in adults are similar
to children; sex has only a small influence on the
outcome but of increasing importance is cytogenetic
1 9
analysis (Bloomfield et al, 1986)
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In a German multicentre study (Hoelzer et al, 1984) ,
they initially treated all adult patients with the same
regimen and from this study they identified various
prognostic indicators which were able to predict a high
likelihood of relapse. Having now identified this group,
they treat patients with these characteristics with a
different more aggressive induction regimen. The most
recent analysis suggests that these patients now do as
well as the patients identified as having a good
91
prognosis at presentation (Hoelzer et al, 1986) . T cell
80
patients although small in number seem to have a




Once relapse has occurred the chance of long-term
survival is poor.
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In a prospective study (Johnson et al, 1981)
patients with ALL in 2nd or subsequent CR were given BMT
if a matched sibling donor was available or treated with
chemotherapy in the absence of a suitable donor. Of 21
patients treated with chemotherapy all have relapsed and
1 remains alive, while 8 of 24 BMT recipients continue in
unmaintained CR with a follow-up of 3-6 years.
ALLOGENEIC BMT
The position of allografting for patients with ALL is
not clear. Following BMT for ALL the complication rate is
the same as after BMT for AML but there is a much higher
relapse rate. The leukaemic relapse rate is more than 50%
after allografting for ALL in 2nd or subsequent CR
150
(Sanders et al, 1985) but still seems to offer the
best hope of long-term survival and cure after a patient
81
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with ALL has relapsed (Thomas et al, 1983) . By analogy
with the improvement in survival in patients with AML
when allografted in 1st CR rather than at relapse or a
later remission, ALL patients considered to have a poor
prognosis have been allografted whilst in 1st CR but
numbers are still small. Data from the European Group for
1 92
Bone Marrow Transplantation (EGBMT)(Zwaan et al, 1986)
suggests that relapse rates are less than 50% for
patients with ALL transplanted in 1st CR.
Since the majority of recurrent leukaemias are of the
23
original host type (Boyd et al,1982) current efforts
are being directed at eradicating the leukaemic clone. At
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Sloane Kettering (Dinsmore et al, 1983) they are using
'hyper-fractionated' irradiation with only a 14% relapse
rate for patients transplanted in 2nd CR. Others are
giving additional chemotherapy post BMT (Woods et al,
188
1983) , in Seattle there is a trial of interferon
1 /TO
(Thomas ED, 1983) , and yet others are trying
alternative conditioning regimens (Santos et al,
1551986)' .
The relapse rate is so high in patients post-
allogeneic transplantation for ALL, that conditioning
regimens will need to be stronger pre-ABMT. It is
unlikely there will be a GVL effect and leukaemic cells
may still reside in the autologous remission marrow. The
depletion of these leukaemic cells by physical (Dicke et
82
SI 142
al, 1979) , immunological (Ritz & Schlossman, 1982) ,
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and pharmacological techniques ( Kaizer et al, 1981)
offer promise for the future. The EBMTG results have so
far failed to demonstrate any benefit from purging (Gorin
& Aegerter, 1 986)^.
Autologous BMT
Adult patients with ALL have a much worse prognosis
than children and therefore, it is these patients with
ALL who are being included in trials of high dose
chemotherapy regimens during CR1. All patients following
relapse have a poor prognosis and represent the bulk of
patients receiving this form of treatment at the present
time.
PATIENTS
18 patients with acute lymphoblastic leukaemia have
been treated between November 1981 and November 1984. The
median age was 22 years (range 6-49 years). 8 adult
patients were autografted in first remission, 7 others (5
adults and two children aged 6 and 13 years) were
autografted in second and one in third remission and two
were reinduced with the protocol at first relapse.
Further details are given in Table 9.
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TABLE 9. PATIENT CHARACTERISTICS: ALL
PATIENTS TREATED WITH ABMT DURING 1ST REMISSION
UPN Sex Age FAB/IM NO . OF DIAG CR- > DIAG- > STATUS DFS SURV. TOTAL CURRENT
CLASS. GRAFTS - > CR ABMT ABMT POST ABMT POST ABMT SURV. STATUS
57 M 23 T-ALL 1 1 3 4 CR 2 8 DEAD
69 F 24 ALL 2 1 4 5 CR 33 42 DEAD
103 M 1 6 CALL 2 2 6 8 CR 32 40 + Relapse
B1 M 1 8 CALL L1 1 1 10 11 NE Died 5 1 6 DEAD
day 146
B2 F 49 CALL L1 2 2 15 17 CR 24 + 41 + A & W
1 50 M 46 CALL 2 2 1 3 NE Died 3 6 DEAD
day 88
157 M 22 CALL L2 1 7 2 9 NE Died 1 1 0 DEAD
day 23
1 64 M 1 6 ALL L2 1 1 3 4 CR 1 0 1 9 + Relapse
PATIENTS 'TREATED WITH ABMT AS REINDUCTION THERAPY OR IN 2ND OR 3RD REMISSION
39+/** M 1 9 ALL 2 1 32 33 CR 5 41 DEAD
51*/** F 35 CALL 2 1 58 59 CR 47 + 1 06 + A & W
67* F 23 ALL 1 2 1 7 1 9 CR 7 28 DEAD
90 M 6 T-ALL 2 1 5 6 CR 3 1 4 DEAD
96* M 23 CALL 1 1 27 28 CR 2 32 DEAD
1 07* M 47 CALL 2 2 39 41 CR 1 0 52 DEAD
118 F 22 NULL ALL 2 2 41 43 CR 9 60 DEAD
1 21 M 38 T-ALL 2 2 30 32 NE Died 4 36 DEAD
day 124
135 F 1 3 ALL 1 **** **** 31 CR 23 + 54 + A S W
B5*»* F 1 9 ALL L2 1 1 59 60 CR 5 68 DEAD
UPN = Unique Patient Number. All patients grafted in the Bloomsbury Transplant
Unit have been given consecutive numbers dependent only on the date of ABMT.
Where the UPN has been prefixed with a 'B' the patients were grafted at the
Queen Elizabeth Hospital, Birmingham; FAB/IM CLASS = French, American, British
classification together with the immunological markers where available; NO. =
Number; DIAG = Diagnosis; CR = Complete remission; DFS SURV. = Disease free
survival; NE = Not Evaluable.
* Patients who were harvested in 1st remission.
** Patients who were treated in 1st relapse.
*** Patient who was harvested and treated in third remission.
**** This patient had CR1 induced abroad. No information as to the time of her
CR1 is available.
All time intervals are recorded as months.
+ indicates continuing survival.
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BONE MARROW HARVESTING, CRYOPRESERVATION AND REINFUSION
Bone marrow was harvested, cryopreserved and reinfused
as previously described (Chapter 2; Linch et al,
107
1982) .13 patients were harvested in CR1, 4 in CR2 and
one in third remission (CR3). The mean number of
g
nucleated cells frozen was 1.98x10 cells/kg body weight
o
(range 0.68-4.04 x10 cells/kg). The time for which the
marrow was stored in liquid nitrogen before both ABMT I &
II is shown in Table 10.
Table 10. Time for which marrow was stored in days: ALL
ABMT I ABMT II
Mean Range Mean Range
CR1 26 7-108 (n = 8) 15 11-22 (n = 4)*
CR2 44 9-127 (n = 4) 22 7-48 (n = 3)
CR3 43 (n = 1 )
HARVEST IN CR1 TREATED
AFTER RELAPSE 682 412-1006 (n = 5) 7 6-9 (n = 3)
*One patient, UPN B2, whose ABMT II was delayed for 1
year has been omitted to prevent distortion of the mean.
The marrow was stored for 361 days.
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TREATMENT PLAN
The treatment plan differs from that for patients with
AML; craniospinal prophylaxis is included pre-ABMT and
maintenance chemotherapy is given post ABMT (Figure 9).
The first bone marrow harvest was performed, where
possible, immediately following recovery from the cranio¬
spinal prophylaxis in first remission patients and as
soon as possible following reinduction therapy in the 5
patients harvested in second or third remission.
All first remission patients were treated within 11
months of their diagnosis, mean 6 months (range 4-11).
Ten patients went on to receive a second autograft.
All had their marrow reharvested as soon as possible
after full haematological recovery and proceeded directly
to ABMT II. The reasons for not proceeding to ABMT II are
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B 13 patients harvested in 1st remission
C 4 patients harvested in 2nd remission
D 5 patients harvested in 1st remission but not treated
E 2 patients treated in relapse
F 4 patient reinduced before treatment
G 10 patients who had ABMT II
See text for an explanation of treament regimens.
Figure 9. Treatment plan : ALL
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Table 11. Reasons for not proceeding to ABMT II: ALL
ALL
DEATH IN PART I 1
RELAPSE 2 (1 CNS)
1 SUSPICIOUS *




* 1 Patient had a suspicious marrow prior to ABMT II
** 1 Patient developed pericarditis during the
chemotherapy of ABMT I
HIGH DOSE CHEMOTHERAPY REGIMEN
We decided to use the same chemotherapy regimen as for
patients with AML as we had already successfully treated
the first two AML patients with the protocol and the
cytotoxic agents used in the combination were known to be
active in patients with ALL. The ablative chemotherapy
used for both ABMT I and II was the same and is as
2
follows: cyclophosphamide 1.5 G/m /day, days -5, -4 and
2 2
-3, adriamycin 50 mg/m day -5, BCNU 300 mg/m day -5,
2
cytosine arabinoside and thioguanine both 200 mg/m given
in two divided doses day -5 to -2 inclusive. The
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autologous bone marrow was returned on day 0 (Table 12).
Table 12 UCH chemotherapy regimen for use in
ABMT I & II.
DAY 1 23456
CYCLOPHOSPHAMIDE * * *
1.5 G / M2
BCNU *
300 MG / M2
CYTOSINE ARABINOSIDE ** ** ** **
100 MG / M2
THIOGUANINE ** ** ** **
100 MG / M2
ADRIAMYCIN *
50 MG / M2
ABMT *
First remission ALL patients had both intrathecal
methotrexate and cranial irradiation as CNS prophylaxis
prior to ABMT.
All patients with ALL were given maintenance
chemotherapy post ABMT. The regime employed combined
methotrexate, mercaptopurine and cytosine arabinoside
with three monthly reinduction courses of vincristine and
prednisolone for at least 2 years or until relapse,
89
whichever was the sooner.
RESULTS
Response to therapy.
First remission ALL : One patient only (12.5%) remains
in remission on maintenance chemotherapy 24 months post
ABMT. Three patients (37.5%) died of infection, one
before recovery from ABMT I, and two before recovery from
ABMT II. One patient (UPN 57) with T-ALL had a CNS
relapse before the second harvest and died 4 months post
ABMT. Three patients have relapsed, the two who had ABMT
I & II relapsed at 32 and 33 months, the third patient
who only had ABMT I relapsed at 10 months post ABMT. One
of the three relapsed patients (UPN 69) had an
extra-medullary relapse 33 months post ABMT and died in
relapse 3 months later. Both the other patients had a
hypoplastic relapse, and remain alive on further
chemotherapy (Figure 10).
Table 13. Response to Therapy: First Remission ALL(n = 8)
DFS POST ABMT (months)
3 DIED - INFECTION 1*, 2, 3
4 RELAPSED 2*, 10*, 32, 33
1 REMAINS IN CCR 24
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Figure 10. DFS in ALL: CR1 vs others.
Patients treated CR1 (n=8)
Patients treated later than CR1 (n=10)
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Relapsed ALL : Two patients with ALL were treated with
this regime as reinduction therapy following relapse.
Both achieved a complete remission and went on to receive
ABMT II. One patient (UPN 51) is still disease free in
second remission 48 months post ABMT (Figure 10).
Second Remission ALL : Seven patients with ALL were
treated in second remission, five have died in relapse,
(4, 8, 8, 12 and 17 months post ABMT) and one died of
aspergillus pneumonia day 124 during the aplasia induced
by ABMT II. The remaining patient (UPN 135) continues in
second remission 22 months post ABMT (Figure 10).
Third Remission ALL : One patient treated in third
remission relapsed and died 8 months post ABMT (Figure
10) .
Table 14. Response to Therapy: Relapsed, Second and
Third Remission ALL(n = 10)
DFS POST ABMT (months)
1 DIED - INFECTION 4
7 RELAPSED 2*, 3, 5, 5*, 7*, 9, 10
2 REMAIN IN CCR 23*, 47
* ABMT I only
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DISCUSSION
Autologous bone marrow transplantation for ALL in
relapse is the most likely situation in which purging
might be beneficial. There is as yet no evidence that
purging improves survival post ABMT (Gorin et al,
79
1985) . The European Bone Marrow Transplant Group
(EBMTG) data did however, suggest that there was a
survival advantage for patients with ALL treated in CR2
who had their marrow purged, but it failed to reach
statistical significance and still fails to do so even
after a further year of follow-up (Gorin & Aegerter,
8 0
1986) . We do not use 'in vitro' purging but feel that
repeating the procedure a second time should reduce the
leukaemic burden further and effect 'in vivo' purging.
The relapse rate after allogeneic transplantation has
been reported to be higher than 50% (Sanders et al,
150
1985) and where it has been possible to do so, this
has generally been demonstrated to be of the original
host type. This suggests that failure to eradicate host
1 55
disease is the likely cause. Santos et al, 1986 , have
used a higher dose of cyclophosphamide, 50 mg/kg x 4, and
TBI administered in four fractions to a total dose of 12
gray. They report only one out of 39 patients treated in
CR1 and CR2 to have relapsed with median follow-up of 24
months. Patients transplanted in CR3 with the same
conditioning regimen had a relapse rate of 35%.
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It will be very difficult to assess the contribution of
purging in autografted patients in view of the many
different conditioning regimens employed. It is likely
that any benefit from purging will only become apparent
when there is a randomised trial of patients given purged
and unpurged marrow.
First remission ALL: The results of treating patients in
first remission with our double ABMT protocol are
strikingly different from the results of treating
patients with AML in first remission, although the
protocols are the same (Figure 11).
Only one patient with ALL treated in CR1 remains in CR
24 months post ABMT. The numbers of patients with ALL
treated in CR1 is small, but the reason for the failure
of our protocol appears two fold. Firstly, as might have
been predicted from the allograft figures (Thomas et al,
175
1983) , there has been a high relapse rate, four of
five patients who survived the procedure. Secondly,
whereas there have been no transplant related deaths in
patients with AML treated in CR1 there have been three
(37.5%) such deaths in the eight patients with ALL
treated in CR1 . I suspect this may be related to the
inclusion of steroids and craniospinal prophylaxis in the
induction regimens used pre-ABMT in patients with ALL.
This difference is discussed further in Chapter 8:
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Figure 11. DFS in CR1: AML vs ALL,
AML (n=1 6 ) X X
ALL (n=8 ) • •
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of patients with ALL in CR1 requires modification.
Five patients with ALL, received a double autograft in
first remission, only one remains alive and disease free
24 month post ABMT, two died procedural deaths and two
have relapsed at 32 and 33 months post ABMT, one has died
and one remains alive on further therapy.
Relapsed patients with ALL: Massive chemotherapy with
ABMT rescue was effective at inducing a CR in the two
relapsed patients treated with the regimen. Ten of our
patients were treated in relapse or second or third
remission, one died a procedural death, seven have
relapsed again within 10 months (2, 3, 5, 5, 7, 9 and 10
months) and all have died. Two remain in CR, 22 and 48
months post ABMT, the first patient had ABMT I only and
the second ABMT I & II. Both these patients had an
initial CR of >18/12 duration and would therefore fall
into a better prognostic group as suggested by Rivera et
1 44
al, 1 986 .
These results are poor and very similar to our results
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Figure 12. DFS in patients treated after CR1: AML vs ALL.
AML (n=8 ) • •
ALL (n=10) * *
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Although our protocol appears to have been
particularly unsuccessful in patients with ALL, the EBMTG
data are much more hopeful. DFS for patients following
ABMT in CR1 is 48% at 3 years, with no difference in DFS
for patients treated in CR1 or CR2. 79% of these patients






The non-Hodgkin's lymphomas (NHL), are a heterogenous
group of disorders which, in the majority of instances
are disseminated neoplasms at the time of diagnosis and
are therefore not amenable to curative radiotherapy.
After surgical staging, stages I and II are infrequent,
except for the 'histiocytic' NHL's where approximately
30% are localized at the time of presentation (Chabner et
40
al, 1977) . Actuarial survival rates at 6 years reported
32
by Bush et al, 1977 , for Stages I and II treated by
curative radiotherapy for all histologies were 70 and 60%
respectively.
There are many pathological subtypes but an early
successful attempt to classify the NHL's by Rappaport,
1 351966 divided patients with NHL into two prognostic
categories: 'favourable' prognosis histology wherein the
median survival will be in excess of 5 to 7 years and
'unfavourable' prognosis where the median survival is
less than 2 years and often less than 1 year. This has
enabled clinical trials of various investigational
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treatments to be compared. However, there is still no
universally accepted histological classification of the
NHL's. The most recent attempt to arrive at an
internationally acceptable classification is the working
1 46
formulation of the NCI group (Rosenberg et al, 1982)
which divided them broadly into 3 categories: low,
intermediate and high grade histology again reflecting
their prognosis.
The optimum treatment of low grade or good prognosis
NHL is not clear in view of their relatively indolent
course and long-term survival.
The intermediate and high grade NHL have been treated
with a variety of combination regimens, with some success
eg. COP-BLEO 59% CR rate, CHOP 59% CR rate in all
histologies (Jones et al, 1979; McKelvey et al, 1976;
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Skarin et al, 1978) ' ' . However, within these
groups, patients with advanced diffuse 'histiocytic'
lymphoma, according to the histological classification of
1 34
Rappaport (1966) did less well. The use of MOPP in
this group of patients with diffuse histiocytic lymphoma
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was reported by DeVita et al, 1975 , to achieve a CR in
41 % with long-term disease free survival being the rule
in those achieving a CR. All studies demonstrate that the
achievement of a CR is the most important factor for
long-term survival. Treatment after relapse has occurred
produces less good CR rates and the duration of remission
1 00
is very limited (Cabanillas et al, 1978; Herrmann et al,
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1981) ' . Consequently the present treatment of the
patient with a high grade NHL is with increasingly
intensive chemoradiotherapy regimens designed to produce
a CR and hopefully long-term survival.
More intensive regimens without marrow rescue have
been reported to have been employed as first line therapy
in patients with advanced poor prognosis histology NHL
groups: high dose adriamycin and cytosine arabinoside
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(Dabich et al, 1985) , F-MACHOP (Amadori et al, 1985) ,
ProMACE-MOPP (Fisher et al, 1985)66, MACOP-B (Klimo &
1 01
Connors, 1985) . These regimens appear to result in
80%+ CR rates with long-term disease free survival in the
majority of patients achieving a CR, resulting in a
median survival in excess of 4 years. These studies were
small pilot studies in tertiary referral centres and up
to 39% of patients treated had stage II disease. Patients
with initial CNS disease and those judged to have
cardiac, liver or renal disease, were excluded from one
of the studies. Another of the studies excluded 2
patients dying in the first week from their final
analysis. Nonetheless, ABMT used as consolidation therapy
must now be compared with these first line regimens and
not compared with historical controls. Proper comparison
would need to be in a randomised controlled trial.
Similarly the success of intensive chemoradiotherapy
regimens with ABMT in relapsed patients must be
1 01
considered in relation to previous chemotherapy +/- DXT
that the patient has already received and then compared
with the best currently available salvage regimen when
used in relapsed patients with comparable prior treatment
eg. IMVP-16 (Ifosphamide (I), Methotrexate (M), Etoposide
(VP-16)(Cabanillas et al, 1 982)~^4.
Cabanillas et al, 1982 ^4, used IMVP-16 in 52 patients
with lymphoma who had failed to attain an initial
remission or had relapsed. 32 patients (62%) responded
(CR 37%, PR 25%). The projected median survival of the
complete responders is 15 months. All relapses have
occurred within 12 months. 2 patients died of sepsis
related to myelosuppression induced by the regime.
It is in an effort to improve the response rate and
prolong survival that we have employed massive doses of
chemotherapy with autologous bone marrow rescue in
patients with NHL who fail to enter CR or relapse after
initial chemotherapy.
PATIENTS
Twenty-one patients with non-Hodgkin's lymphoma, have
been treated between September 1981 and September 1985
with this form of therapy. They were all adults (14
males, 7 females), with a median age of 41 years (range
1 02
19-66 years). 11 patients had received more than one
chemotherapy regime and all had received anthracycline-
containing combinations. 10 patients had also received
radiotherapy. For the purposes of classification of
disease at the time of grafting 'resistant relapse' (RR)
indicates that the patient had progressive disease in
spite of conventional chemotherapy whilst 'non resistant
relapse' (NON RR) indicates that the patient although
relapsed was still responding to either second, third or
fourth line therapy, or that the high dose chemoradio-
therapy regime was employed as the second line regime at
the time of relapse. Histological classification is by
the NCI sponsored working formulation (Rosenberg et al,
1 46
1982) . Further details are given in Table 15.
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TABLE 15. PATIENT CHARACTERISTICS : NON-HODGKINS LYMPHOMA
UPN Age Sex HIST CLASS DIAG PREVIOUS STATUS ABMT STATUS DFS CURRENT
ST § DIAG ->ABMT TREATMENT AT ABMT CHEMO POST ABMT STATUS
34 38 M INT / III 28 CHOP RR UCH ISII CR 7 DEAD 8
M BACOD
65 39 M INT / IV 10 CHOP X 7 RR UCH I&II PR A & W 42+
BACOP
M BACOP
75 49 M HIGH / IIB 11 CHOP RR UCH I NE DEAD day 9
HD MTX
DXT
94 50 M INT / II 21 ORCHIDECT NON RR UCH I CR 9 DEAD 11
CHOP X 6
101 47 M INT / 46 CHOP X 6 NON RR UCH I&II PR REL 28+
CONJUNCTIVAL DXT
102 28 F INT 10 CHOP X 3 RR UCH I NR DEAD day 33
HD MTX X 4
DXT
114 29 M INT / MES 6 CHOP X 4 RR UCH I NR DEAD day 44
MASS EVAP X 1





133 41 M INT / II 4 CHOP X 2 RR BEAM NR DEAD 3
136 1 9 M HIGH / I 1 0 DXT RR BEAM NR DEAD day 50
M BACOD X 4
137 45 F INT / I 39 CHOP X 6 RR BEAM NR DEAD 2
M BACOD X 4
DXT X 2
153 33 F HIGH / IVB 1 2 CHOP X 6 NON RR BEAM CR 2 DEAD 8
Cis Plat X 1
158 50 M INT / IVA 10 CHOP X 6 NON RR BNLI PR DEAD 7
161 47 M INT / 1 7 CHOP NON RR BNLI NE DEAD day 15
JEJUNUM





168 56 F HIGH / IVA 15 CHOP X 7 NON RR BNLI NE DEAD day 5
183 39 F HIGH / IV 10 CHOP X 6 NON RR BNLI CR 4 REL 9 +
DXT
187 50 M HIGH / III 21 ProMACE/ NON RR BEAM CR 7 + A & W
MOPP
191 30 F NON RR BNLI CR 6 + A & w
195 45 F INT / IIA 29 COP X 4 NON RR BEAM CR 6 + A & w
MBACOD X 4
DXT
196 66 M HIGH / II 17 ORCHIDECT NON RR TBI/CYCLO CR 1 REL 5 +
( + CNS ) MBACOD X 6 CNS
DXT(CRANIAL)
IT MTX X 10
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Legend Table 15: UPN = Unique patient number; HIST CLASS
= Histological classification; INT = Intermediate grade
diffuse; HIGH = High grade diffuse; ST @ DIAG = Stage at
diagnosis (This refers to the Ann Arbor staging
classification); DIAG -> ABMT = The time interval between
diagnosis and ABMT; PREVIOUS TREATMENT: CHOP = Cyclophos¬
phamide, Adriamycin, Vincristine, Prednisolone; M BACOD =
Methotrexate, Bleomycin, Adriamycin, Cyclophosphamide,
Vincristine, Dexamethasone; BACOP = Bleomycin, Adriamy¬
cin, Cyclophosphamide, Vincristine, Prednisolone; M BACOP
= Methotrexate, Bleomycin, Adriamycin, Cyclophosphamide,
Vincristine, Prednisolone; HD MTX = High dose methotrex¬
ate; DXT = Radiotherapy; EVAP = VP16, Vinblastine, Adria¬
mycin, Prednisolone; Cyt/Thio/Cyclo = Cytosine Arabinos-
ide, Thioguanine, Cyclophosphamide; IT MTX = Intrathecal
methotrexate; MOPP = Nitrogen Mustard, Vincristine, Proc¬
arbazine, Prednisolone; LOPP = Chlorambucil, Vincristine,
Procarbazine, Prednisolone; Cis Plat = Cis Platinum; VIND
/VP16/CCNU/DEX = Vindesine, VP16, Lomustine, Dexamethas¬
one; ProMACE = Prednisolone, Methotrexate, Adriamycin,
Cyclophosphamide, VP16; COP = Cyclophosphamide, Vincrist¬
ine, Prednisolone; ORCHIDECT = Orchidectomy; STATUS AT
ABMT: RR = Resistant Relapse; NON RR = Non Resistant Rel¬
apse; ABMT CHEMO = ABMT Chemotherapy; STATUS POST ABMT:
CR = Complete Remission; PR = Partial Remission; NE = Not
Evaluable; NR = No Response; DFS = Disease Free Survival;
CURRENT STATUS: A & W = Alive and Well; REL = Relapse;
All time intervals are months unless otherwise stated.
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BONE MARROW HARVESTING, CRYOPRESERVATION AND REINFUSION
Bone marrow was harvested, cryopreserved and reinfused
as previously described (Chapter 2; Linch et al,
1982)107.
Bone marrow was harvested at relapse in 18 cases and
during CR1, CR2 and CR3 respectively in the remaining
three cases. Only one patient was known to have had
marrow involvement at some stage prior to her bone marrow
harvest. The mean number of nucleated cells frozen per kg
8 8
body weight was 1.64x10 cells/kg (range 0.36-2.4x10
cells/kg). The marrow was stored in liquid nitrogen for a
median of 1 2 days (range 6-572 days) between harvesting
and reinfusion of the first aliquot.
TREATMENT PLAN
The treatment plan varied depending on the treatment
regimen to be employed. If the UCH double protocol was
employed then only one marrow harvest was performed and
g
providing that more than 1.2x10 nucleated cells/kg body
weight were obtained post processing, the harvested
marrow was divided and half given after each course. UCH
II was given as soon as there was haematological recovery
from UCH I. Seven patients received UCH I but only 3
received UCH I & II. Three of the patients did not
continue to UCH II because of septicaemic death following
1 06
UCH I (UPN 75) or rapid progression of disease (UPN 102 &
114). One patient who attained a CR after UCH I, declined
UCH II. The BEAM and BNLI protocols were used as single
ABMT protocols.
HIGH DOSE CHEMOTHERAPY REGIMENS
Three separate chemotherapy regimens were used, UCH I
& II, BEAM and the BNLI protocol. UCH I & II was a two
cycle regime designed to introduce as many new, poten¬
tially non-cross-resistant drugs as possible. UCH I was
based on the UCH double protocol for patients with acute
leukaemia (Table 16).
The adriamycin was dropped from the protocol as it was
argued that all patients would have received it already,
and its inclusion at conventional dosage would therefore
only serve to increase the toxicity of the regimen
without additional anti-tumour benefit. It was also
assumed that the patients general condition would be
worse than the leukaemic patients who were generally
treated during remission. For UCH II methotrexate was
added instead of the cyclophosphamide, it was to be used
at high dose with folinic acid rescue. This drug has
since been used at much higher dosage without ABMT
rescue, and indeed, the UCH II regimen proved much less
myelotoxic in the three patients who received it, than
1 07
did UCH I.
Table 16. UCH double protocol for AML.
DAY 1 23456
CYCLOPHOSPHAMIDE * * *
1.5 G / M2
BCNU *
300 MG / M2
CYTOSINE ARABINOSIDE ** ** ** **
100 MG / M2
THIOGUANINE ** ** ** **
100 MG / M2
ADRIAMYCIN *
50 MG / M2
ABMT *
The regimen was as follows: UCH I : Cyclophosphamde
2 2 2
4.5 g/m , BCNU 300 mg/m , Cytosine Arabinoside 800 mg/m ;
2
UCH II : Methotrexate 1 g/m with folinic acid rescue,
2 2
BCNU 300 mg/m , Cytosine Arabinoside 800 mg/m (Table
17).
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Table 17. UCH I & II.
UCH I DAY
CYCLOPHOSPHAMIDE
1.5 G / M2
BCNU
300 MG / M2
CYTOSINE ARABINOSIDE




1.0 G / M2
BCNU
300 MG / M2
CYTOSINE ARABINOSIDE
100 MG / M2
ABMT






The BEAM regime was employed as a single therapeutic
procedure. The regimen was adopted as a collaborative
protocol with other European centres, in the hope of
accruing sufficient numbers of patients so as to enable a
rapid assessment of the worth of this form of therapy.
2
The regimen is as follows: BCNU 300 mg/m and cytosine
2
arabinoside 800 mg/m were common to UCH I. Melphalan 140
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2
mg/m was used in BEAM instead of the cyclophosphamide
4.5 g/m2 in UCH I. BEAM also contains VP16 400 mg/m2
(Table 18).
Table 18. BEAM protocol.
DAY
BCNU
300 MG / M2
VP1 6
50 MG / M2
CYTOSINE ARABINOSIDE
100 MG / M2
MELPHALAN
140 MG / M2
ABMT
1 2 3 4 5 6 7
*
*
The BNLI protocol (Table 19) is the protocol adopted
by the British National Lymphoma Investigation in
protocol C of their current study of generalised grade II
NHL (BNLI NHL GEN GDII 85 )25.
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Table 19. BNLI protocol.
DAY 2 3 4 5 6 7
CYCLOPHOSPHAMIDE
1.5 G / M2
* * * *
BCNU
300 MG / M2
*
VP1 6
75 MG / M2
* * *
CYTOSINE ARABINOSIDE
100 MG / M2
ABMT *
The objectives of the study are: 1 . To determine, in
patients with Stage III/IV NHL without bone marrow
involvement, the CR rate using highly intensive
chemotherapy with ABMT in those patients not in CR after
3 courses of CHOP. 2. To determine whether high dose
chemotherapy and ABMT can produce prolonged DFS in those
patients who have not completely responded to 3 courses
of CHOP. 3. To assess the value of high dose chemotherapy
and ABMT as initial salvage therapy in those patients
relapsing after CHOP therapy. It consists of the same
agents as in UCH I together with the addition of VP 16.
Details of the dose variations are given in Table 15. The
first patients we treated with this protocol were
generally patients with more advanced disease and not
111
eligible for entry into the BNLI trial.
RESULTS
Response To Therapy
Response to therapy was evaluated both clinically and
by repeat computed axial tomography (CAT) scanning where
previously abnormal. A complete remission was defined as
the complete resolution of all signs and abnormal
investigations in patients surviving beyond 30 days.
Of 21 patients with NHL 8 (39%) achieved a CR and 3
(14%) a PR. In 2 of these patients with a PR, there was a
clinical CR but the repeat CAT scans showed a residual
mass in the abdomen. One of these patients (UPN 65) was
given 29.80 gray DXT post ABMT, to the abdominal mass
which had no effect as judged by further CAT scanning.
This patient however remains alive and well 42 months
post ABMT. The other patient (UPN 101) was given no
further treatment at this stage. At day 263 a laparotomy
and cholecystectomy were performed following an episode
of cholecystitis. Splenectomy and multiple para-aortic
and mesenteric node biopsies showed no disease. However,
a biopsy from retroperitoneal tissue near the base of the
left ureter showed a lymphocytic infiltration, strongly
suggestive of lymphoma. The patient was then treated
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with para-aortic irradiation and further chemotherapy. He
continues alive in remission 32 months post ABMT. The
third patient (UPN 158) had generalised residual disease
and died 5 months post ABMT in spite of further
chemotherapy. There was no response in six patients. Four
patients were non-evaluable, two because of death from
septicaemia at day 9 and 15, and two because of death due
to either tumour progression or drug toxicity at day 3
and 5. Of 11 responding patients 5 are still alive 42,
32, 7, 6, and 6 months post ABMT.
One further patient (UPN 126) was treated with ABMT
when thought to have failed induction therapy with CHOP x
4, because a CAT scan showed a residual mass in the
mediastinum. A repeat CAT scan post ABMT showed no
change. He was therefore given boost DXT to the
mediastinum. Over the next few months the mass shrank. He
has therefore been classified as a non-responder but he
remains well with no other evidence of disease and on no
treatment 25 months post ABMT.
DISCUSSION
g
Appelbaum et al, 1981 , used high dose chemoradio-
therapy followed by syngeneic bone marrow transplantation
in 8 patients with disseminated NHL who failed
conventional combination chemotherapy. 7 achieved a CR, 2
1 1 3
have relapsed and one died of Pseudomonas pneumonia
whilst still in CR. 4 remained in CR at the time of
reporting, 12, 21, 32 and 126 months post transplant.
7
Appelbaum et al, 1983 , following the success of
intensive chemoradiotherapy and a syngeneic graft used
allogeneic transplantation in 20 patients with
intermediate and high grade NHL1s who had failed on
conventional chemotherapy regimens. There were 14 CR's, 4
NR1s and 2 early transplant related deaths. 4 patients
remain in CR at 6, 8, 27 and 65 months, 4 have relapsed
and 6 further patients have died of transplant related
complications.
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Phillips et al, 1984 , reported the use of high dose
cyclophosphamide and TBI followed by ABMT in 27 patients
with malignant lymphoma; 24 NHL: 3 HD. 15 patients
achieved a CR (56%) 5 of whom remain in CR 19-71 months
post ABMT. There were 6 transplant related deaths 3 from
interstitial pneumonitis, 2 from sepsis and one due to
congestive cardiac failure.
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Verdonck et al, 1985 , used a similar regimen with
ABMT in 14 patients. 8 of whom had relapsed or had
primary resistant disease and 7 of these attained a CR.
The remainder were patients with a bad prognosis who were
treated as consolidation during first or second CR. Only
one of the patients treated for relapsed or resistant
disease remains in CR at 28 months, one died of sepsis
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and the others of recurrent lymphoma. 5 of the patients
treated as consolidation remain in CR 7-31 months post
ABMT. The other patient died of acute myeloid leukaemia
which may have been secondary to his previous treatment.
This series demonstrates not only less toxicity for ABMT
than allografting but also a possible benefit from using
the treatment earlier in the course of the disease in
fitter patients.
Our early results in this study demonstrated that in
patients with lymphoma resistant to conventional therapy,
very high dose chemotherapy could still produce
significant responses and even complete remission in some
cases. These responses were not in general sustained. We
have therefore tried to use the very high dose
chemotherapy regimes earlier in the course of the
disease. The success of this strategy can best be
demonstrated by comparing the results of patients
regarded as being in resistant relapse (RR) with those
treated whilst still thought to be responding (non-
resistant relapse, NON RR). 10 patients classsified as
being in RR were treated with our intensive chemotherapy
regimes followed by ABMT and only 1 achieved a CR and 1 a
PR, there were 6 non-responders and 2 early deaths. We
have treated 11 patients regarded as having a poor
prognosis with the high dose chemotherapy when they were
still responding to conventional therapy, NON RR, and
they have an improved response rate. Two of the eleven
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patients treated died septicaemic deaths, but of the 9
evaluable patients, 7 achieved a CR and 2 a PR (Figure
13). These patients are only recently treated with the
protocol and whether the treatment will produce long-term
survivors or even longer survival than the previous more
conventional protocols cannot yet be assessed.
The ability of this type of treatment to prolong DFS
may be assessed by considering the outcome in the first
12 patients we treated with the UCH I and II, and BEAM
protocols. There was a total of 3 CR's and 2 PR's. The 3
CR's relapsed 2, 7 and 9 months post ABMT and are now
dead. Of the 2 patients designated as PR because of
apparent residual abdominal disease on CAT scanning, one
patient (UPN 65), who received boost DXT post ABMT and no
further treatment, remains alive and well 42 months post
ABMT and the other patient (UPN 101 ) has had a laparotomy
at which residual disease was detected but he continues
well after further treatment 28 months post ABMT. The
patient treated as a CHOP failure in this group (UPN 126)
and designated NR because of no change on the CAT scan
post ABMT, received boost DXT to the mediastinum with
gradual resolution of the residual mass over the
following months, he remains well on no treatment 26
months post ABMT. It is sometimes difficult to determine,
with CAT scanning, whether a residual mass represents
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Figure 13. Survival in NHL: RR vs NON RR.
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In the 9 patients treated since then, 8 patients
although relapsed have been treated with the protocol as
second or third line therapy, where DXT had already been
employed. Only one was a patient with resistant relapse.
There were 5 CR's, 2 have already relapsed day 41 (CNS
relapse) and day 118, the three others remain in CR 6, 6
and 7 months post ABMT. One patient who only acheived a
PR has already died of disease 7 months post ABMT. Three
of the patients were non evaluable because of early
deaths.
The morbidity in this series has been high. To improve
upon these results it will be necessary to proceed to
ABMT at an earlier stage in the disease process when the
patients are in better clinical condition and have less
resistant disease. This strategy of bringing forward high
dose therapy to an earlier stage of the disease has been
successful for allogeneic bone marrow transplantation in
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AML (Thomas ED, 1983) , but the situation is more
complex for the lymphomas. Unlike AML some patients with
NHL, can be cured by much safer initial therapy. It is
therefore important to try and define patients with a
poor prognosis. In the disseminated Stage III/IV NHL with
aggressive histology, those patients not in CR after 3
courses of CHOP have a very poor prognosis with <10%
long-term survivors, (BNLI CHOP study - unpublished data)
and such patients should be considered for alternative
therapy such as ABMT at this stage. We have only used
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intensive chemotherapy with ABMT rescue in one such
patient who had minimal morbidity from the procedure,
achieved a CR and is now 6 months post ABMT on no
therapy. Her results are not included further in this
1 01
report. In the study reported by Philip et al, 1983 ,
it should be noted that whereas all 4 patients treated
with resistant disease died within 90 days, 5 out of 9
patients grafted because of early failure to obtain a CR
or in a second complete remission, are alive at 100-900
days.
In this and other studies of autologous bone marrow
transplantation in lymphoma (Philip et al, 1983; Phillips
128 130
et al, 1984) ' the marrows were not infiltrated as
determined by morphological criteria, but clearly the
presence of occult disease cannot be excluded. This
anxiety has prompted some groups to 'purge' the harvested
bone marrow of potentially malignant B cells in cases of
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B cell NHL (Nadler et al, 1984) . However, in this
130
study and that of Phillips et al, 1984 , the main cause
of failure in patients with NHL, was primary resistance
to the high dose therapy used, and in those responding
patients who relapsed, the relapses were mainly localized
to a site of previous lymphomatous involvement.
This study thus shows that in patients with advanced
relapsed NHL, resistant to conventional dosage
chemotherapy very high dose chemotherapy and ABMT may
1 1 9
still produce a significant anti-tumour response. The
morbidity and relapse rate have been high and it is clear
that future studies of very high dose chemoradiotherapy
must be directed at poor prognosis patients in an earlier





Localized Hodgkin's disease (HD) is today a disease
that is curable by radiotherapy in the majority of cases
185
(Weller et al, 1976) even a fair proportion of
patients presenting with advanced HD will be cured by
52
combination chemotherapy (DeVita et al, 1980) . In 1954,
however, HD was still described as "a progressive
111
condition leading inexorably to death" (Lumb GD) .As
72
early as 1922, Gilbert began to administer increased
doses of radiation, not only to involved lymph node
chains but to cover entire chains not obviously involved
by the disease and he reported long-term survival without
recurrence in a few cases. Both his and similar reports
(Baker & Mann, 1 939; Slaughter & Craver, 1942)^^ #^161
which also appeared in the literature after surgical
extirpation or surgery and radiotherapy were not accepted
as cures because of the recognition of isolated cases of
HD which can pursue an unusually benign course consistent
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with survival for many years (Stout AP,1949)
Jelliffe & Thomson (1955)94, Peters & Middlemiss
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(1957) , Kaplan HS (1962) and others demonstrated a
dose-response curve for radiation therapy in HD. Kaplan's
study at Stanford University established that doses in
excess of 3,600 and less than 4,500 rads could cure most
patients with stage IA and IIA disease and this
observation has been confirmed in many later studies.
Much of the advance in treating HD with radiotherapy was
made possible by the improvements in radiotherapy
equipment and techniques.
Various compounds including iron, arsenic, vitamins
and cod-liver oil had been used in the treatment of HD
9 2
since 1823 (Hoster & Dratman, 1948) but none had
consistently improved the disease. In 1946, Goodman and
7 6
associates reported the first clear evidence of
response in some patients with advanced HD when treated
49
with nitrogen mustard. DeVita et al, 1965 were the
first to use four agents in the management of advanced
HD. They reported an 80% complete response rate for the
combination of nitrogen mustard, vincristine,
methotrexate and prednisone (MOMP)in a single cycle. From
this pilot study they went on to develop the MOPP
50
combination (DeVita et al, 1970) in which methotrexate
was replaced by procarbazine. Patients were treated with
6 cycles and then followed in unmaintained response. The
initial complete response rate was 81 % and at the time of
initial reporting the median duration response was not
reached but likely to be between 29-42 months and the
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median survival had not been reached with a minimum
follow up of 32 months. This represented a monumental
turn of events in the treatment of advanced HD where
after 6 months of chemotherapy 47% of those at risk for
four years had been continuously free of disease. These
results have now been confirmed in many other centres
(Frei et al, 1 973; Case et al, 1 977)^'^ and no other
combination has yet been produced which demonstrates
significantly better results (Bonadonna et al, 1975;
McElwain et al, 1 977)^'^^.
Frei et al, 1 973^ not only confirmed the early MOPP
results in patients with advanced HD but randomized
patients who achieved a complete response to one of two
treatment arms. One received no maintenance after 6
cycles of MOPP and the other continued with MOPP given at
two monthly intervals for 2 years. The complete response
duration curve for maintained patients was always above
that for unmaintained patients. 55% of patients receiving
only 6 cycles were still in remission 2 years after
treatment whereas 77% of patients treated for 2 years
were in CR 2 years later. However, with follow up past
240 weeks, there is no statistically significant
difference in survival of the complete responders. The
explanation is that patients who relapsed after only 6
courses of MOPP had a 77% chance of achieving a second CR
on retreatment with MOPP but in contrast all of those who
relapsed after 15 cycles failed to be reinduced with
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MOPP. This is a recurrent observation in the management
of MOPP failures.
Their study also showed an excellent correlation
between the sites of the largest masses of tumour before
MOPP treatment and the site of initial recurrence, this
being consistent with relapse of residual tumour rather
than reinduction of disease.
With the improvement in the prognosis of patients with
HD and the recognition of contiguous spread of disease it
became necessary to develop staging procedures to
identify accurately patients who might be cured by
radiation alone thus avoiding the increase in morbidity
associated with chemotherapy or combined modality treat¬
ment. The use of the Ann Arbor staging classification
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(Carbone et al, 1971) including the use of laparotomy
to pathologically stage patients in clinical trials over
many years has revealed that even this is not enough and
other prognostic indicators within any stage may also
influence the outcome eg the bulk of mediastinal
involvement in patients with Stage II disease is vital to
determining whether or not the patient may be cured by
radiation alone. Radiotherapy alone in patients with
Stage IB and IIB disease has been reported to be followed
by a 20% relapse rate, the majority in unirradiated sites
(Goodman et al, 1 977; Rosenberg et al, 1 978 )^'^^.
However, the British National Lymphoma Investigation
1 24
(BNLI) studies have reported that only 25% remain free of
O r
recurrence at 5 years (Haybittle et al, 1985) . Hellman
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et al, 1978 , attempted to increase relapse free
survival by combining MOPP chemotherapy with radiotherapy
in these patients. The alternative is to treat with MOPP
at the time of relapse when half of these patients may be
expected to remain disease free with two thirds surviving
3 years after induction of the second complete response
185
(Weller et al, 1976) . Initial treatment morbidity is
less with this approach and approximately 90% of the
total group may achieve extended disease free survival.
Patients relapsing after combination chemotherapy do
not respond as well to further courses. Attempts have
been made to produce non-cross-resistant chemotherapy
20
regimes. Bonadonna et al, 1975 , developed the regime
ABVD (adriamycin, bleomycin, vinblastine and imidazole
carboximide) which when used in previously untreated
patients produced a CR rate of 75% which was equivalent
to MOPP. When used in patients who have failed induction
therapy the results with ABVD have been variable with a
good overall response rate of 37-70% but with a CR rate
of only 4-40%. Patients who are primary induction
failures respond less well than patients who relapse
after a CR no matter how short that remission lasted.
However, even in studies showing a good response rate,
remission duration is short and ABVD does not appear to
be an effective curative regimen for patients with HD who
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have failed MOPP (Case et al, 1977; Krikorian et al,
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1978) ' It is because of this inability to produce
significant long-term survival after MOPP failure and the
failure of maintenance therapy to improve disease free
survival, that efforts have been made to intensify the
initial induction therapy. Non-cross-resistant combin¬
ations such as ABVD, have therefore been used either
sequentially or in an alternating sequence with MOPP for
21
induction therapy (Bonadonna et al, 1978) and latterly
these two regimes have been used in a hybrid form for
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induction (Klimo & Connors, 1985) but at present
numbers of patients are small and no clear survival
advantage has yet been demonstrated.
Intensification of induction regimes means that
patients who would have achieved a CR and long-term DFS
on conventional chemotherapy with MOPP are being
submitted to regimens with increased morbidity, therefore
attempts to identify these patients and prevent
unnecessary treatment of good prognosis patients has
become increasingly important. One very poor prognosis
group which has been identified by the BNLI study group
is a very small subgroup of patients with lymphocyte
depleted HD these patients appear to have only a 10%
long term survival (BNLI study unpublished data) and
would therefore be eligible for inclusion in a trial of
intensive induction chemotherapy.
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Patients with advanced HD are now treated mainly by
MOPP combination chemotherapy or an equivalent regimen as
primary treatment, up to 80% will achieve a CR, but
approximately 30% of these patients will relapse (DeVita
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et al, 1980) . Only a small proportion of the 20% of
patients with primary MOPP resistance will achieve a CR
with the use of an alternative non-cross-resistant
regimen such as ABVD. Patients who relapse after MOPP
chemotherapy may also achieve a second CR after ABVD or
similar non-cross-resistant regimen but only 20-25% of
these patients are likely to be disease free 3 years
after finishing therapy (Santoro et al, 1982; Tannir et
al, 1 983 )1 51 '167.
In an effort to improve the CR rates and reduce the
relapse rates regimes which alternate non-cross-resistant
regimens eg MOPP/ABVD from the start of treatment are now
used by many centres. These have produced an improvement,
as might be expected, but have resulted in less success
with salvage regimens upon relapse (Santoro et al,
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1984) . One of the more successful salvage regimens
following primary resistance to MOPP and ABVD or relapse
after treatment with MOPP and ABVD whether given
sequentially or alternately, is CEP (CCNU, Etoposide,
22
Prednimustine). Bonadonna et al, 1985 , reported a CR in
35% and a PR in a further 25%. Median duration of relapse
free survival was 17 months and survival in CR >30
months.
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It is because of the poor response rate and long-term
DFS of conventional salvage regimens that we have
employed intensive chemoradiotherapy regimes as salvage
therapy using autologous bone marrow rescue to ameliorate
the severe myelotoxicity thus produced in heavily
pre-treated relapsed patients with HD.
It is in the context of primary resistance or relapse
in these patients who have already received fairly
intensive treatment, many of whom will also have had DXT,
that intensive chemoradiotherapy with marrow rescue,
whether allogeneic, syngeneic or autologous must be
viewed.
PATIENTS
Fifteen patients with Hodgkin's disease, have been
treated between August 1982 and August 1985 with this
form of therapy. They were 13 males and 2 females. The
median age was 29 years (range 13-55 years). 14 patients
had received more than one chemotherapy regime and 11 had
received anthracycline-containing combinations. 9
patients had also received radiotherapy. For the purposes
of classification of disease at the time of grafting
'resistant relapse' (RR) indicates that the patient had
progressive disease in spite of conventional chemotherapy
whilst 'non resistant relapse' (NON RR) indicates that
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the patient although relapsed was still responding to
either second, third or fourth line therapy, or that the
high dose chemoradiotherapy regime was employed as the
second line regime at the time of relapse. Further
details are given in Table 20.
BONE MARROW HARVESTING, CRYOPRESERVATION AND REINFUSION
Bone marrow was harvested, cryopreserved and reinfused
as previously described (Chapter 2; Linch et al,
1 07
1 982) ' .
Bone marrow was harvested at relapse in 14 patients
and at diagnosis in the remaining patient. The mean
number of nucleated cells frozen per kg body weight was
1.62x10^ cells/kg (range 0.7-3.3x10^ cells/kg). The
marrow was stored in liquid nitrogen for a median of 13
days (range 5-749 days) between harvesting and reinfusion
of the first aliquot.
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TABLE 20. PATIENT CHARACTERISTICS : HODGKIN'S DISEASE
UPN AGE SEX HIST CLASS DIAG PREVIOUS STATUS ABMT STATUS DFS CURRENT
ST § DIAG ->ABMT TREATMENT AT ABMT CHEMO POST ABMT STATUS
61 55 M NS / III 52 MOPP X 6 RR UCH I&II CR DEAD 8
BACOP X 5




99 37 M NS / IA 65 LOPP RR UCH I NE DEAD day
ABVD
DXT X 2
113 46 M NS / IIIB 15 MOPP X 3 RR UCH I CR 29 + A S W
AVD X 5
116 24 F NS / HAS 22 MOPP X 3 RR UCH I CR DEAD day
CCNU/Bl/Vbl
/P X 6
1 46 25 F NS / IIA 25 LOPP X 6 RR TBI 875 PR DEAD 3
EVAP X 7
DXT





185 1 3 M MC / IVB 15 BACOP/ NON RR TBI/CYCLO CR 3 REL 8
OPEC X 4
124 29 M ATYPICAL 7 CHOP X 1 RR BEAM CR DEAD day
/ IB HD ARA C X 1
146 25 F NS / IIA 25 LOPP X 6 RR TBI PR DEAD 3
EVAP X 7 875
DXT
155 30 M NS / IIA 32 BACOP/ RR BEAM CR 17+ A & W
OPEC X 3
DXT
170 30 M NS / IIIB 11 LOPP X 3 RR BEAM CR REL 14+
CCNU/BLEO/
Vind X 9
171 25 M NS / IIB 40 MOPP X 9 RR BEAM PR DEAD 7
EVAP X 8
DXT





180 25 M NS / IIB 25 MOPP X 6 RR TBI PR DEAD 5




185 13 M MC / IVB 15 BACOP/ NON RR TBI/ CR 3 REL 8 +
ATYPICAL OPEC X 4 CYCLO




188 30 M NS / ivb 19 LOPP X 9 NON RR BEAM CR 7 + A & W
DXT
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Legend for Table 20.
UPN = Unique patient number; HIST CLASS = Histological
classification; NS = Nodular sclerosing; MC = Mixed
cellularity; ST @ DIAG = Stage at diagnosis (This refers
to the Ann Arbor staging classification); DIAG -> ABMT =
The time interval between diagnosis and ABMT; PREVIOUS
TREATMENT: CHOP = Cyclophosphamide, Adriamycin, Vinc¬
ristine, Prednisolone; BACOP = Bleomycin, Adriamycin,
Cyclophosphamide, Vincristine, Prednisolone; DXT = Radio¬
therapy; EVAP = VP16, Vinblastine, Adriamycin, Prednisol¬
one; MOPP = Nitrogen Mustard, Vincristine, Procarbazine,
Prednisolone; LOPP = Chlorambucil, Vincristine, Procarb¬
azine, Prednisolone; CCNU/Bl/Vbl/P = Lomustine (CCNU),
Bleomycin, Vinblastine, Prednisolone; ABVD = Adriamycin,
Bleomycin, Vinblastine, Imidazole Carboximide; AVD =
Adriamycin, Vinblastine, Imidazole Carboximide; HD ARA C
= High dose Cytosine Arabinoside; OPEC = Vincristine,
Prednisolone, VP16, Cyclophosphamide; CCNU/Bleo/Vind =
Lomustine, Bleomycin, Vindesine; C/Vbl/Bl = Cyclophos¬
phamide, Vinblastine, Bleomycin; STATUS AT ABMT: RR =
Resistant Relapse; NON RR = Non Resistant Relapse; ABMT
CHEMO = ABMT Chemotherapy; STATUS POST ABMT: CR =
Complete Remission; PR = Partial Remission; NE = Not
Evaluable; NR = No Response; DFS = Disease Free Survival;
CURRENT STATUS: A & W = Alive and Well; REL = Relapse;




The treatment plan varied depending on the treatment
regimen to be employed. If the UCH double protocol was
employed then only one marrow harvest was performed and
g
providing that more than 1.2x10 nucleated cells/kg body
weight were obtained post processing the harvested marrow
was divided and half given after each course. If the
harvested marrow contained <1.2x10 cells/kg then a
second harvest was performed after recovery from ABMT I.
UCH II was given as soon as there was haematological
recovery from UCH I. Five patients received UCH I but
only 2 received UCH I & II. UCH II was not given either
because of septicaemic death following UCH I (UPN 99 &
116) or because having attained a CR after UCH I the
patient declined UCH II (UPN 113).
The BEAM protocol was used as a single ABMT protocol.
HIGH DOSE CHEMOTHERAPY REGIMENS
Two separate chemotherapy regimens were used; UCH I &
II and BEAM. Three patients received total body
irradiation (TBI) one with additional cyclophosphamide.
We decided to use the same regimen as for patients
with NHL as the combination chemotherapy employed should
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also produce a good response in patients with HD (Table
21 ) . To avoid the use of more than one protocol in the
unit we also adopted the BEAM protocol, for patients with
HD, when we entered the collaborative protocol with the
European centres for patients with NHL (Table 22).
Table 21. UCH I & II.
UCH I DAY 1 2 3 4 5 6 7
CYCLOPHOSPHAMIDE * * *
1.5 G / M2
BCNU
300 MG / M2
*
CYTOSINE ARABINOSIDE




1.0 G / M2
*
BCNU
300 MG / M2
CYTOSINE ARABINOSIDE
100 MG / M2
ABMT *
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Table 22. BEAM regimen.
DAY
MELPHALAN
1 40 MG / M2
BCNU
300 MG / M2
CYTOSINE ARABINOSIDE
100 MG / M2
VP 16
50 MG / M2
ABMT
1 2 3 4 5 6 7
*
*
In view of the sensitivity of HD to radiotherapy,
occasional patients who had not had prior radiotherapy
were treated with TBI. One patient received 10 grays TBI
together with 60 mg/kg of cyclophosphamide on each of two
consecutive days preceeding the radiotherapy. The other





Response to therapy was evaluated both clinically and
by repeat computed axial tomography (CAT) scanning where
previously abnormal. A complete remission was defined as
the complete resolution of all signs and abnormal
investigations in patients surviving beyond 30 days.
One patient with HD was non-evaluable because of a
septicaemic death at day 14.
The remaining 14 patients all showed a response, 11
patients (79%) acheived a CR. In two of these patients
marrow regeneration was delayed and these two patients
died in aplasia at day 40 and 51 (UPN 116 and 124
respectively). Post mortem examination showed foci of
necrosis without evidence of viable lymphoma. One patient
(UPN 61) died in CR (8 months post ABMT) of acute cardiac
failure of uncertain cause. Another 4 patients have
relapsed, 3 are alive on further treatment 36, 13 and 8
months post ABMT, the fourth patient died in relapse 42
months post ABMT. Four patients remain alive and in CR
29, 17, 7, and 7 months post ABMT. Three patients only
achieved a PR, they have since died with progressive
disease 3, 5 and 7 months post ABMT (Figure 14).
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Months
Figure 14. DFS in patients with HD who achieved a CR vs
total survival of the group.
Patients who achieved a CR (n=11) # #
All patients (n=15) 0 O
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DISCUSSION
The Seattle group who pioneered the use of bone marrow
transplantation in leukaemia, have treated 8 patients
1 0
with MOPP-resistant disease (Appelbaum et al, 1985) ,
with high dose chemoradiotherapy followed by an allograft
from an HLA identical sibling. 6 of these patients had
received other chemotherapeutic agents as well as MOPP
and 6 prior radiotherapy. All received TBI as part of the
conditioning regimen, 7 cylophosphamide and one
additional BCNU. 7 were thought to have achieved a CR. 5
died of complications, one patient relapsed at 4 months
and has since died and 2 (25%) remain in unmaintained CR
at 38 and 39 months. One of these survivors had
transplantation as the first treatment for relapse after
a MOPP induced CR of 6 months duration. This form of
treatment demonstrates a very high response rate for
MOPP-resistant disease and the authors suggest the
long-term survival is comparable or better than most
third line salvage regimens. However, in view of the high
morbidity, it may not compare favourably with second line
therapy for those who relapse after a long first CR (ie.
>12 months).
3 8
Carella et al, 1985 , reported the use of intensive
chemotherapy with ABMT rescue in 13 patients with HD who
either had primary resistance or who had relapsed after
MOPP/ABVD given either sequentially or alternately, many
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of whom had also received CEP and all of whom had had
previous mantle DXT. 8 (61.5%) acheived a CR and 2 a
PR. Much better response rates than any other
conventional salvage regimen. 2 patients relapsed at 3
and 4 months, 6 (39%) remain in CR 2-34 months post ABMT
on no treatment. In contrast to the allogeneic series
reported from Seattle there was only one toxic death.
35
Canellos GP, 1985 , has reviewed the use of BMT as
salvage therapy for advanced HD (which includes the
3 8
series of Carella et al, 1985) in which he cites 49
patients treated with a variety of intensive regimens
followed by ABMT. 25 (51%) achieved a CR, 10 (20%) of
whom remain alive in CR (2-48 months) post ABMT. Only 3
of this 49 patients were treated with TBI, because of the
high incidence of prior radiotherapy. One of the three
achieved a CR and one died of interstitial pneumonitis.
Most relapses occurred within 6 months.
Our early results in this study demonstrated similarly
that in patients with disease resistant to conventional
therapy, very high dose chemotherapy could still produce
significant responses. This was particularly noticeable
in the patients with relapsed resistant Hodgkin's
Disease, in whom 9 of the 13 evaluable patients achieved
a complete response. These responses were not in general
sustained (Figure 14). We have therefore tried to use the
very high dose chemoradiotherapy regimes earlier in the
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course of the disease.
Of the eleven CR's in patients with HD 7 patients are
alive but only 4 are still disease free 29, 17, 7 and 7
months post ABMT. 3 patients have died of procedural
related complications whilst in CR, infection in two and
cardiac failure in one. 4 patients have relapsed, 3 are
still alive on chemotherapy 36, 14 and 7 months post
ABMT, the other patient who relapsed died with
progressive disease 9 months post ABMT.
The morbidity in this series has been high although
not so high as following allograft (Appelbaum et al,
1 0
1985) . To improve upon these results it will be
necessary to proceed to ABMT at an earlier stage in the
disease process when the patients are in better clinical
condition and have less resistant disease. Most patients
with HD can be cured by much safer initial therapy. It is
therefore important to try and define patients with a
poor prognosis. In the BNLI LOPP/MOPP study in HD, 3
situations have been identified in which early ABMT might
be appropriate; i) no response to initial treatment; ii)
PR or relapse from first line treatment if other poor
prognostic features eg Grade II histology, Stage III or
IV disease, a high ESR and B symptoms are also present;
iii) all patients failing 2 modalities (either 2
chemotherapy regimens or chemotherapy and radiotherapy)
as 5 year survival is only 20% (D Linch, 1 986 )^®.
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In this and other studies of autologous bone marrow
transplantation in lymphoma (Philip et al, 1983; Phillips
1 ft 110
et al, 1984) ' the marrows were not infiltrated as
determined by morphological criteria, but clearly the
presence of occult disease cannot be excluded. However,
1 30
in this study and that of Phillips et al, 1984 , the
main cause of failure was primary resistance to the high
dose therapy used, and in those responding patients who
relapsed, the relapses were mainly localized to a site of
previous lymphomatous involvement.
This study thus shows that in patients with advanced
relapsed HD, resistant to conventional dosage
chemotherapy, very high dose chemoradiotherapy and ABMT
may still produce a significant anti-tumour response. The
morbidity and relapse rate have been high and future
studies of very high dose chemotherapy must be directed





LARGE UNSTAINED CELLS (LUC'S)
It was observed during the course of this study that
blood samples run on a Hemalog D90, often had a high
percentage of LUC's in the period immediately prior to a
detectable return of the WBC count. As this observation
if confirmed might be relevant to clinical decisions as
to whether or not to give the second half of a stored
marrow (eg. in lymphoma patients in this study) or for
allografted patients whether or not to reharvest the
donor, we investigated this finding (Martin et al,
115
1986) .
An elevated percentage LUC count was detected
following 105 transplant procedures. In only 2 cases was
a rise in the percentage of LUC's not detected. Serial
counts were available in 78 cases and in these cases the
mean peak LUC count was 19.3% +/- (SE) with a range of
3.2-56.8%.
The relationship of the rise in total white cell count
to the rise in percentage LUC's is shown for all 105
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cases in which a rise occurred (Figure 15). In 72% of the
78 cases in which serial data was available, the rise in
LUC's preceeded the rise in WBC by an average of 4 days.
In 23 further cases in which the serial data is
incomplete but evaluable in this respect, 20 also showed
a rise in the percentage of LUC's predating the rise in
WBC. In 17% the rise in LUC's and WBC were simultaneous
and in only 8% of cases did the rise in WBC predate the
rise in LUC percentage. The relationship between the rise
in percentage LUC's and the rise in total WBC was similar
for both the allografts and autografts (Table 23). The
rise in percentage of LUC's predated the rise in WBC by
an average of 4.0 days in patients with acute leukaemia,
3.0 days in patients with lymphoma, 4.1 days in patients
with solid tumours and in the patients allografted was an
average of 3.9 days.
Table 23. Relationship of rise in WBC to rise in the %
of LUC's.
TYPE OF BMT FOLLOWED COINCIDED PRECEEDED NO RISE
ALLOGENEIC 11 8 0 2 1
AUTOLOGOUS 67 48 13 5 1
TOTALS 78 56 13 7 2
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Days
Figure 15. Appearance of total WBC and LUC's in the blood
following allogeneic and autologous BMT.
+ Total Leucocytes
0 % LUC's




Two patients showed regeneration of leucocytes without
a rise in percentage of LUC's. One of these patients had
ALL and was thought to have suffered from opportunistic
lung infection. The other was a patient treated with a
double cycle of high dose cyclophosphamide for small cell
carcinoma of the lung. She suffered from a systemic
Candida infection in both cycles.
In only 2 cases in which a rise in the percentage of
LUC's was noted was there failure of the WBC to rise. In
one case this was due to death from an intra-cerebral
haemorrhage on day 12 at a time when the percentage of
LUC's was rising but the WBC had not risen above
0.3x10^/L. In the other case the percentage of LUC's rose
to a peak of 22% on day 19 and then fell back to the
normal range by 28 days. This patient developed an
Aspergillus pneumonia during the regeneration period and
died on day 33 without a leucocyte count ever rising
above 0.3x10^/L.
The significance of these unusual patterns of LUC
recovery is not clear.
Six patients received repeated granulocyte infusions
for uncontrolled sepsis early after transplantation
before evidence of regeneration. In no instance was there
a rise in the percentage of LUC's detected.
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THE NATURE OF LUC's
Careful inspection of blood films with very high
percentage LUC counts, during the early regeneration
period, reveals that these cells are large mononuclear
cells, often with indented nuclei showing some chromatin
condensation but no nucleoli. They have moderate
quantities of faintly basophilic cytoplasm which contains
no obvious granules. These cells most commonly resemble
monocytes, but LUC's are by definition non-specific
esterase (NSE) and peroxidase negative. The NSE
negativity has been confirmed by manual techniques.
Furthermore, adherence for 1 hour to plastic, of ficoll
hypaque separated mononuclear cells, did not reduce the
percentage of LUC's as determined by re-analysis on the
Hemalog D90 in two cases tested.
In four further cases, adherent cell depleted mono¬
nuclear cells containing more than 10% LUC were pheno-
typed with a range of monoclonal antibodies. The
predominant cell type present was a CD8+ T cell (mean
CD3% = 47%, mean CD8% = 42%). B cells as detected by
anti-Bl represented only 3.5% of cells. There were no
monocytic cells detected by staining with UCHM1 or Leu
M3.
In one case over 20% of all leucocytes prior to
separation were LUC's. Mononuclear cells from this
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patient were analysed on a fluorescent activated cell
sorter (FACS IV) and 34% of cells were found to be large
cells distinct in size from a typical lymphocyte (Figure
16a). Analysis of the fluorescence profiles revealed that
virtually all large cells were CD3+ CD8+ T cells (Figure
16b and 16c). Approximately half the large cells
expressed HLA-DR antigens (Figure 16d). This CD3+ CD8+
phenotype of the large mononuclear cells in the early
regenerative period was confirmed in 5 further cases by
immuno-histological staining of blood smears.
1 46
»i r.#-.




-,v" ■■'■/ •; * ' - ..





anti CD8 anti HLA-DR
Light Scatter (Size) »-►
Figure 16a,b,c,d. Size and fluorescence profiles of




The time taken for haematological recovery until a
g
total WBC count of >1.0x10 /L, a neutrophil count of
9 9
>0.5x10 /L and a platelet count of >50x10 /L is shown in
Table 24.
All, except six patients, eventually achieved a
g
platelet count of >100x10 /L. Two of the six patients who
failed to get full recovery died before evidence of re¬
generation, one regenerated with relapsed disease and 3
patients who were treated after first relapse, achieved a
g
CR but their platelet counts were still <100x10 /L at the
time they relapsed again.
The longer recovery time of patients with AML did not
reach statistical significance, although delayed haemato¬
logical recovery was the main reason for patients with
AML failing to proceed to ABMT II.
Recovery of all parameters was statistically delayed
after the second autograft (Table 25).
Assays of the GM CFC did not predict the speed of
haematological recovery in this study (Table 26).
1 48
Table 24. The mean time in days for haematological




TOTAL WBC >1.0 X 1 09/L 1 9 1 1 -40 n = 42 * / **
NEUTROPHILS >0.5 X 109/L 23 1 2-52
PLATELETS >50 X 109/L 36 13-228
ALL RANGE AML RANGE
n = 18 ** n = 24 *
TOTAL WBC >1.0 X 109/L 1 7 1 1 -28 21 i o
NEUTROPHILS >0.5 X 1 09/L 20 1 2-42 26 1 6-52
PLATELETS >50 X 109/L 25 1 3-71 44 17-228
There is no significant difference between AML and ALL.
p > 0.05 < 0.1
* One patient died day 12 before recovery and is not
included
** A further patient's WBC is included but he died before
platelet recovery
1 49
Table 25. Comparison of haematological recovery ABMT I
VS II
AML ( n = 8 )
ABMT I ABMT II
TOTAL WBC >1 .0 X 109/L 18 26 P <0.05
NEUTROPHILS >0.5 X 109/L 21 30 NS
PLATELETS >50 X 109/L 27 42 P <0.01
ALL ( n = 11 )
ABMT I ABMT II
TOTAL WBC >1.0 X 109/L 1 7 21 P <0.01
NEUTROPHILS >0.5 X 109/L 20 24 P <0.05
PLATELETS >50 X 109/L 22 35 P <0.01
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Table 26. Comparison of GM CFC with haematological
recovery : ABMT I VS II*
GM CFC TOTAL WBC NEUTS PLATELETS
>1 X 109/L >0.5 X 109/L >50 X 109/L
I II I II I II I II
GM CFC HIGHER IN ABMT I
1.09 0.87 13 25 17 32 28 51
1.66 1.28 12 13 20 17 17 26
3.49 1.69 17 31 18 36 35 36
6.23 0.94 21 33 21 33 21 47
6.32 3.89 13 18 14 18 20 34
6.9 3.09 20 26 31 28 33 45
MEAN 4.28 1.96 16 24 20 27 26 40
GM CFC HIGHER IN ABMT II
0.69 1.42 18 32+ 19 32+ 22 32+
3.06 3.6 20 25 27 25 26 28
4.49 6.44 14 17 20 28 20 35
9.66 10.46 28 24 39 35 39 49
13.62 15.04 19 26 21 26 33 45
1 2.54 1 5 1 4 1 6 1 6 1 4 20 26
MEAN 7.34 8.66 19 23 24 27 27 38
* 12 patients who had adequate marrow aliquots stored to
allow the assays to be run concurrently.
1 51
lymphoma
31 out of 36 patients survived beyond 30 days and were
evaluable for haematological recovery. Two patients had
not shown haematological recovery at the time of their
deaths at days 40 and 51. In the 29 remaining patients
the mean time from the day of ABMT to achieving a
g
neutrophil count of >0.5x10 /L was 21 days (range 13-34
g
days) and a platelet count >50x10 /L was 26 days (range
12-43 days). Among these patients there was no
relationship between the number of nucleated cells
infused and the time to recovery of the neutrophil and
platelet count.
In the two patients surviving beyond 30 days who did
not regenerate the number of nucleated cells infused was
0.85x10^ cells/kg and 0.7x10^ cells/kg which was well
O O
below the mean of 1.67x10 cells/kg (range 0.36-3.3x10
cells/kg). These patients both had Hodgkin's disease and
had been heavily pre-treated. With increasing numbers of
patients there appears to be a more prolonged time to
recovery in patients treated for HD although the mean
O
nucleated cell count is similar: 1.62x10 cells/kg and
O
1.64x10 cells/kg in patients with HD and NHL
respectively. Further details are given in Table 27.
All patients surviving the procedure achieved a
platelet count of >100x10^/l except for one patient who
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only achieved a PR and whose disease progessed before
full recovery.
Table 27. The mean time in days for haematological
recovery: Lymphoma (Day 0 = Day of marrow reinfusion).
ABMT I ONLY NHL* RANGE HD** RANGE
(n = 17) (n = 12)
TOTAL WBC >1.0 X 109/L 14 11-26 20 10-32
NEUTROPHILS >0.5 X 109/L 19 13-29 25 13-34
PLATELETS >50 X 109/L 23 14-38 29*** 13-43
* Four patients died before recovery day 3, 5, 9 & 15,
their results are not included
** Three patients died before recovery day 14, 40 & 51,
their results are not included
*** Two further patient's WBC is included but both
progressed and died before platelet recovery.
DISCUSSION
An unexpected result of our study is the difference
emerging between patients with AML and ALL in
haematological recovery although in the small numbers in
the study it fails to reach statistical significance.
This difference has also been noted in the EBMTG study
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(Gorin & Aegerter, 1986) . A difference in our study was
also noted in the rise in the percentage of LUC's in
patients with ALL, with an apparent reduction in the
rise, when compared to the results of patients with AML.
If all the available LUC results for these two patient
groups are compared, then patients with AML (n = 23
transplant procedures) showed an average rise in the
percentage of LUC's to 22% (range 6.4-45.9%), four days
before a demonstrable rise in the total WBC count, whilst
patients with ALL (n = 14 transplant procedures) only
showed an average rise to 15% (range none-29.2%), two
days prior to a demonstrable rise in the total WBC count.
These observations include both ABMT I & II results, but
using a t test to compare the average rise in the
percentage of LUC's p<0.05. If ABMT II results are
excluded the average for the AML patient group is still
significantly higher than that of the patients with ALL
(p<0.05) (AML n = 16; ALL n = 8). The relevance of this
observation is not clear.
g
The mean nucleated cell count was 1.9x10 cells/kg and
g
1.98x10 cells/kg in patients with AML and ALL
respectively.
Assays of GM CFC have been reported (Spitzer et al,
1980) to offer some predictive value in relation to
numbers of stem cells present in the harvested bone
marrow and the length of time to haematological recovery
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post autografting. In those patients who have had a
double ABMT, we have the unique opportunity of comparing
results following 2 transplants in which the same
conditioning regimen was given pre ABMT on each occasion
to the same individual. There is no consistent difference
between the number of GM CFC obtained in the first and
second harvest (Table 26). In all except one patient the
time to recovery of total WBC to >1.0x10 /L was prolonged
after the second ABMT compared to the first and the time
to recovery of platelets to >50x10^/L, increased in all
patients without exception. Neutrophil recovery to
Q
>0.5x10 /L, was variable but separate analysis shows the
changes did not coincide with the change in GM CFC.
A rise in the percentage of LUC's counted on the
Hemalog D 90 appears indicative of successful engraftment
following bone marrow transplantation. In 72% of cases
this rise can be detected before the rise in total WBC
count (ie. >0.3x10 /L) can be reliably measured on the
Coulter counter. In these cases the rise in percentage of
LUC's is detected an average of 4 days before the
leucocyte rise. In only one case, surviving long enough
for evaluation, was a rise in the percentage of LUC's not
followed by subsequent engraftment. This patient had
developed a fungal pneumonia and it is likely that this
caused toxic suppression of the graft after early
engraftment had already commenced. Serial marrow biopsies
were not performed and firm support for this hypothesis
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that the percentage rise in LUC's predicted impending
myeloid engraftment is lacking. This information is
frequently of value to the clinician, particularly when
engraftment is slow, the patient sick and reinfusion of
further marrow is being considered. This applies to
allografts and autografts in which only half the
harvested marrow has been reinfused (lymphoma protocol in
this study). It is in this context worthy of note that
granulocyte transfusions did not cause a rise in the
percentage of LUC's which might have been falsely
interpreted as evidence of engraftment. The kinetics of
early engraftment were similar in autografts and
allografts regardless of the underlying disease, although
Q
the time to reach 0.5x10 /L neutrophils in the peripheral
blood was delayed in patients with acute leukaemia
receiving autografts (24.3 days in patients autografted
for acute leukaemia compared to 11.4 days in the
remainder).
The LUC's, although of monocytoid appearance, are
shown to be T lymphocytes of the CD8+ subset (See earlier
this Chapter). It has previously been reported that CD8+
lymphocytes predominate in the peripheral blood after
both autologous and allogeneic marrow transplants (Linch
108
et al, 1983) and it is now apparent that in the
majority of cases this type of lymphocyte is among the
first to appear in the blood. It is possible that this
initial T cell expansion may facilitate myeloid
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engraftment. There is some evidence that extensive T cell
depletion of donor marrow for the prevention of GVHD may
lead to delayed engraftment and even graft failure in
180
some cases (Waldmann et al, 1984)
The delay in haematological recovery following ABMT I
in patients with AML has been the major reason for our
deferring patients who would otherwise have been eligible
to proceed to ABMT II (Table 5, Chapter 3). This has
resulted in only eight patients (33%) with AML receiving
both ABMT I & II, whilst eleven (61%) of patients with
ALL have received both ABMT I & II. Although the delay
has failed to reach a statistical significance when
compared to the recovery of patients with ALL, we regard
this as the major toxicity of our double ABMT approach to
the treatment of patients with AML in first remission.
The prolonged thrombocytopenia which may follow
74
(Goldstone et al, 1986) has been particularly worrying
and has been associated with haemorrhagic complications
including two deaths after WBC recovery, both from a
cerebral haemorrhage (patient details not included in
this study).
We have studied some of these patients for auto¬
antibodies but have not demonstrated any platelet auto¬
antibodies. Bone marrow aspirates and trephines suggest a
reduction in cellularity is more likely to be responsible
for the slow recovery seen in some patients.
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The haematological recovery following ABMT in patients
with NHL and HD is similar to that occurring after ABMT
in patients with leukaemia. There is a tendency for
patients with HD to take longer to regenerate than
patients treated for NHL but this does not reach
statistical significance. The nucleated cell count
g
returned in each group was similar; 1.64x10 cells/kg in
g
patients with NHL and 1.62x10 cells/kg in patients with
HD. The longer regeneration in patients with HD may
reflect their heavier prior treatment when compared to
the patients with NHL.
There has been no failure to graft in either the
patients treated for leukaemia or NHL, but there have
been two patients with HD who have died in aplasia day 40
and 51. One patient (UPN 116) was treated with UCH I and
the other (UPN 124) with BEAM. They both received
nucleated cell counts in the lower range; 0.7 and
0.85x10 cells/kg. It is therefore possible that this
contributed to both their deaths. This is the reason we
g
now recommend a minimum of 1.0x10 cells/kg body weight
should be stored before the patient proceeds to
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autograft. Interestingly, AH Goldstone, 1986 , reporting
the collective EBMTG study results, found that the
nucleated cell count was the only factor analysed which
correlated with overall survival in patients with HD,
post ABMT. This was no longer significant if patients who
died procedure related deaths were excluded, suggesting
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low cell yields at marrow harvest in these patients may
be a significant problem associated with the use of ABMT
in patients with HD, and may contribute significantly to
an increase in morbidity.
If high dose chemoradiotherapy is to be successful in
Hodgkin's disease, it will need to be used earlier in the
course of the disease, when the marrow is more likely to
be cellular, thus avoiding low cell yields at marrow







Patients remained as in-patients at University College
Hospital for an average of 37 days, during treatment and
recovery post ABMT. In spite of the greater delay in
haematological recovery post ABMT for AML, the time in
hospital was similar for both groups: 34 days for ALL
compared to 36 days for AML. The 5 patients treated in
relapse stayed an average of 44 days, which probably
reflects their poorer physical condition at the time of
treatment. The average in-patient stay during ABMT I and
II for those who had both (17 patients), was 31 and 41
days respectively.
Blood product support was similar in both AML and ALL,
with a greater amount being required for patients
undergoing ABMT II. There were too few patients treated
as reinduction to note a significant difference. The
number of units of blood required to support patients
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undergoing ABMT I & II was 8 and 12 units respectively,
and the number of units of platelets required 74 and 93.
Delay in haematological recovery was the main reason
for not proceeding to ABMT II. As might be expected, the
number of units of blood and platelets required during
ABMT I by those patients who proceeded to ABMT II were
less than the number of units required by those who had
ABMT I only. Patients who had ABMT I & II required on
average 7 units of blood and 56 units of platelets each
during ABMT I, whilst those who had only ABMT I required
9 units of blood and 92 units of platelets each.
In 9 out of 50 procedures (18%), normal donor
granulocytes were collected and given because of severe
sepsis. In the same number other blood products were
required, eg. FFP during bleeding episodes. There was no
difference between AML and ALL, or between ABMT I and II.
Blood products were not irradiated prior to reinfusion
but no patient in this series developed evidence of
clinically recognisable GVHD.
All except 3 patients became pyrexial with their
temperature rising to >38 during either ABMT I or II.
The average number of days patients had a temperature
>38.0^C during ABMT I and during ABMT II was 9 and 8 days
respectively.
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The average number of antibiotics used in each patient
to treat pyrexial/infective episodes was five (this
included acyclovir, metronidazole and intravenous
amphotericin) in all groups. Only one patient required no
antibiotic therapy during ABMT I.
Weight loss was a common problem, averaging 5.7 kg in
patients with both AML and ALL; parenteral nutrition was




5 patients died during the procedure; 2 during ABMT I
and 3 during ABMT II. Four were thought clinically to be
infective deaths as there was rapidly progressive
pulmonary shadowing and fever, with death occurring at
days 23, 25, 28 and 32. All four patients had ALL. One
was proven due to aspergillus fumigatus. The other three
had no organism isolated. Post mortem changes were
consistent with the adult respiratory distress syndrome
but were not specific for any infective organism, drug
toxicity cannot therefore be excluded.
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One patient developed an aspergilloma during ABMT II
from which she eventually recovered (UPN 69) another
patient developed a Candida septicaemia from which she
also recovered (UPN 51), both these were also patients
with ALL. No patient with AML developed a proven systemic
fungal or yeast infection or died an infective death.
By contrast, Gram negative infections appeared more
common in the patients with AML than in the patients with
ALL (Table 28). There were ten episodes of gram negative
septicaemia in the 32 autograft procedures (31%)
performed in patients with AML and only three episodes in
the 29 procedures (10%) performed in patients with ALL. A
further three patients with AML developed an ecthyma
gangrenosum with pseudomonas isolated. Only one patient
with ALL developed an abscess from which pseudomonas was
isolated. This difference in the incidence of severe gram
2
negative infections is statistically significant (X =5.2,
p<0.05). Gram positive septicaemias were more common in
patients with ALL (41%) than AML (22%), but this
difference did not reach statistical significance.
Further details of the infections and significant
microbiological isolates can be found in Table 28 & 29.
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Table 28. Comparison of septicaemic episodes: AML vs ALL,
and associated lesions.
AML ALL
(n = 24) (n = 18)
BACTERAEMIA/SEPTICAEMIA
GRAM -VE * 10 3
GRAM +VE ** 7 12
CANDIDA 0 2
2 OR MORE ORGANISMS. 4/12 6/9
SAME ORGANISM ABNT I&II 1/12
ECTHYMA GANGRENOSUM 3 0
Pseudomonas aeruginosa isolated
ABSCESS (Not Septicaemic) 0 1
Pseudomonas aeruginosa isolated
* Pseudomonas aeruginosa 4, Escherichia coli 5,
Klebsiella aerogenes 2, Flavobacterium species 1, 1
unidentified organism of doubtful significance.
** Coagulase -ve staphylococci 7, Streptococcus sanguis
3, Streptococcus mitis 2, a haemolytic streptococcus 1, B
haemolytic streptoccocus 1, Staphylococcus aureus 1,
Streptococcus mitior 1, Streptococcus faecalis 1,
Streptococcus milleri 1, Clostridium sporogenes 1 .
6 were of doubtful significance.
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Table 29. Comparison of other positive microbiological
isolates: AML vs ALL
+VE CNDIDA SPECIES ISOLATES
1 OR MORE SITES
AML ALL
(n = 24) (n = 18)
14 11
ISOLATES FROM HICKMAN ENTRY SITES
Coagulase -ve staphylococci 21 1 5
Diptheroids 1 1 4
Staphylococcus aureus 3 2
OTHERS: 0 3







Clostridium difficile 4 4
Toxin only 3 1
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NON-INFECTIVE COMPLICATIONS
Cytotoxic induced nausea and vomiting occurred in all
patients but was not usually severe.
Haemorrhagic
Haemorrhagic cystitis occurred in only two patients,
one patient with AML and one with ALL. This was in spite
of the use of 600 mg of mesna / 1 gm of cyclophosphamide.
After this all patients received 1 gm of mesna / 1 gm of
cyclophosphamide.
One early death (UPN 92) was from an intra-cerebral
haemorrhage day 12, before regeneration. One patient (UPN
103) had mild but continuous bleeding per-vaginum
throughout ABMT I, even though she was treated with
norethisterone. The bleeding resolved spontaneously when
her platelet count rose. Two patients (UPN 55 & 125) had
significant gastro-intestinal haemorrhage consuming large
amounts of platelets (ie. >200 units of platelets each),
resolution occurred upon autologous platelet recovery
without identification of a specific lesion. Except for
the one patient with ALL who developed haemorrhagic
cystitis post cyclophosphamide, all patients who ex¬




One patient (UPN 174) with ALL developed pericarditis
post the chemotherapy of ABMT I and did not continue to
ABMT II because of this. One patient (UPN B4) with AML
developed left ventricular failure day -4, presumed due
to the cyclophosphamide and the final days dose of this
drug was therefore omitted. Delayed haematological
recovery prevented ABMT II in this patient who relapsed
day 191 and has since died.
Other
One patient (UPN 143) with AML and with no past
history of epilepsy had a grand mal convulsion, for which
there was no obvious explanation, day 98 (day 24 post
ABMT II) when the platelet count was 36x10^/L,
unsupported, and the total WBC and neutrophil count were
g
2.6 and 1.1x10 /L respectively. When the anticonvulsants
were withdrawn 1 month later he suffered a further fit




One patient (UPN 51) with ALL developed a Listeria
septicaemia nearly 2 years post ABMT.
Two patients (UPN 67 & 69) both with ALL suffered
Herpes zoster infections treated with intravenous
acyclovir, one occurring within the first month after
discharge and the other at the end of the first year.
All the above patients had ALL and were therefore on
maintenance chemotherapy at the time of their infections.
Patients with AML received no maintenance chemotherapy
and the only patient with AML (UPN 108) to experience
infective problems post ABMT, had a Herpes simplex lesion
on her lip treated with oral Acyclovir 4 months post
ABMT.
A further patient with AML (UPN 161) developed a
transient thrombocytopenia which resolved without
treatment and may have been due to an intercurrent viral
infection, as has previously been reported following
allografts (Deeg et al, 1 984 : First et al, 1 985 )^'^
although no infection was demonstrated.
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NON-INFECTIVE COMPLICATIONS
Pulmonary: One patient with ALL (UPN 69) was treated with
several months of intravenous amphotericin for a
pulmonary aspergilloma post ABMT II. She was noted to
have a severe restrictive ventilatory defect with a very
reduced TCO more than 2 years after ABMT. Before this
could be further investigated, she suffered an
extra-medullary relapse which presented as a breast lump,
biopsy proving it to be sheets of lymphoblasts.
Extramedullary relapse presenting as a breast lump
appears to have been reported only once before (Ellegaard
5 B
et al 1984) . She received further chemotherapy but
suffered a medullary relapse and died 36 months post
ABMT. Her last admission was complicated by a spontaneous
pneumothorax but the nature of her underlying pulmonary
problem was never resolved.
Fertility: Gonadal failure post TBI is almost universal.
However, in patients treated with high dose cyclophos¬
phamide only, before marrow transplantation for aplastic
anaemia, two thirds of adult male patients have a return
of gonadal function with normal gonadotrophin levels and
low to normal sperm counts. In women the result appears
dependent on age : if <26 years at the time of treatment
the secondary amennorrhoea lasts for a median of 6 months
and gonadotrophin levels are normal, if treated when >26
years old then ovarian failure with an early menopause is
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the rule (Deeg et al, 1984)
We have not routinely measured gonadotrophin levels in
our patients.
One male patient (UPN 19), was 24 years old when
treated for AML with the double ABMT protocol. He
requested fertility investigations 18 months post ABMT.
He has a normal sperm count and is potentially fertile
but he has a raised gonadotrophin level suggesting
testicular damage.
Two female patients with AML (UPN 108 & 128) were
treated at 39 and 32 years of age respectively. The older
has remained amenorrhoeic since her double ABMT over 2
years ago and is presumed to have ovarian failure, the
other continues to have erratic menstruation. She has
been reviewed by the gynaecologists but has not been
investigated for infertility.
Other: One patient with ALL (UPN 51) has developed a
cataract 2 years post ABMT. This may be the result of the
chemotherapy regimen used for ABMT but could also be
caused by steroid therapy as she has ALL and has received




An unexpected result of
emerging between patients
incidence and morbidity of
thus in overall survival.
our study is the difference
with AML and ALL in the
the various infections and
One patient with ALL treated in first remission
developed an aspergilloma; two further serious fungal
infections occurred in the ten patients with ALL treated
at a later stage of their disease, one a fatal
aspergillus pneumonia and the other a Candida septicaemia
from which the patient recovered. Systemic fungal
infection caused by Aspergillus and Candida species are
generally associated with defects in neutrophil function
or total low neutrophil counts. The ABMT protocol was
identical in the two groups and patients with AML were
generally neutropenic for longer periods, but there were
no systemic fungal infections documented in patients with
AML. The patients treatment prior to ABMT may be the
important difference, with the craniospinal prophylaxis
or the steroids which all patients with ALL receive,
being a possible cause.
LUC results available for patients with ALL (n=14)
showed an average rise in the percentage of LUC's to 15%
(range none-29.2%), two days prior to a demonstrable rise
in the total WBC count compared to an average rise of 22%
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(range 6.4-45.9%), four days before a rise in the total
WBC count in patients with AML (n=23). The average rise
in the percentage of LUC's in patients with AML is
significantly higher (p<0.05) when compared to patients
with ALL (Chapter 7). We have demonstrated these LUC's to
be T lymphocytes. This raises the possibility that T
lymphocyte recovery may be impaired in patients with ALL,
putting them at greater risk of fungal infection when
compared to patients with AML.
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de Gast et al, 1985 , have suggested that T cell
proliferation after ABMT is mainly due to proliferation
of mature T cells in the graft, not regeneration from
stem cells. This might explain the normal pattern of rise
in the percentage of LUC's in the two patients who died
of aspergillus infection, although they never showed any
evidence of engraftment, if mature T cells remain
unaffected whilst stem cells are inhibited. Aspergillus
infection in patients not undergoing transplantation has
been demonstrated to be associated with clinical anaemia
and 'in vivo' studies have demonstrated inhibition of
erythroid colony formation, probably by a soluble factor
1 90
(Zanjani et al, 1982) . If this same inhibition could
be demonstrated for granulocyte colonies it might explain
the failure of both our patients who died of aspergillus
pneumonia to engraft.
The higher incidence of severe gram -ve infections
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which is statistically significant (X =5.2, p<0.05), in
patients with AML compared to patients with ALL does not
appear to have been reported from other series. Enhanced
susceptibility to infection with these bacteria is
caused by neutropenia and defects in cell-mediated
immunity. The greater period of neutropenia following
ABMT in patients autografted for AML may be responsible
for the increase in the incidence of these infections
compared to patients autografted for ALL.
Immune reconstitution has been demonstrated to be
disordered for prolonged periods post ABMT (Linch et al,
108
1983) , however, in this series no serious infective
episodes have occurred in patients who were not on
maintenance chemotherapy.
Fertility investigations of future patients will
establish whether this double protocol results in
sterility or not. If it does not result in universal
infertility, which is the rule after an allograft with
cyclophosphamide and TBI conditioning, then this would be
an advantage of high dose chemotherapy and ABMT regimens





Five patients (14%) died of sepsis before engraftment.
Septicaemia: Four of the patients who died had clinical
septicaemia. The organisms isolated varied (Table 30).
One patient had multiple isolates in the week before his
death including a coagulase negative staphylococcus which
was isolated on 5 occasions.
Table 30. Organisms isolated from the blood in patients
dying of septicaemia.
UNIQUE PATIENT NUMBER
75 No Positive isolate
99 Acinetobacter species
1 1 6 Staphylococcus aureus




* Isolated 5 times in the week before death.
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Organisms were isolated from the blood in 15 patients
(50%) with many having more than one positive isolate
















Although there was a large number of positive isolates
of coagulase negative staphylococci, these organisms were
almost universally isolated from skin sites and it is not
clear how many of the positive blood isolates represent
sepsis rather than contamination.
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Fungal Infections:
The cause of death in one of the patients who died
before regeneration was a fungal pneumonia, due to
Aspergillus fumigatus.
Candida was isolated from multiple sites in 22 patients
(73%) in spite of anti-fungal prophylaxis but no systemic
Candida infection was identified.
Other: There were other non-fatal infections with
pyrexias occurring in 30 of the remaining 31 patients.
One patient had a pneumococcal pneumonia.
9 patients had urinary tract infections, 7 Gm -ve.
Infection necessitated removal of the Hickman catheter in
5 patients, 3 because of associated septicaemia with a
coagulase negative staphylococcus and 2 because of severe
infection at the exit site.
NON-INFECTIVE COMPLICATIONS
Immediate: Two patients (UPN 166 & 168) died at day 3 and
5, one was presumed due to tumour infiltration of the
myocardium and the other to tracheal obstruction by
tumour, neither patient had a post mortem and it is
possible that both deaths were contributed to by drug
toxicity.
Cardiotoxicity: One patient (UPN 61) died a cardiac death
8 months post ABMT whilst in CR. This patient had HD and
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his death may reflect cumulative toxicity from drugs and
irradiation.
Other drug related toxicity: One patient (UPN 88)
suffered haemorrhagic cystitis, in spite of adequate
hydration and mesnum administration. One patient (UPN
181) suffered a severe generalised skin rash which
appeared likely to be due to one of the drugs (the
chemotherapy protocol used in this patient was BEAM).
Other: One patient (UPN 34) had his Hickman catheter
removed because of a subclavian vein thrombosis.
DISCUSSION
The morbidity in this series has been high with sepsis
the major complication and procedural related deaths
occurring in 8 of the 36 patients (22%). This is perhaps
not surprising in view of the poor clinical condition of
many of these patients with either end stage or relapsed
disease. Similarly high numbers of treatment related
deaths have been reported in two other series of high
dose therapy and ABMT in patients with lymphoma who had
received extensive previous therapy (Philip et al, 1983;
Phillips et al, 1 984)^®'^®.
Our current aim is to employ this treatment earlier in
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the course of the disease. It is hoped that by-
transplanting patients early they will be in a better
clinical condition and there will be less morbidity, as
in our group of patients with AML treated in CR1.
The lymphoma patients had all received steroids and
many of them had also received radiotherapy prior to
being treated with the intensive chemoradiotherapy
regimens followed by ABMT employed here. Systemic fungal
infections have occurred in the patients treated with
ABMT for lymphoma as they have in the patients treated
for ALL. In this present series, the poor clinical
condition of many of the lymphoma patients when treated
with the pre-ABMT conditioning regimen may have
contributed to their susceptibility to these infections.
The inclusion of patients who are clinically fitter in
the future, may make it possible to ascertain whether the
incidence of systemic fungal infections is related to the




CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE PROTOCOLS
The results of this study demonstrate the feasibility of
using intensive chemoradiotherapy regimens with auto¬
logous marrow rescue in the treatment of patients with
acute leukaemia in remission or relapse and patients with
relapsed heavily pre-treated Hodgkin's disease and non-
Hodgkin's lymphoma. The number of patients treated is
still small and follow up still relatively short.
The following are my suggestions for regimens to treat
each of these diseases in the light of the experience




The most important pre-requisite for long term DFS and
possible cure is to acheive a CR. Once a CR has been
induced some form of intensive consolidation must be
1 79
given in an attempt to achieve long-term DFS.
At presentation patients should be induced on one of
the more intensive induction regimes now available (eg
2
daunorubicin 50 mg/m x 3, cytosine arabinoside and
2
thioguanine both 200 mg/m daily for 10 days, this is one
120
arm of the MRC AML IX protocol) . As soon as possible
after achieving a CR the patients should be treated by
some form of intensive consolidation therapy.
The risk of leukaemic relapse post allogeneic marrow
transplantation is approximately 15% and is not affected
by the age of the patient.
Patients who have an HLA identical sibling donor
should therefore be considered for an allograft. However,
because of the impact of non-leukaemic deaths, the chance
of being alive at 2 years is approximately 70% for
patients <20 years of age, 50% for patients 20-29 years
old and 40% for patients 30-50 years of age (Thomas et
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al, 1 982) 1 ' .
In our series of 16 patients with AML treated with
high dose chemotherapy (Table 32) followed by ABMT in CR1
there have been no non-leukaemic deaths, 13/16 were >30
years of age (the oldest was 55 years, UPN B4). Their
actuarial survival in unmaintained remission at 2 years
is 62%. (No further relapses have occurred in this group
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last date of follow-up 30.9.86).
Table 32. High dose chemotherapy regimen for
patients with acute leukaemia ABMT I & II.
DAY 1 2 3 4 5 6
CYCLOPHOSPHAMIDE * * *
1.5 G / M2
BCNU *
300 MG / M2
CYTOSINE ARABINOSIDE ** ** ** **
100 MG / M2
THIOGUANINE ** ** ** **
100 MG / M2
ADRIAMYCIN *
50 MG / M2
ABMT
I would therefore propose that as the risk of relapse
is higher post ABMT, as demonstrated by our series
(Chapter 3; AML), patients <20 years of age with an HLA
identical sibling should be allografted.
Patients >30 years of age should be treated by our
existing ABMT protocol, as the higher relapse rate is
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counter balanced by the absence of non-leukaemic deaths
resulting in much better long-term survival.
There are only two patients in our series between
20-29 years (UPN 19 & 148) and both are alive and in CR1,
2 and 5 years post ABMT. Assuming the same relapse rate
then this age group should still have a survival
advantage when treated with our ABMT protocol compared to
allografting. I would therefore recommend ABMT in this
age group also.
The importance of the double protocol is difficult to
assess. No relapse has occurred in patients completing
ABMT I & II. If completion of the double protocol is
important to prevent relapse, with 60% relapse occurring
after a single ABMT. Then our ABMT protocol for patients
completing only ABMT I has no advantage to allografting
in any age group.
All the patients who have relapsed took longer than
two months to achieve CR1 and this may account in part
for their slower haematological recovery, preventing the
implementation of ABMT II, as they had received more
treatment pre-ABMT. I would propose that any patient who
takes longer than two months to acheive CR1 should have
two harvests before ABMT I. An alternative would be to
halve the first harvest as has been done in some of our
lymphoma patients but halving a marrow in this group who
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were slow to regenerate anyway, may further prolong their
period of aplasia and significantly increase morbidity
and possibly mortality. Once these patients had recovered
physically from ABMT I, they could progress to ABMT II,
any delay in haematological recovery post ABMT I could be
ignored unless very severe as there is no need for a







HARVEST I & II
ABMT I
ABMT II
Figure 17. Plan for treating patients with AML in first
remission who are <20 years old, a) patients who acheive
CR1 in <2/12, b) patients who take >2/12 (see text for




HARVEST I HARVEST I & II
ABMT I ABMT I
HARVEST II ABMT II
ABMT II
Figure 18. Plan for treating patients with AML in first
remission who are >20 years old, a) patients who acheive
CR1 in <2/12, b) patients who take >2/12 (see text for
further explanation and drug regimens).
If the time to achieve CR1 continues to prove a good
predictor of relapse following our ABMT protocol,
irrespective of whether or not the patient receives ABMT
I or ABMT I & II, then patients who take longer than 2
months to reach CR1 would have a very high likelihood of
relapse following ABMT and should be allografted if they
have a suitable donor.
It is possible that the predictive value of this time
interval is partly because it indicates those patients
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most likely to be able to tolerate 2 grafts - only one
patient in our series who took more than 2/12 to achieve
CR1 has so far tolerated the second autograft.
There is at present no relapse in the patients who
complete both ABMT I & II on this protocol, but 60% of
those who received only ABMT I have already relapsed.
A separate study to investigate the best time to
reharvest patients post ABMT would be useful. It may be
possible to identify a time post ABMT at which a higher
yield of stem cells may be obtained, as has been reported
to occur in the peripheral blood post conventional dosage
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chemotherapy (Richman et al, 1976) . It may be useful
to consider boosting the harvest with stem cells
collected from the peripheral blood.
Patients who refuse BMT should be treated with the
most intensive chemotherapy regimen possible eg. VAPA
1 O/ 1 ? f)
(Weinstein et al, 1983) , MRC AML9
Data is at present very limited but there is some
evidence that patients treated with a consolidation
regimen containing different drugs to the initial
induction regimen have better DFS (Bloomfield CD, 1985;
1 ft 1 ft 7
Wolff et al, 1985) ' . This would be in keeping with
the accumulating evidence in favour of this approach in
patients with advanced Hodgkin's disease and ALL (Skipper
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et al, 1 964; Goldie et al 1 982)^^'^. If patients
treated with ABMT I & II start to relapse, then patients
would need to be randomised to either the double protocol
as at present or to a protocol in which the pre ABMT
conditioning was changed for ABMT II. I would suggest
that the second autograft was then conditioned with
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either cyclophosphamide and TBI (Thomas et al, 1975)
or with cyclophosphamide and busulphan (Yaeger et al,
Maintenance therapy is probably of no benefit
following such intensive regimens and should not be
given, particularly as it appears to have increased
morbidity as demonstrated in ALL patients in this study
(Chapter 8: Morbidity).
RELAPSED PATIENTS
Patients with relapsed AML may be successfully
reinduced or consolidated with our current regime without
undue morbidity, but there have been no long-term
survivors. 4/8 of our patients were harvested in CR1 with
no obvious difference in relapse free survival.
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Yeager et al, 1986 , report a 40% long-term survival
post ABMT in patients treated with high dose busulphan
and cylophosphamide (Bu/Cy) conditioning in a second or
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later remission. The autologous marrow was harvested
during remission, incubated with 4 hydroperoxycylophos-
phamide (4HC) and then cryopreserved until the time of
reinfusion (Table 33).
TABLE 33. Busulphan and cyclophosphamide regimen as
1 89
used by Yeager et al, 1986
DAY 123456
CYCLOPHOSPHAMIDE * * * *
50 MG /KG
BUSULPHAN **** **** **** ****
1 MG / KG
ABMT *
There has been no controlled study to ascertain
whether the incubation of the marrow with 4HC is
necessary. I would therefore propose a pilot study,
whereby the first 10 patients with relapsed AML, who
achieve a further CR should be treated with the Bu/Cy
regimen but with marrow which has not been incubated with
4HC. The next 10 patients should be treated the same but
assuming an adequate harvest, their marrow should be
halved and they should go on to a double ABMT. The second
ABMT being with our regimen, which uses different drugs
and should therefore reduce the risk of drug resistance
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developing. It also appears to be less toxic and is
therefore likely to be better tolerated as a second
procedure (Figure 19).
REINDUCTION
HARVEST I HARVEST I
ABMT I BU/CY ABMT I BU/CY
(1/2 Marrow only)
ABMT II UCH REGIMEN
(1/2 Marrow only)
Figure 19. Treatment plan for patients with relapsed AML
a) first 10 patients b) next 10 patients.
This should be useful in determining:
(1) Whether it is the conditioning regimen which has
resulted in the better DFS post ABMT with Bu/Cy or
whether it is the incubation with 4HC of the harvested
marrow.
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(2) Whether a double ABMT is likely to result in
better DFS than a single one.
This pilot study should further indicate whether
incubation with 4HC is significantly prolonging
haeraatological recovery. If the median time to recovery
of neutrophils >0.5x10^/L and platelets to >50x10^/L
reported by Yeager et al, is compared with our own
results, being 29 and 57 days and 22 and 33 days
respectively, then it would seem likely this is the case.
(Chapter 7: Haematological recovery). This prolongation
in recovery may be responsible for the increase in
mortality in the purged group.
It would be interesting to compare the results of ABMT
in CR2 with marrow which had been collected either in CR1
or CR2. This would give some idea as to the relative
efficacy of the conditioning regimen to eradicate host
disease.
This sort of study would only be of value to assess
this problem because it would not be possible to store
large numbers of patients CR1 marrow, and current results
would suggest it is in the patients interest to proceed
to ABMT during CR1.
The median time to relapse in all our patients treated
after 1st CR and of the 6 patients who relapsed after
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Bu/Cy reported by Yaeger et al, 1986 , was 165 days in
both groups. It would therefore, become rapidly evident
whether this regimen was proving better than our present
protocol or at least as good as the results of Yeager et
al. If Bu/Cy was demonstrated to produce improved results
in relapsed patients compared to our current double ABMT
regimen then it would merit evaluation in first remission
patients, as a single ABMT regimen, with or without
purging.
As in CR1 patients it may be useful to consider 2
harvests pre ABMT I, or even halving the first harvest,
although the same objections as discussed before would
arise. In relapsed patients either of these two manouvres
would result in the loss of any possible 'in vivo'
purging effect of the double autograft. Theoretically,





Our results in 1st CR are very disappointing with 7 of
8 patients dead or relapsed, suggesting our current
approach is not useful. We have used the same regimen in
ALL as in AML but have encountered a marked increase in
morbidity. It is possible that the difference in
morbidity between patients with AML and ALL treated on
our regimen may be due to either the steroids employed
during induction therapy or else the CNS irradiation.
I would like to test this theory by treating a small
pilot group of patients with our current ABMT protocol
after induction therapy which had no steroids in it and
who had only intrathecal treatment for CNS prophylaxis
(Figure 20).
If the morbidity was reduced after not using steroids
and cranial irradiation, I would then wish to investigate
escalation of the drugs used in an effort to reduce the
relapse rate. BCNU has produced little non-haematological
toxicity as a single agent until doses in excess of 1200
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mg/m (Herzig et al, 1981) were used and no relevant
non-haematological toxicity was reported in adults given
1000mg/m^ followed by ABMT (Brun del Re, 1 986)^ or when
1 91
2
used in combination regimens at 800mg/m (Meloni et al,
1 21
1986) . The cyclophosphamide could probably also be
increased without undue toxicity (Table 34).







Figure 20. Treatment plan for ALL in CR1 if using the
current pre ABMT conditioning regimen.
However, better relapse free survival in patients with
ALL has been reported after TBI regimens, than after our
8 0
protocol (Gorin & Aegerter, 1986) . It would therefore
seem inappropriate to initiate any further studies on our
current ABMT protocol in ALL patients.
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Table 34. Proposed changes ( ) in the UCH
chemotherapy regimen (ABMT I & II) for
patients with ALL.
DAY 1234
CYCLOPHOSPHAMIDE * * * (*)
1.5 G / M2
BCNU * (*)
300 MG / M2
CYTOSINE ARABINOSIDE ** ** ** **
100 MG / M2
THIOGUANINE ** ** ** **
100 MG / M2
ADRIAMYCIN *
50 MG / M2
ABMT
Most patients will be referred for treatment after
they have already been induced. These patients should not
be treated with our current regimen. Santos et al, 1986
126 2
, gave high dose cyclophosphamide (50mg/m x 4)
followed by TBI (3 gray x 4) to condition patients with
ALL in first or second CR pre-allograft, this regimen
appears to have a very low relapse rate (1/39). I would
propose that this is used as a single ABMT regimen in
patients in CR1, until it is seen whether or not it is
associated with as high a morbidity as our double
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protocol. A further group should be treated with the
Bu/Cy regimen (Figure 21).
HARVEST I HARVEST I
ABMT I BU/CY ABMT I CY/TBI
NO TREATMENT NO TREATMENT
Figure 21. Proposed treatment plan for patients with
ALL in CR1 - Single ABMT.
There should be no maintenance therapy post ABMT for
ALL as there is no clear benefit, but there is an
apparent increase in infective morbidity (Chapter 8:
Morbidity).
RELAPSED PATIENTS
Although allogeneic BMT may offer the best currently
available hope of long-term survival after relapse only
about 30% of patients will have a suitable sibling donor.
Autologous transplantation may offer an alternative.
Relapse rates are high following allogeneic trans¬
plantation, it might therefore be anticipated that the
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relapse rate will be even higher if the same preparative
regimen is used with the return of autologous marrow, as
a proportion of leukaemic cells may be reinfused with the
marrow innoculum, and there will be no graft-versus-
leukaemia effect (Weiden et al, 1979 & 1981,182,183^
In relapsed patients with ALL our ABMT regimen was
successful in achieving a CR but although 6 had both ABMT
I and II only 2 patients remain in CR, one of whom has
now been in 2nd CR for longer than her original marrow
was stored and the 2nd is a girl who had already had 2
CNS relapses as well as a marrow relapse, all the
remaining patients relapsed again within 12 months.
Numbers in ABMT studies are generally small and follow
up relatively short. The latest EBMTG report (Gorin &
8 0
Aegerter, 1986) demonstrates no difference in survival
for patients with ALL whether treated in CR1 or CR2 and
no significant benefit has yet been demonstrated for
purging. 2 year survival is 48%. Most of these patients
(79%) were treated with a TBI regimen.
I would recommend that ABMT regimens for relapsed
patients with ALL, should be the same in CR2 as proposed
for use in CR1 (Figure 21).
If both the high dose cyclophosphamide with TBI and
the BU/Cy protocols are well tolerated by patients
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treated in CR1 and CR2, then a second autograft should be
considered, crossing over the two conditioning regimens
(Figure 22).
HARVEST I HARVEST I
ABMT I BU/CY ABMT I CY/TBI
HARVEST II HARVEST II
ABMT II CY/TBI ABMT II BU/CY
NO TREATMENT NO TREATMENT
Figure 22. Proposed plan of treatment for patients
with ALL in CR1 and CR2 - Double ABMT.
Purging autologous marrow in ALL patients is
undergoing extensive investigation. One such recent study
patients in a 2nd or subsequent remission for ALL was
harvested and purged 'in vitro' with monoclonal
antibodies plus complement reports that 7 remain disease
free with a median follow-up of 21.4 months. Purging may
need to be considered if benefit is demonstrated in the
future.
(Ramsay et al, 1985)
1 36
in which the bone marrow of 23
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NON-HODGKIN'S LYMPHOMA
To assess the place of intensive chemoradiotherapy
regimens with ABMT in the treatment of NHL is difficult.
The use of regimens to intensify treatment has proved of
only limited success where the patient was already deemed
resistant to conventional combination chemotherapy
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(Philip et al, 1985) . In our series 10 patients with
resistant relapse were treated, 6 had no response, 1 a
PR, 1 a CR and two were non-evaluable because of early
death. It may be that after the use of more intensive
induction regimens as being currently evaluated, further
escalation of therapy with or without marrow rescue may
not prove beneficial where the patients have primary
resistant disease or relapse has occurred.
The situation is further complicated by having no
international agreement on the histological class¬
ification of this very heterogeneous group of non-
Hodgkin's lymphomas, so results are difficult to compare.
The most recent attempt to arrive at an internationally
agreed classification is the NCI working formulation
1 46
(Rosenberg et al, 1982)
A further difficulty in assessing the results of
current regimens is that patients with different stages
of disease, including stages IB and IIB, have been
included in some of the recent trials.
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It can be seen from Table 35, that different stages of
disease in the BNLI patients are associated with a very
different prognosis. (G. Vaughan Hudson, 1986, personal
communication)
Table 35. Response to CHOP in 428 patients
BNLI April 1986 (unpublished data)
STAGE CR 5 YEAR RELAPSE FREE SURVIVAL




IVB 30% 1 6%
It has been suggested that high grade NHL's with poor
prognosis should be consolidated with ABMT during CR1.
The difficulty has always been to define these poor
prognosis categories.
The BNLI have identified various factors in their CHOP
study, that have predictive value as to whether CR will
be obtained. Once a CR has been obtained however, these
factors are of less significance, and patients achieving
a CR on CHOP have a 5 year survival of 68% (DC Linch et
1 98
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al, 1986) . If this is true of other therapeutic
regimens, ABMT is not appropriate to consolidate these
patients.
Patients with NHL who fail to achieve a CR on first
line treatment (primary treatment failures) have a
particularly bad prognosis. Many of these patients are in
poor clinical condition at the end of attempted remission
induction. The BNLI have identified that patients not in
CR after 3/12 of treatment have only a 25% 5 year
survival. This group of patients would therefore be
suitable for alternative treatment at this stage, high
dose chemoradiotherapy with ABMT being one of the
possibilities.
Relapse occurring either on primary treatment or after
its cessation is also a group with poor long-term
survival. ABMT may be preferable to conventional second
line treatment in this situation.
The BNLI is at present investigating the use of ABMT
in both the above situations.
The appropriate regimen to achieve eradication of
relapsed disease has not yet been found. The early
incidence of relapse in previously involved sites
suggests failure to eradicate host disease is the primary
cause of relapse and not occult disease reinfused with
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the marrow innoculum. In an effort to increase tumour
kill, it would seem appropriate to recommend a second
cycle of intensive chemoradiotherapy with ABMT rescue as
soon as possible on recovery from the first cycle (Figure
23). The second treatment regimen should be composed of
different cytotoxic agents to prevent the selection of
resistant cells. The marrow collected before the first
cycle of cytotoxic agents could be divided if there was
O
an initial cell count of >2.0x10 cells/kg body weight,
but should be repeated if the cell count is less.
FAILED INDUCTION FIRST RELAPSE
HARVEST
ABMT I ( +1/2 marrow )
ABMT II ( + 1/2 marrow )
Figure 23. Treatment plan for patients with NHL.
The numbers treated with a double ABMT protocol in our
study are too small to draw any conclusions and there are
no other reports of the use of a double ABMT protocol in
the treatment of lymphoma. However, our own data on the
use of a double protocol in patients with AML in CR1 is
200
encouraging.
I would propose that the conditioning regimen for ABMT
I should be the present BNLI protocol but with adriamycin
included as in our protocol for patients with acute
leukaemia. Adriamycin has been shown in animal studies to
be synergistic with cyclophosphamide (Tobias et al,
1 77
1975) . The BEAM protocol with adriamycin added could
be used as the conditioning regimen for ABMT II (Table
36).
I suspect that even such a double regimen as proposed
will not be adequate in patients with advanced relapsed
disease and these patients should not be autografted. If
the toxicity of the above regimen is no higher than our
present protocol I would investigate increasing the dose
of the individual drugs employed in the regimen.
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Table 36. BNLI & BEAM protocols with added adriamycin.
ABMT I DAY 1234
CYCLOPHOSPHAMIDE * * * *
1.5 G / M2
BCNU * (*)
300 MG / M2
CYTOSINE ARABINOSIDE ** ** ** **
100 MG / M2
ypl g * * * *
75 MG / M2 ( 100 MG / M2 )
ADRIAMYCIN *
50 MG / M2
ABMT
ABMT II DAY 1 23456
BCNU * (*)
300 MG / M2
CYTOSINE ARABINOSIDE ** ** ** **
100 MG / M2
VP16 ** ** ** **
50 MG / M2
MELPHALAN *
140 MG / M2
ADRIAMYCIN *
50 MG / M2
ABMT
( ) represent the proposed change in drug dosage.
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In the BNLI protocol it is likely that both the BCNU
and VP16 doses could be increased to a total dose of 600
2 2
mg/m and 400 mg/m respectively without an undue
increase in the non-marrow toxicity. Meloni et al,
121
1986 , have used a high dose chemotherapy regimen
consisting of 800 mg/m2 BCNU, 450 mg/m2 AMSA, 450 mg/m2
VP16 and cytosine arabinoside 900 mg/m as the
conditioning regimen for ABMT I in a double protocol to
treat 3 patients with AML in relapse. They report no
relevant non-haematological complications. The BCNU in
the BEAM regimen could be increased to the same extent.
If the conditioning regimen can be altered to achieve
eradication of host disease without an unacceptable
increase in non-marrow toxicity then bone marrow
transplantation particularly ABMT may have a place in the
future treatment of patients with advanced diffuse NHL.
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HODGKIN'S DISEASE
In our own series of 15 heavily pre-treated patients
with relapsed HD who were treated with intensive chemo-
radiotherapy regimens there was a 100% response rate in
evaluable patients. One patient was not evaluable owing
to an early septicaemic death. There were 11 CRs and 3
PRs. 3 patients have died whilst apparently in CR. Only
four patients remain alive in unmaintained CR 7, 7, 17
and 29 months post ABMT. The EBMTG report a similar
response rate of 92% for patients with HD treated with
various high dose chemoradiotherapy regimens followed by
ABMT (63% CR; 29% PR). Overall survival is however, only
about 40% (AH Goldstone, 1986)^ .
It is clear that even heavily pre-treated patients
with HD remain sensitive to this form of dose escalation.
All studies at present employing intensive regimens with
bone marrow rescue would tend to suggest that in the
relapsed, heavily pre-treated patients the chemoradio¬
therapy regimens employed although valuable are failing
to eradicate host disease in most patients. There is
considerable toxicity of this form of treatment. This
might be reduced and greater success at eradicating the
disease might be obtained by using intensive chemo¬
radiotherapy earlier in the course of the disease when
patients would be better able to physically tolerate the
204
therapy and the disease would be less resistant to the
cytotoxic regimen employed, as has already been
demonstrated to be beneficial in patients treated by
allografting for acute myeloid leukaemia (Thomas ED,
1 6 91983)1Dy.
There is as yet no obvious stage at which patients
with HD should be autografted. This is because survival
in patients with HD, even those who are destined to
ultimately die of their disease, is generally longer than
in patients with acute leukaemia or NHL.
Poor prognostic groups can be identified, such as
patients failing after 2 courses of treatment. These
patients have a 5 year survival of only 34%, nonetheless
they have a median survival which is more than 2 years
109
(Linch et al, 1986) . It would therefore seem
appropriate to initiate randomised studies to compare the
use of ABMT in the following situation: Failure of 2
treatment regimens ie either primary failure or at second
relapse (Figure 24).
The only absolute contraindication to ABMT is marrow
involvement, as no suitable method of purging the
autologous marrow is yet available in HD, but if a
further CR can be induced then ABMT may be considered for
consolidation.
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PRIMARY FAILURE SECOND RELAPSE
HARVEST
ABMT I BNLI(+ 1/2 marrow)
ABMT II BEAM(+ 1/2 marrow)
Figure 24. Treatment plan for patients with HD.
Because of the high number of patients who will have
had prior DXT, particularly mantle DXT and the high
complication rate reported in series utilising TBI
(Buckner et al, 1 982; Appelbaum et al, 1 985)^'^, TBI is
probably best avoided in both the regimens for
allografting and autografting.
The relapse rate following intensive chemoradiotherapy
and ABMT in patients with advanced disease, is still
high, therefore in patients undergoing treatment
following 2 or more non-cross-resistant regimens, the
intention should be to use a double cycle of high dose
chemotherapy with ABMT rescue. I would suggest using the
BNLI protocol followed by the BEAM protocol both with
additional adriamycin as proposed for use in patients
with NHL (Figure 24). The two protocols being used for
either ABMT I or II, with patients being randomised to
206
which they receive first. The inclusion of adriamycin
(Table 36) in the regimen for treating patients with HD
is likely to be beneficial although many patients with HD
will now have received this drug as part of their first
line therapy.
The high success rate of conventional regimens in
inducing a CR in the majority of patients, and their
relatively low toxicity, suggests that there is no place
for this intensive form of therapy as primary treatment
of HD at the present time. Intensive chemoradiotherapy
has a small but significant mortality. If the morbidity/
mortality is reduced by its use earlier in the course of
the disease and its use is demonstrated to improve
survival in the two situations already suggested then the
next step might be to randomise patients at first relapse
to either ABMT or other second line treatment.
CONCLUSION
ABMT allows escalation of the dose of cytotoxic agents
which can successfully be administered at a single time,
with a substantial improvement in the immediate response
rate. This form of treatment is complete in a relatively
short period of time which is an advantage when compared
to the extended treatment period of most current
intensive chemotherapy regimes not employing ABMT. ABMT
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regimens currently employed cause much less morbidity
than allograft regimes, particularly in relation to the
absence of GVHD and they are therefore applicable to a
much wider patient population. Unless current research
leads to the successful elimination of GVHD, I would
envisage the use of ABMT to extend the treatment of
haematological malignancies will expand rapidly in the
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APPENDIX I
PATIENT DATA - ACUTE LEUKAEMIA
245
ABBREVIATIONS
NA, Data not available.
PP, Private patient.
QE Hospital, Queen Elizabeth Hospital.
SEX:
M, male; F, female.
DIAGNOSIS:
AML, Acute Myeloid Leukaemia; ALL, Acute Lymphoblastic
Leukaemia.
CLASSIFICATION:
This is by the French, American, British Classification
1 5
(Bennett et al, 1976) together with the immunological
markers where available.
DXT; Radiotherapy.
IT MTX; Intrathecal methotrexate.
STATUS AT TIME OF ABMT:
1st CR, first complete remission; 2nd CR, second complete
remission; 3rd CR, third complete remission.
STATUS POST ABMT:
CR, Complete Remission; NE, Not Evaluable.
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OTHER BLOOD PRODUCTS USED:
PPF, Purified Protein Fraction.
FFP, Fresh Frozen Plasma.
Cryo, Cryoprecipitate.
MICROBIOLOGY:
Coag -ve staph, Coagulase negative staphylococci
H.S., Hickman entry site.
Pseud, Pseudomonas
E coli, Escherichia coli
H tip, Hickman tip
a haem strep, a haemolytic streptococcus







Gp B, Group B
PV, per vaginum.
CNS, central nervous system.
LVF, left ventricular failure.
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UNIQUE PATIENT NUMBER 1 9
PATIENT NAME G TANNER
HOSPITAL NUMBER AX5090
DATE OF BIRTH 12.2.56




DATE OF DIAGNOSIS 15.9.80
DATE OF 1 ST CR 10.11.80
DATE OF CR PRE-ABMT 10.11.80
STATUS AT TIME OF 1 ST HARVEST 1 ST CR
DATE OF HARVEST I : 30.12.80
DATE OF HARVEST II: 25.2.81
STATUS AT TIME OF ABMT I : 1ST CR
DATE OF ABMT I : 6.1.81
DATE OF ABMT II: 6.3.81
NUCLEATED CELL COUNT X 108/KG I : 3.1
NUCLEATED CELL COUNT X 108/KG II: 1 .7
GM CFC X 104/KG I : 1 .66
GM CFC X 104/KG II: 1 .28
DAYS UNTIL WBC >1.0 X 109/L I : 1 2
DAYS UNTIL WBC >1.0 X 109/L II: 1 3
DAYS UNTIL NEUTS >0.5 X 109/L I : 20
DAYS UNTIL NEUTS >0.5 X 109/L II: 1 7
DAYS UNTIL PLATELETS >50 X 109/L I : 1 7
DAYS UNTIL PLATELETS >50 X 109/L II: 26
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DAYS UNTIL PLATELETS >100 X 10 /L
DAYS UNTIL PLATELETS >100 X 109/L
LENGTH OF ADMISSION IN DAYS
LENGTH OF ADMISSION IN DAYS
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 38.0°C
,0,NO. OF DAYS TEMP. > 38.0 C
NO. OF ANTIBIOTICS USED
NO. OF ANTIBIOTICS USED
NO. OF UNITS OF BLOOD
NO. OF UNITS OF BLOOD
NO. OF UNITS OF PLATELETS USED
NO. OF UNITS OF PLATELETS USED
OTHER BLOOD PRODUCTS USED
OTHER BLOOD PRODUCTS USED
WEIGHT LOSS IN KG
WEIGHT LOSS IN KG
TOTAL PARENTERAL NUTRITION ADMINISTERED I




















































I : SALMONELLA INFECTION
II: NIL OF NOTE




















DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 1 09/L
DAYS UNTIL NEUTS >0.5 X 109/ L
DAYS UNTIL PLATELETS >50 X 109/L







































DAYS UNTIL PLATELETS >100 X 10^/L
DAYS UNTIL PLATELETS >1 00 X 1 09/L
LENGTH OF ADMISSION IN DAYS
LENGTH OF ADMISSION IN DAYS
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 38.0°C
NO. OF DAYS TEMP. > 38.0°C
NO. OF ANTIBIOTICS USED
NO. OF ANTIBIOTICS USED
NO. OF UNITS OF BLOOD
NO. OF UNITS OF BLOOD
NO. OF UNITS OF PLATELETS USED
NO. OF UNITS OF PLATELETS USED























OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG I : NA
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NA





































DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 10 /KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L



























DAYS UNTIL PLATELETS >50 X 10 /L II: 35
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DAYS UNTIL PLATELETS >100 X 1CT/L
DAYS UNTIL PLATELETS >100 X 109/L
LENGTH OF ADMISSION IN DAYS
LENGTH OF ADMISSION IN DAYS
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 38.0°C
,0,NO. OF DAYS TEMP. > 38.0 C
NO. OF ANTIBIOTICS USED
NO. OF ANTIBIOTICS USED
NO. OF UNITS OF BLOOD
NO. OF UNITS OF BLOOD
NO. OF UNITS OF PLATELETS USED
NO. OF UNITS OF PLATELETS USED
OTHER BLOOD PRODUCTS USED
OTHER BLOOD PRODUCTS USED
WEIGHT LOSS IN KG
WEIGHT LOSS IN KG
TOTAL PARENTERAL NUTRITION ADMINISTERED I




















COMPLICATIONS DURING ABMT I : NIL OF NOTE
COMPLICATIONS DURING ABMT II: NIL OF NOTE
































DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 1 09/L
DAYS UNTIL WBC >1.0 X 1 09/L
DAYS UNTIL NEUTS >0.5 X 1 09/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L







































DAYS UNTIL PLATELETS >100 X 109/L I: 141
DAYS UNTIL PLATELETS >100 X 109/L II:
LENGTH OF ADMISSION IN DAYS I : 43
LENGTH OF ADMISSION IN DAYS II:
NO. OF DAYS TEMP. > 37.2°C 1:12
NO. OF DAYS TEMP. > 37.2°C II:
NO. OF DAYS TEMP. > 38.0°C I : 9
NO. OF DAYS TEMP. > 38.0°C II:
NO. OF ANTIBIOTICS USED I : 3
NO. OF ANTIBIOTICS USED II:
NO. OF UNITS OF BLOOD 1:12
NO. OF UNITS OF BLOOD II:
NO. OF UNITS OF PLATELETS USED I : 177
NO. OF UNITS OF PLATELETS USED II:
OTHER BLOOD PRODUCTS USED I : NONE
OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG 1:10
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NO










I : Candida; Throat
Serratia marascens;
Urine


















UNIQUE PATIENT NUMBER 51
PATIENT NAME G SINCLAIR
HOSPITAL NUMBER ES6623
DATE OF BIRTH 7.2.47




DATE OF DIAGNOSIS APRIL 77
DATE OF 1 ST CR 30.5.77
DATE OF CR PRE-ABMT 30.5.77
STATUS AT TIME OF 1 ST HARVEST 1ST CR
DATE OF HARVEST I : 6.3.80
DATE OF HARVEST II: 14.6.82
STATUS AT TIME OF ABMT I : 1ST RELAPSE
DATE OF ABMT I : 8.3.82
DATE OF ABMT II: 23.6.82
NUCLEATED CELL COUNT X 108/KG I : 1 .9
NUCLEATED CELL COUNT X 108/KG II: NA
GM CFC X 104/KG I : 6.9
GM CFC X 104/KG II: 3.09
DAYS UNTIL WBC >1.0 X 109/L I : 20
DAYS UNTIL WBC >1.0 X 109/L II: 26
DAYS UNTIL NEUTS >0.5 X 109/L I : 31
DAYS UNTIL NEUTS >0.5 X 109/L II: 28
DAYS UNTIL PLATELETS >50 X 109/L I : 33
DAYS UNTIL PLATELETS >50 X 109/L II: 45
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DAYS UNTIL PLATELETS >100 X 10 /L
DAYS UNTIL PLATELETS >100 X 109/L
LENGTH OF ADMISSION IN DAYS
LENGTH OF ADMISSION IN DAYS
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 38.0°C
NO. OF DAYS TEMP. > 38.0°C
NO. OF ANTIBIOTICS USED
NO. OF ANTIBIOTICS USED
NO. OF UNITS OF BLOOD
NO. OF UNITS OF BLOOD
NO. OF UNITS OF PLATELETS USED
NO. OF UNITS OF PLATELETS USED
OTHER BLOOD PRODUCTS USED
OTHER BLOOD PRODUCTS USED
WEIGHT LOSS IN KG
WEIGHT LOSS IN KG
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NO
































I : CANDIDA SEPTICAEMIA
II: NO MAJOR
COMPLICATIONS

















•• CATARACT / LISTERIA
SEPTICAEMIA











DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 10 /KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 1 09/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 1 09/L







































DAYS UNTIL PLATELETS >100 X 109/L I : NEVER
DAYS UNTIL PLATELETS >100 X 109/L II:
LENGTH OF ADMISSION IN DAYS I : 38
LENGTH OF ADMISSION IN DAYS II:
NO. OF DAYS TEMP. > 37.2°C 1:11
NO. OF DAYS TEMP. > 37.2°C II:
NO. OF DAYS TEMP. > 38.0°C I : 4
NO. OF DAYS TEMP. > 38.0°C II:
NO. OF ANTIBIOTICS USED I : 3
NO. OF ANTIBIOTICS USED II:
NO. OF UNITS OF BLOOD 1:16
NO. OF UNITS OF BLOOD II:
NO. OF UNITS OF PLATELETS USED I : 233
NO. OF UNITS OF PLATELETS USED II:
OTHER BLOOD PRODUCTS USED I : NONE
OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG 1:4
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NO






I : HICKMAN INFECTION /
BLEEDING
II:




























DATE OF 1ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 1 09/L
DAYS UNTIL PLATELETS >50 X 1 09/L







































DAYS UNTIL PLATELETS >100 X 109/L 1:25
DAYS UNTIL PLATELETS >100 X 109/L II:
LENGTH OF ADMISSION IN DAYS I : 35
LENGTH OF ADMISSION IN DAYS II:
NO. OF DAYS TEMP. > 37.2°C I : 22
NO. OF DAYS TEMP. > 37.2°C II:
NO. OF DAYS TEMP. > 38.0°C 1:16
NO. OF DAYS TEMP. > 38.0°C II:
NO. OF ANTIBIOTICS USED I : 5
NO. OF ANTIBIOTICS USED II:
NO. OF UNITS OF BLOOD I : 4
NO. OF UNITS OF BLOOD II:
NO. OF UNITS OF PLATELETS USED I : 45
NO. OF UNITS OF PLATELETS USED II:
OTHER BLOOD PRODUCTS USED I : GRANULOCYTES
5 DAYS
OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG 1:5
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : YES
TOTAL PARENTERAL NUTRITION ADMINISTERED II:
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COMPLICATIONS DURING ABMT I : HAEMORRHAGIC CYSTITIS
COMPLICATIONS DURING ABMT II:

































DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 1 09/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L







































DAYS UNTIL PLATELETS >100 X 109/L I : 30
DAYS UNTIL PLATELETS >100 X 109/L II:
LENGTH OF ADMISSION IN DAYS I : 30
LENGTH OF ADMISSION IN DAYS II:
NO. OF DAYS TEMP. > 37.2°C 1:17
NO. OF DAYS TEMP. > 37.2°C II:
NO. OF DAYS TEMP. > 38.0°C I : 8
NO. OF DAYS TEMP. > 38.0°C II:
NO. OF ANTIBIOTICS USED I : 5
NO. OF ANTIBIOTICS USED II:
NO. OF UNITS OF BLOOD I : 8
NO. OF UNITS OF BLOOD II:
NO. OF UNITS OF PLATELETS USED I : 68
NO. OF UNITS OF PLATELETS USED II:
OTHER BLOOD PRODUCTS USED I : NO
OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG 1:1.5
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : YES










































DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 1 09/L
DAYS UNTIL PLATELETS >50 X 109/L





























DAYS UNTIL PLATELETS >100 X 1 0 /L
DAYS UNTIL PLATELETS >100 X 109/L
LENGTH OF ADMISSION IN DAYS
LENGTH OF ADMISSION IN DAYS
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 38.0°C
.0,NO. OF DAYS TEMP. > 38.0 C
NO. OF ANTIBIOTICS USED
NO. OF ANTIBIOTICS USED
NO. OF UNITS OF BLOOD
NO. OF UNITS OF BLOOD
NO. OF UNITS OF PLATELETS USED
NO. OF UNITS OF PLATELETS USED
OTHER BLOOD PRODUCTS USED
OTHER BLOOD PRODUCTS USED
WEIGHT LOSS IN KG
WEIGHT LOSS IN KG
TOTAL PARENTERAL NUTRITION ADMINISTERED I
























POSITIVE MICROBIOLOGY ISOLATES I :








































DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L





























DAYS UNTIL PLATELETS >100 X 1 0 /L
DAYS UNTIL PLATELETS >1 00 X 1 09/L
LENGTH OF ADMISSION IN DAYS
LENGTH OF ADMISSION IN DAYS
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 38.0°C
,0,NO. OF DAYS TEMP. > 38.0 C
NO. OF ANTIBIOTICS USED
NO. OF ANTIBIOTICS USED
NO. OF UNITS OF BLOOD
NO. OF UNITS OF BLOOD
NO. OF UNITS OF PLATELETS USED
NO. OF UNITS OF PLATELETS USED
OTHER BLOOD PRODUCTS USED
OTHER BLOOD PRODUCTS USED
WEIGHT LOSS IN KG
WEIGHT LOSS IN KG
TOTAL PARENTERAL NUTRITION ADMINISTERED I



































I : Coag -ve staph; H.S./
Strep sanguis; Blood/




II: Coag -ve staph; Blood
/Staph aureus; Nose/



















DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
4
GM CFC X 10 /KG
GM CFC X 104/KG
9
DAYS UNTIL WBC >1.0 X 10 /L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 1 09/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 1 09/L







































DAYS UNTIL PLATELETS >100 X 1 0 /L
DAYS UNTIL PLATELETS >1 00 X 1 09/L
LENGTH OF ADMISSION IN DAYS
LENGTH OF ADMISSION IN DAYS
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 38.0°C
NO. OF DAYS TEMP. > 38.0°C
NO. OF ANTIBIOTICS USED
NO. OF ANTIBIOTICS USED
NO. OF UNITS OF BLOOD
NO. OF UNITS OF BLOOD
NO. OF UNITS OF PLATELETS USED
NO. OF UNITS OF PLATELETS USED
























OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG 1:7.15
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NO
TOTAL PARENTERAL NUTRITION ADMINISTERED II:
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COMPLICATIONS DURING ABMT I : NECK HAEMATOMA /
INFECTION
COMPLICATIONS DURING ABMT II:
POSITIVE MICROBIOLOGY ISOLATES I : Coag -ve staph;
Neck, H.S./Candida;
Throat, Faeces























DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L







































DAYS UNTIL PLATELETS >100 X 109/L I : 41
DAYS UNTIL PLATELETS >100 X 109/L II:
LENGTH OF ADMISSION IN DAYS I : 35
LENGTH OF ADMISSION IN DAYS II:
NO. OF DAYS TEMP. > 37.2°C 1:10
NO. OF DAYS TEMP. > 37.2°C II:
NO. OF DAYS TEMP. > 38.0°C I : 6
NO. OF DAYS TEMP. > 38.0°C II:
NO. OF ANTIBIOTICS USED I : 6
NO. OF ANTIBIOTICS USED II:
NO. OF UNITS OF BLOOD I : 4
NO. OF UNITS OF BLOOD II:
NO. OF UNITS OF PLATELETS USED I : 69
NO. OF UNITS OF PLATELETS USED II:
OTHER BLOOD PRODUCTS USED I : PPF / FFP
OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG 1:0
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NO





I : GRAM -VE SEPTICAEMIA
II:


























UNIQUE PATIENT NUMBER 98
PATIENT NAME A GALLO
HOSPITAL NUMBER EZ5711
DATE OF BIRTH 7.2.39




DATE OF DIAGNOSIS 7.7.82
DATE OF 1 ST CR 4.1.83
DATE OF CR PRE-ABMT 13.4.83
STATUS AT TIME OF 1 ST HARVEST 2ND CR
DATE OF HARVEST I : 15.4.83
DATE OF HARVEST II: 15.7.83
STATUS AT TIME OF ABMT I : 2ND CR
DATE OF ABMT I : 9.5.83
DATE OF ABMT II: 23.7.83
NUCLEATED CELL COUNT X 10'S/KG I : 1 .3
NUCLEATED CELL COUNT X 108/KG II: NA
GM CFC X 104/KG I : 1 .09
GM CFC X 104/KG II: 0.87
DAYS UNTIL WBC >1.0 X 109/L I : 1 3
DAYS UNTIL WBC >1.0 X 109/L II: 25
DAYS UNTIL NEUTS >0.5 X 1 09/L I : 1 7
DAYS UNTIL NEUTS >0.5 X 1 09/L II: 32
DAYS UNTIL PLATELETS >50 X 109/L I : 28
DAYS UNTIL PLATELETS >50 X 109/L II: 51
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DAYS UNTIL PLATELETS >100 X 1 0 /L
DAYS UNTIL PLATELETS >1 00 X 1 09/L
LENGTH OF ADMISSION IN DAYS
LENGTH OF ADMISSION IN DAYS
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 38.0°C
.0.
NO. OF DAYS TEMP. > 38.0 C
NO. OF ANTIBIOTICS USED
NO. OF ANTIBIOTICS USED
NO. OF UNITS OF BLOOD
NO. OF UNITS OF BLOOD
NO. OF UNITS OF PLATELETS USED
NO. OF UNITS OF PLATELETS USED
OTHER BLOOD PRODUCTS USED
OTHER BLOOD PRODUCTS USED
WEIGHT LOSS IN KG
WEIGHT LOSS IN KG
TOTAL PARENTERAL NUTRITION ADMINISTERED I :








































COMPLICATIONS DURING ABMT I :
COMPLICATIONS DURING ABMT II:
POSITIVE MICROBIOLOGY ISOLATES I :




































DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L







































DAYS UNTIL PLATELETS >100 X 109/L I : NEVER
DAYS UNTIL PLATELETS >100 X 109/L II:
LENGTH OF ADMISSION IN DAYS I : 45
LENGTH OF ADMISSION IN DAYS II:
NO. OF DAYS TEMP. > 37.2°C 1:13
NO. OF DAYS TEMP. > 37.2°C II:
NO. OF DAYS TEMP. > 38.0°C I : 6
NO. OF DAYS TEMP. > 38.0°C II:
NO. OF ANTIBIOTICS USED I : 4
NO. OF ANTIBIOTICS USED II:
NO. OF UNITS OF BLOOD I : 9
NO. OF UNITS OF BLOOD II:
NO. OF UNITS OF PLATELETS USED I : 125
NO. OF UNITS OF PLATELETS USED II:
OTHER BLOOD PRODUCTS USED I : NONE
OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG 1:5
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NO
TOTAL PARENTERAL NUTRITION ADMINISTERED II:
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COMPLICATIONS DURING ABMT I :
COMPLICATIONS DURING ABMT II:

























UNIQUE PATIENT NUMBER « 1 03
PATIENT NAME •• R SMITHERS
HOSPITAL NUMBER •• FA0610
DATE OF BIRTH •• 11 .10.67




DATE OF DIAGNOSIS •• OCTOBER 82
DATE OF 1 ST CR •• 2.12.82
DATE OF CR PRE-ABMT •• 2.12.82
STATUS AT TIME OF 1ST HARVEST •• 1ST CR
DATE OF HARVEST I : 29.4.83
DATE OF HARVEST II: 5.8.83
STATUS AT TIME OF ABMT I : 1 ST CR
DATE OF ABMT I : 12.6.83
DATE OF ABMT II: 17.8.83
NUCLEATED CELL COUNT X 108/KG I : 2.4
NUCLEATED CELL COUNT X 108/KG II: 3.0
GM CFC X 104/KG I : NA
GM CFC X 104/KG II: NA
DAYS UNTIL WBC >1.0 X 109/L I : 1 3
DAYS UNTIL WBC >1.0 X 109/L II: 20
DAYS UNTIL NEUTS >0.5 X 109/L I : 1 5
DAYS UNTIL NEUTS >0.5 X 109/L II: 21
DAYS UNTIL PLATELETS >50 X 109/L I : 1 3
DAYS UNTIL PLATELETS >50 X 109/L II: 20
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DAYS UNTIL PLATELETS >100 X 1 0 /L
DAYS UNTIL PLATELETS >100 X 109/L
LENGTH OF ADMISSION IN DAYS
LENGTH OF ADMISSION IN DAYS
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 38.0°C
>0,NO. OF DAYS TEMP. > 38.0 C
NO. OF ANTIBIOTICS USED
NO. OF ANTIBIOTICS USED
NO. OF UNITS OF BLOOD
NO. OF UNITS OF BLOOD
NO. OF UNITS OF PLATELETS USED
NO. OF UNITS OF PLATELETS USED
OTHER BLOOD PRODUCTS USED
OTHER BLOOD PRODUCTS USED
WEIGHT LOSS IN KG
WEIGHT LOSS IN KG
TOTAL PARENTERAL NUTRITION ADMINISTERED I




































I : Staph, aureus; Nose

















DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 1 09/L
DAYS UNTIL WBC >1.0 X 1 09/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 1 09/L





























DAYS UNTIL PLATELETS >100 X 1 0 /L
DAYS UNTIL PLATELETS >1 00 X 1 09/L
LENGTH OF ADMISSION IN DAYS
LENGTH OF ADMISSION IN DAYS
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 38.0°C
,0,NO. OF DAYS TEMP. > 38.0 C
NO. OF ANTIBIOTICS USED
NO. OF ANTIBIOTICS USED
NO. OF UNITS OF BLOOD
NO. OF UNITS OF BLOOD
NO. OF UNITS OF PLATELETS USED
NO. OF UNITS OF PLATELETS USED
OTHER BLOOD PRODUCTS USED
OTHER BLOOD PRODUCTS USED
WEIGHT LOSS IN KG
WEIGHT LOSS IN KG
TOTAL PARENTERAL NUTRITION ADMINISTERED I




















COMPLICATIONS DURING ABMT I :
COMPLICATIONS DURING ABMT II:
























UNIQUE PATIENT NUMBER •• 1 07
PATIENT NAME •• R CHOUDARI
HOSPITAL NUMBER • ES5020
DATE OF BIRTH • 20.6.36




DATE OF DIAGNOSIS a 8.2.80
DATE OF 1 ST CR • 16.4.80
DATE OF CR PRE-ABMT •a 5.5.83
STATUS AT TIME OF 1ST HARVEST •• 1ST CR
DATE OF HARVEST I : 9.10.80
DATE OF HARVEST II: 2.9.83
STATUS AT TIME OF ABMT I : 2ND CR
DATE OF ABMT I : 12.7.83
DATE OF ABMT II: 8.9.83
NUCLEATED CELL COUNT X 108/KG I : 1 .6
NUCLEATED CELL COUNT X 108/KG II: NA
GM CFC X 104/KG I : 6.32
GM CFC X 104/KG II: 3.89
DAYS UNTIL WBC >1.0 X 109/L I : 1 3
DAYS UNTIL WBC >1.0 X 109/L II: 1 8
DAYS UNTIL NEUTS >0.5 X 109/L I : 1 4
DAYS UNTIL NEUTS >0.5 X 109/L II: 1 8
DAYS UNTIL PLATELETS >50 X 1 09/L I : 20
DAYS UNTIL PLATELETS >50 X 109/L II: 34
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DAYS UNTIL PLATELETS >100 X 1 0 /L
DAYS UNTIL PLATELETS >100 X 109/L
LENGTH OF ADMISSION IN DAYS
LENGTH OF ADMISSION IN DAYS
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 38.0°C
,0,NO. OF DAYS TEMP. > 38.0 C
NO. OF ANTIBIOTICS USED
NO. OF ANTIBIOTICS USED
NO. OF UNITS OF BLOOD
NO. OF UNITS OF BLOOD
NO. OF UNITS OF PLATELETS USED
NO. OF UNITS OF PLATELETS USED
OTHER BLOOD PRODUCTS USED
OTHER BLOOD PRODUCTS USED
WEIGHT LOSS IN KG
WEIGHT LOSS IN KG
TOTAL PARENTERAL NUTRITION ADMINISTERED I








































II: Coag -ve staph; H.S./











UNIQUE PATIENT NUMBER 1 08
PATIENT NAME U PARRY
HOSPITAL NUMBER FB3966
DATE OF BIRTH 30.1.44




DATE OF DIAGNOSIS 22.10.82
DATE OF 1 ST CR 4.12.82
DATE OF CR PRE-ABMT 4.12.82
STATUS AT TIME OF 1 ST HARVEST 1ST CR
DATE OF HARVEST I : 8.7.83
DATE OF HARVEST II: 9.9.83
STATUS AT TIME OF ABMT I : 1 ST CR
DATE OF ABMT I : 22.7.83
DATE OF ABMT II: 17.9.83
NUCLEATED CELL COUNT X 108/KG I : 1 .5
NUCLEATED CELL COUNT X 108/KG II: 1 .9
GM CFC X 104/KG I : NA
GM CFC X 104/KG II: NA
DAYS UNTIL WBC >1.0 X 109/L I : 1 8
DAYS UNTIL WBC >1.0 X 109/L II: 41
DAYS UNTIL NEUTS >0.5 X 109/L I : 1 8
DAYS UNTIL NEUTS >0.5 X 109/L II: 45
DAYS UNTIL PLATELETS >50 X 109/L I : 20





DAYS UNTIL PLATELETS >100 X 1 0 /L
DAYS UNTIL PLATELETS >1 00 X 1 09/L
LENGTH OF ADMISSION IN DAYS
LENGTH OF ADMISSION IN DAYS II: 58
NO. OF DAYS TEMP. > 37.2°C I : 20
NO. OF DAYS TEMP. > 37.2°C II: 30
NO. OF DAYS TEMP. > 38.0°C I : 8
NO. OF DAYS TEMP. > 38.0°C II: 11
NO. OF ANTIBIOTICS USED I : 4
NO. OF ANTIBIOTICS USED
NO. OF UNITS OF BLOOD
NO. OF UNITS OF BLOOD
NO. OF UNITS OF PLATELETS USED
NO. OF UNITS OF PLATELETS USED
OTHER BLOOD PRODUCTS USED I : NONE
OTHER BLOOD PRODUCTS USED II: NONE
WEIGHT LOSS IN KG I : 3.4
WEIGHT LOSS IN KG II: NIL



















I : NIL OF NOTE
II: NIL OF NOTE















UNIQUE PATIENT NUMBER 11 8
PATIENT NAME S McCARRISON
HOSPITAL NUMBER EZ9358
DATE OF BIRTH 23.5.61




DATE OF DIAGNOSIS 26.3.80
DATE OF 1ST CR 28.5.80
DATE OF CR PRE-ABMT 6.10.82
STATUS AT TIME OF 1 ST HARVEST 2ND CR
DATE OF HARVEST I : 10.6.83
DATE OF HARVEST II: 9.12.83
STATUS AT TIME OF ABMT I : 2ND CR
DATE OF ABMT I : 15.10.83
DATE OF ABMT II: 26.1.84
NUCLEATED CELL COUNT X 108/KG I : 1 .35
NUCLEATED CELL COUNT X 108/KG II: 1 .4
GM CFC X 104/KG I : 3.06
GM CFC X 104/KG II: 3.6
DAYS UNTIL WBC >1.0 X 109/L I : 20
DAYS UNTIL WBC >1.0 X 109/L II: 25
DAYS UNTIL NEUTS >0.5 X 109/L I : 27
DAYS UNTIL NEUTS >0.5 X 1 09/L II: 25
DAYS UNTIL PLATELETS >50 X 109/L I : 26
DAYS UNTIL PLATELETS >50 X 109/L II: 28
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DAYS UNTIL PLATELETS >100 X 1 0 /L
DAYS UNTIL PLATELETS >100 X 109/L
LENGTH OF ADMISSION IN DAYS
LENGTH OF ADMISSION IN DAYS
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 38.0°C
.0,
NO. OF DAYS TEMP. > 38.0 C
NO. OF ANTIBIOTICS USED
NO. OF ANTIBIOTICS USED
NO. OF UNITS OF BLOOD
NO. OF UNITS OF BLOOD
NO. OF UNITS OF PLATELETS USED
NO. OF UNITS OF PLATELETS USED
OTHER BLOOD PRODUCTS USED
OTHER BLOOD PRODUCTS USED
WEIGHT LOSS IN KG
WEIGHT LOSS IN KG
TOTAL PARENTERAL NUTRITION ADMINISTERED I




































I : Coag -ve staph; H.S.
E coli; Urine/
Staph aureus; Nose













UNIQUE PATIENT NUMBER 1 21
PATIENT NAME R ROBINSON
HOSPITAL NUMBER FB9169
DATE OF BIRTH 3.10.45




DATE OF DIAGNOSIS FEBRUARY 81
DATE OF 1 ST CR 16.4.81
DATE OF CR PRE-ABMT 16.4.81
(MEDULLARY)
STATUS AT TIME OF 1 ST HARVEST : 2ND CR (POST
TESTICULAR
RELAPSE)
DATE OF HARVEST I : 14.10.83
DATE OF HARVEST II: 13.1.84
STATUS AT TIME OF ABMT I : 2ND CR
DATE OF ABMT I : 23.10.83
DATE OF ABMT II: 23.1.84
NUCLEATED CELL COUNT X 108/KG I : 1.12
NUCLEATED CELL COUNT X 108/KG II: NA
GM CFC X 104/KG I : 0.69
GM CFC X 104/KG II: 1 .42
DAYS UNTIL WBC >1.0 X 109/L I : 1 8
DAYS UNTIL WBC >1.0 X 109/L II: NEVER
DAYS UNTIL NEUTS >0.5 X 109/L I : 1 9
DAYS UNTIL NEUTS >0.5 X 109/L II: NEVER
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DAYS UNTIL PLATELETS >50 X 109/L I
DAYS UNTIL PLATELETS >50 X 109/L II
DAYS UNTIL PLATELETS >100 X 109/L I
DAYS UNTIL PLATELETS >100 X 109/L II
LENGTH OF ADMISSION IN DAYS I
LENGTH OF ADMISSION IN DAYS II
NO. OF DAYS TEMP. > 37.2°C I
NO. OF DAYS TEMP. > 37.2°C II
NO. OF DAYS TEMP. > 38.0°C I
NO. OF DAYS TEMP. > 38.0°C II
NO. OF ANTIBIOTICS USED I
NO. OF ANTIBIOTICS USED II
NO. OF UNITS OF BLOOD I
NO. OF UNITS OF BLOOD II
NO. OF UNITS OF PLATELETS USED I
NO. OF UNITS OF PLATELETS USED II
OTHER BLOOD PRODUCTS USED I
OTHER BLOOD PRODUCTS USED II
WEIGHT LOSS IN KG I :
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I :





































I : CANDIDA OESOPHAGITIS
II: ASPERGILLUS PNEUMONIA






















DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L







































DAYS UNTIL PLATELETS >100 X 109/L 1:30
DAYS UNTIL PLATELETS >100 X 109/L II:
LENGTH OF ADMISSION IN DAYS I : 26
LENGTH OF ADMISSION IN DAYS II:
NO. OF DAYS TEMP. > 37.2°C I : 8
NO. OF DAYS TEMP. > 37.2°C II:
NO. OF DAYS TEMP. > 38.0°C I : 5
NO. OF DAYS TEMP. > 38.0°C II:
NO. OF ANTIBIOTICS USED I : 7
NO. OF ANTIBIOTICS USED II:
NO. OF UNITS OF BLOOD 1:13
NO. OF UNITS OF BLOOD II:
NO. OF UNITS OF PLATELETS USED I : 80
NO. OF UNITS OF PLATELETS USED II:
OTHER BLOOD PRODUCTS USED I : NONE
OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG I : NA
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NO





I : NIL OF NOTE
II:





















UNIQUE PATIENT NUMBER 125
PATIENT NAME K MARLBOROUGH
HOSPITAL NUMBER EV5987
DATE OF BIRTH 8.3.63




DATE OF DIAGNOSIS 4.8.80
DATE OF 1 ST CR 2.10.80
DATE OF CR PRE-ABMT 30.9.83
STATUS AT TIME OF 1 ST HARVEST 1 ST CR
DATE OF HARVEST I : 21.1.81
DATE OF HARVEST II: 27.1.84
STATUS AT TIME OF ABMT I : 2ND CR
DATE OF ABMT I : 26.11.83
DATE OF ABMT II: 8.2.84
NUCLEATED CELL COUNT X 108/KG I : NA
NUCLEATED CELL COUNT X 108/KG II: 1 .2
GM CFC X 104/KG I : 6.23
GM CFC X 104/KG II: 0.94
DAYS UNTIL WBC >1.0 X 109/L I : 21
DAYS UNTIL WBC >1.0 X 109/L II: 33
DAYS UNTIL NEUTS >0.5 X 109/L I : 21
DAYS UNTIL NEUTS >0.5 X 109/L II: 33
DAYS UNTIL PLATELETS >50 X 1 09/L I : 21
DAYS UNTIL PLATELETS >50 X 109/L II: 47
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DAYS UNTIL PLATELETS >100 X 1 0 /L
DAYS UNTIL PLATELETS >1 00 X 1 09/L
LENGTH OF ADMISSION IN DAYS
LENGTH OF ADMISSION IN DAYS
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 38.0°C
.0.
NO. OF DAYS TEMP. > 38.0 C
NO. OF ANTIBIOTICS USED
NO. OF ANTIBIOTICS USED
NO. OF UNITS OF BLOOD
NO. OF UNITS OF BLOOD
NO. OF UNITS OF PLATELETS USED
NO. OF UNITS OF PLATELETS USED
OTHER BLOOD PRODUCTS USED
OTHER BLOOD PRODUCTS USED
WEIGHT LOSS IN KG
WEIGHT LOSS IN KG
TOTAL PARENTERAL NUTRITION ADMINISTERED I






















































































DATE OF 1ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 10 /KG
GM CFC X 104/KG
9
DAYS UNTIL WBC >1.0 X 10 /L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L







































DAYS UNTIL PLATELETS >100 X 109/L I : 494
DAYS UNTIL PLATELETS >100 X 109/L II:
LENGTH OF ADMISSION IN DAYS I : 54
LENGTH OF ADMISSION IN DAYS II:
NO. OF DAYS TEMP. > 37.2°C I : 26
NO. OF DAYS TEMP. > 37.2°C II:
NO. OF DAYS TEMP. > 38.0°C 1:17
NO. OF DAYS TEMP. > 38.0°C II:
NO. OF ANTIBIOTICS USED I : 4
NO. OF ANTIBIOTICS USED II:
NO. OF UNITS OF BLOOD 1:17
NO. OF UNITS OF BLOOD II:
NO. OF UNITS OF PLATELETS USED I : 177
NO. OF UNITS OF PLATELETS USED II:
OTHER BLOOD PRODUCTS USED I : NONE
OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG 1:7.4
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NO
TOTAL PARENTERAL NUTRITION ADMINISTERED II:
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COMPLICATIONS DURING ABMT I :
COMPLICATIONS DURING ABMT II:





























DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L







































DAYS UNTIL PLATELETS >100X109/L 1:51
DAYS UNTIL PLATELETS >100 X 109/L II:
LENGTH OF ADMISSION IN DAYS I : 49
LENGTH OF ADMISSION IN DAYS II:
NO. OF DAYS TEMP. > 37.2°C I : 20
NO. OF DAYS TEMP. > 37.2°C II:
NO. OF DAYS TEMP. > 38.0°C I : 8
NO. OF DAYS TEMP. > 38.0°C II:
NO. OF ANTIBIOTICS USED I : 6
NO. OF ANTIBIOTICS USED II:
NO. OF UNITS OF BLOOD I : 8
NO. OF UNITS OF BLOOD II:
NO. OF UNITS OF PLATELETS USED I : 89
NO. OF UNITS OF PLATELETS USED II:
OTHER BLOOD PRODUCTS USED I : GRANULOCYTES
6 DAYS
OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG I : 9.4
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : YES





I : GM -VE SEPTICAEMIA
II:
































DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 1 09/L







































DAYS UNTIL PLATELETS >100 X 109/L I : 73
DAYS UNTIL PLATELETS >100 X 109/L II:
LENGTH OF ADMISSION IN DAYS I : 47
LENGTH OF ADMISSION IN DAYS II:
NO. OF DAYS TEMP. > 37.2°C I : 21
NO. OF DAYS TEMP. > 37.2°C II:
NO. OF DAYS TEMP. > 38.0°C I : 6
NO. OF DAYS TEMP. > 38.0°C II:
NO. OF ANTIBIOTICS USED I : 5
NO. OF ANTIBIOTICS USED II:
NO. OF UNITS OF BLOOD I : 8
NO. OF UNITS OF BLOOD II:
NO. OF UNITS OF PLATELETS USED I : 51
NO. OF UNITS OF PLATELETS USED II:
OTHER BLOOD PRODUCTS USED I : NONE
OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG 1:2.5
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NO





I : NIL OF NOTE
II:




























DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L







































DAYS UNTIL PLATELETS >100 X 109/L 1:35
DAYS UNTIL PLATELETS >100 X 109/L II:
LENGTH OF ADMISSION IN DAYS I : 35
LENGTH OF ADMISSION IN DAYS II:
NO. OF DAYS TEMP. > 37.2°C 1:15
NO. OF DAYS TEMP. > 37.2°C II:
NO. OF DAYS TEMP. > 38.0°C 1:15
NO. OF DAYS TEMP. > 38.0°C II:
NO. OF ANTIBIOTICS USED I : 6
NO. OF ANTIBIOTICS USED II:
NO. OF UNITS OF BLOOD I : 6
NO. OF UNITS OF BLOOD II:
NO. OF UNITS OF PLATELETS USED I : 54
NO. OF UNITS OF PLATELETS USED II:
OTHER BLOOD PRODUCTS USED I : NONE
OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG I : 5.5
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NO





I : NIL OF NOTE
II:































DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 10 /KG
GM CFC X 104/KG
9
DAYS UNTIL WBC >1.0 X 10 /L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L






































DAYS UNTIL PLATELETS >50 X 10y/L II:
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DAYS UNTIL PLATELETS >100 X 109/L I : 22
DAYS UNTIL PLATELETS >100 X 109/L II:
LENGTH OF ADMISSION IN DAYS I : NA
LENGTH OF ADMISSION IN DAYS II:
NO. OF DAYS TEMP. > 37.2°C I : NA
NO. OF DAYS TEMP. > 37.2°C II:
NO. OF DAYS TEMP. > 38.0°C I : NA
NO. OF DAYS TEMP. > 38.0°C II:
NO. OF ANTIBIOTICS USED I : NA
NO. OF ANTIBIOTICS USED II:
NO. OF UNITS OF BLOOD I : NA
NO. OF UNITS OF BLOOD II:
NO. OF UNITS OF PLATELETS USED I : NA
NO. OF UNITS OF PLATELETS USED II:
OTHER BLOOD PRODUCTS USED I : NA
OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG I : NA
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NA


























UNIQUE PATIENT NUMBER 1 43
PATIENT NAME • D FIGG
HOSPITAL NUMBER : FD0170
DATE OF BIRTH : 20.9.35




DATE OF DIAGNOSIS ' 27.1.84
DATE OF 1 ST CR : 16.2.84
DATE OF CR PRE-ABMT : 16.2.84
STATUS AT TIME OF 1 ST HARVEST : 1ST CR
DATE OF HARVEST I : 13.4.84
DATE OF HARVEST II: 27.7.84
STATUS AT TIME OF ABMT I : 1ST CR
DATE OF ABMT I : 29.5.84
DATE OF ABMT II: 11.8.84
NUCLEATED CELL COUNT X 108/KG I : 2.46
NUCLEATED CELL COUNT X 108/KG II: 2.63
GM CFC X 104/KG I : 1 2.54
GM CFC X 104/KG II: 1 5
DAYS UNTIL WBC >1.0 X 109/L I : 1 4
DAYS UNTIL WBC >1.0 X 109/L II: 1 6
DAYS UNTIL NEUTS >0.5 X 109/L I : 1 6
DAYS UNTIL NEUTS >0.5 X 109/L II: 1 4
DAYS UNTIL PLATELETS >50 X 109/L I : 20
DAYS UNTIL PLATELETS >50 X 109/L II: 26
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DAYS UNTIL PLATELETS >100 X 10 /L
DAYS UNTIL PLATELETS >100 X 109/L
LENGTH OF ADMISSION IN DAYS
LENGTH OF ADMISSION IN DAYS
NO. OF DAYS TEMP. >37.2°C
NO. OF DAYS TEMP. >37.2°C
NO. OF DAYS TEMP. >38.0°C
NO. OF DAYS TEMP. >38.0°C
NO. OF ANTIBIOTICS USED
NO. OF ANTIBIOTICS USED
NO. OF UNITS OF BLOOD
NO. OF UNITS OF BLOOD
NO. OF UNITS OF PLATELETS USED
NO. OF UNITS OF PLATELETS USED
OTHER BLOOD PRODUCTS USED
OTHER BLOOD PRODUCTS USED
WEIGHT LOSS IN KG I
WEIGHT LOSS IN KG II: 5
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NO































I : INFECTION HICKMAN /
TIFFLITIS
II: ECTHYMA GANGRENOSUM
ON FACE/GRAND MAL FIT














: GRAND MAL FIT WHEN
ANTI-CONVULSANTS
STOPPED
CURRENT STATUS : WELL
331
UNIQUE PATIENT NUMBER 1 47
PATIENT NAME •• M HOWDEN
HOSPITAL NUMBER • FD3183
DATE OF BIRTH : 3.3.49




DATE OF DIAGNOSIS • 14.12.83
DATE OF 1 ST CR : 6.2.84
DATE OF CR PRE-ABMT : 6.2.84
STATUS AT TIME OF 1 ST HARVEST : 1ST CR
DATE OF HARVEST I : 22.6.84
DATE OF HARVEST II: 7.9.84
STATUS AT TIME OF ABMT I : 1ST CR
DATE OF ABMT I : 30.6.84
DATE OF ABMT II: 15.9.84
NUCLEATED CELL COUNT X 108/KG I : 1 .76
NUCLEATED CELL COUNT X 108/KG II: 2.04
GM CFC X 104/KG I : 1 3.62
GM CFC X 104/KG II: 15.04
DAYS UNTIL WBC >1.0 X 109/L I : 1 9
DAYS UNTIL WBC >1.0 X 109/L II: 26
DAYS UNTIL NEUTS >0.5 X 109/L I : 21
DAYS UNTIL NEUTS >0.5 X 109/L II: 26
DAYS UNTIL PLATELETS >50 X 1 09/L I : 33
DAYS UNTIL PLATELETS >50 X 109/L II: 45
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DAYS UNTIL PLATELETS >100 X 10 /L I
DAYS UNTIL PLATELETS >100 X 109/L II
LENGTH OF ADMISSION IN DAYS I
LENGTH OF ADMISSION IN DAYS II
NO. OF DAYS TEMP. >37.2°C I
NO. OF DAYS TEMP. >37.2°C II
NO. OF DAYS TEMP. >38.0°C I
NO. OF DAYS TEMP. >38.0°C II
NO. OF ANTIBIOTICS USED I
NO. OF ANTIBIOTICS USED II
NO. OF UNITS OF BLOOD I
NO. OF UNITS OF BLOOD II
NO. OF UNITS OF PLATELETS USED I
NO. OF UNITS OF PLATELETS USED II
OTHER BLOOD PRODUCTS USED I
OTHER BLOOD PRODUCTS USED II
WEIGHT LOSS IN KG I
WEIGHT LOSS IN KG II
TOTAL PARENTERAL NUTRITION ADMINISTERED I





I : INFECTION HICKMAN
II: NO MAJOR
COMPLICATIONS





















UNIQUE PATIENT NUMBER 1 48
PATIENT NAME M WESTON
HOSPITAL NUMBER FC3978
DATE OF BIRTH 14.9.57




DATE OF DIAGNOSIS 23.12.83
DATE OF 1 ST CR 31.1.84
DATE OF CR PRE-ABMT 31.1.84
STATUS AT TIME OF 1 ST HARVEST 1 ST CR
DATE OF HARVEST I : 29.6.84
DATE OF HARVEST II: 12.10.84
STATUS AT TIME OF ABMT I : 1 ST CR
DATE OF ABMT I : 9.7.84
DATE OF ABMT II: 22.10.84
NUCLEATED CELL COUNT X 108/KG I : 1 .65
NUCLEATED CELL COUNT X 108/KG II: 1 .54
GM CFC X 104/KG I : 9.66
GM CFC X 104/KG II: 1 0.46
DAYS UNTIL WBC >1.0 X 1 09/L I : 28
DAYS UNTIL WBC >1.0 X 109/L II: 24
DAYS UNTIL NEUTS >0.5 X 109/L I : 39
DAYS UNTIL NEUTS >0.5 X 109/L II: 35
DAYS UNTIL PLATELETS >50 X 109/L I : 39
DAYS UNTIL PLATELETS >50 X 109/L II: 49
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DAYS UNTIL PLATELETS >100 X 1 0 /L
DAYS UNTIL PLATELETS >1 00 X 1 09/L
LENGTH OF ADMISSION IN DAYS
LENGTH OF ADMISSION IN DAYS
NO. OF DAYS TEMP. >37.2°C
NO. OF DAYS TEMP. >37.2°C
NO. OF DAYS TEMP. >38.0°C
NO. OF DAYS TEMP. >38.0°C
NO. OF ANTIBIOTICS USED
NO. OF ANTIBIOTICS USED
NO. OF UNITS OF BLOOD
NO. OF UNITS OF BLOOD
NO. OF UNITS OF PLATELETS USED
NO. OF UNITS OF PLATELETS USED
OTHER BLOOD PRODUCTS USED
OTHER BLOOD PRODUCTS USED
WEIGHT LOSS IN KG
WEIGHT LOSS IN KG II: 10
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NO































I : PAIN AT SITE OF
HICKMAN
II: NIL OF NOTE












CURRENT STATUS : WELL
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UNIQUE PATIENT NUMBER •• 1 50
PATIENT NAME •• A SAMAD
HOSPITAL NUMBER •• FD0570
DATE OF BIRTH •• 10.8.37




DATE OF DIAGNOSIS 8.4.84
DATE OF 1 ST CR •• 6.6.84
DATE OF CR PRE-ABMT • 6.6.84
STATUS AT TIME OF 1ST HARVEST •• 1ST CR
DATE OF HARVEST I : 5.7.84
DATE OF HARVEST II: 7.9.84
STATUS AT TIME OF ABMT I : 1ST CR
DATE OF ABMT I : 17.7.84
DATE OF ABMT II: 18.9.84
NUCLEATED CELL COUNT X 108/KG I : 1 .37
NUCLEATED CELL COUNT X 108/KG II: 3.07
GM CFC X 104/KG I : NA
GM CFC X 104/KG II: NA
DAYS UNTIL WBC >1.0 X 109/L I : 1 5
DAYS UNTIL WBC >1.0 X 109/L II: NEVER
DAYS UNTIL NEUTS >0.5 X 109/L I : 20
DAYS UNTIL NEUTS >0.5 X 109/L II: NEVER
DAYS UNTIL PLATELETS >50 X 1 09/L I : 20
DAYS UNTIL PLATELETS >50 X 1 09/L II: NEVER
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DAYS UNTIL PLATELETS >100 X 109/L I
DAYS UNTIL PLATELETS >100 X 109/L II
LENGTH OF ADMISSION IN DAYS I
LENGTH OF ADMISSION IN DAYS II
NO. OF DAYS TEMP. > 37.2°C I
NO. OF DAYS TEMP. > 37.2°C II
NO. OF DAYS TEMP. > 38.0°C I
NO. OF DAYS TEMP. > 38.0°C II
NO. OF ANTIBIOTICS USED I
NO. OF ANTIBIOTICS USED II
NO. OF UNITS OF BLOOD I
NO. OF UNITS OF BLOOD II
NO. OF UNITS OF PLATELETS USED I
NO. OF UNITS OF PLATELETS USED II
OTHER BLOOD PRODUCTS USED I
OTHER BLOOD PRODUCTS USED II
WEIGHT LOSS IN KG I
WEIGHT LOSS IN KG II
TOTAL PARENTERAL NUTRITION ADMINISTERED I



























































DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L







































DAYS UNTIL PLATELETS >100 X 109/L 1:24
DAYS UNTIL PLATELETS >100 X 109/L II:
LENGTH OF ADMISSION IN DAYS I : 30
LENGTH OF ADMISSION IN DAYS II:
NO. OF DAYS TEMP. >37.2°C I : 22
NO. OF DAYS TEMP. >37.2°C II:
NO. OF DAYS TEMP. >38.0°C 1:12
NO. OF DAYS TEMP. >38.0°C II:
NO. OF ANTIBIOTICS USED I : 7
NO. OF ANTIBIOTICS USED II:
NO. OF UNITS OF BLOOD I : 7
NO. OF UNITS OF BLOOD II:
NO. OF UNITS OF PLATELETS USED I : 80
NO. OF UNITS OF PLATELETS USED II:
OTHER BLOOD PRODUCTS USED I : NONE
OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG 1:1.4
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NO














I : NO MAJOR
COMPLICATIONS
II:





















DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 1 09/L
DAYS UNTIL PLATELETS >50 X 109/L







































DAYS UNTIL PLATELETS >100 X 1 0 /L
DAYS UNTIL PLATELETS >1 00 X 1 09/L
LENGTH OF ADMISSION IN DAYS
LENGTH OF ADMISSION IN DAYS
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 37.2°C
NO. OF DAYS TEMP. > 38.0°C
NO. OF DAYS TEMP. > 38.0°C
NO. OF ANTIBIOTICS USED
NO. OF ANTIBIOTICS USED
NO. OF UNITS OF BLOOD
NO. OF UNITS OF BLOOD
NO. OF UNITS OF PLATELETS USED
NO. OF UNITS OF PLATELETS USED




















OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG I :
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I :













I : LUNG INFECTION
II:


























DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 1 09/L







































DAYS UNTIL PLATELETS >100 X 109/L I : 43
DAYS UNTIL PLATELETS >100 X 109/L II:
LENGTH OF ADMISSION IN DAYS I : 40
LENGTH OF ADMISSION IN DAYS II:
NO. OF DAYS TEMP. >37.2°C 1:12
NO. OF DAYS TEMP. >37.2°C II:
NO. OF DAYS TEMP. >38.0°C I : 9
NO. OF DAYS TEMP. >38.0°C II:
NO. OF ANTIBIOTICS USED I : 7
NO. OF ANTIBIOTICS USED II:
NO. OF UNITS OF BLOOD I : 5
NO. OF UNITS OF BLOOD II:
NO. OF UNITS OF PLATELETS USED I : 106
NO. OF UNITS OF PLATELETS USED II:
OTHER BLOOD PRODUCTS USED I : NONE
OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG I : 10.5
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NO
TOTAL PARENTERAL NUTRITION ADMINISTERED II:
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COMPLICATIONS DURING ABMT I :
COMPLICATIONS DURING ABMT II;






























DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L







































DAYS UNTIL PLATELETS >100 X 109/L I : 35
DAYS UNTIL PLATELETS >100 X 109/L II:
LENGTH OF ADMISSION IN DAYS I : 32
LENGTH OF ADMISSION IN DAYS II:
NO. OF DAYS TEMP. >37.2°C 1:10
NO. OF DAYS TEMP. >37.2°C II:
NO. OF DAYS TEMP. >38.0°C I : 3
NO. OF DAYS TEMP. >38.0°C II:
NO. OF ANTIBIOTICS USED I : 4
NO. OF ANTIBIOTICS USED II:
NO. OF UNITS OF BLOOD I : 6
NO. OF UNITS OF BLOOD II:
NO. OF UNITS OF PLATELETS USED I : 39
NO. OF UNITS OF PLATELETS USED II:
OTHER BLOOD PRODUCTS USED I : NONE
OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG 1:1
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NO
TOTAL PARENTERAL NUTRITION ADMINISTERED II:
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COMPLICATIONS DURING ABMT I :
COMPLICATIONS DURING ABMT II:





































DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L






































DAYS UNTIL PLATELETS >100 X 109/L 1:23
DAYS UNTIL PLATELETS >100 X 109/L II:
LENGTH OF ADMISSION IN DAYS I : NA
LENGTH OF ADMISSION IN DAYS II:
NO. OF DAYS TEMP. > 37.2°C I : NA
NO. OF DAYS TEMP. > 37.2°C II:
NO. OF DAYS TEMP. > 38.0°C I : NA
NO. OF DAYS TEMP. > 38.0°C II:
NO. OF ANTIBIOTICS USED I : NA
NO. OF ANTIBIOTICS USED II:
NO. OF UNITS OF BLOOD I : NA
NO. OF UNITS OF BLOOD II:
NO. OF UNITS OF PLATELETS USED I : NA
NO. OF UNITS OF PLATELETS USED II:
OTHER BLOOD PRODUCTS USED I : NA
OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG I : NA
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NA
TOTAL PARENTERAL NUTRITION ADMINISTERED II:
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COMPLICATIONS DURING ABMT I : PERICARDITIS
COMPLICATIONS DURING ABMT II:
POSITIVE MICROBIOLOGY ISOLATES I : Candida; Throat/Coag




























DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 1 09/L







































DAYS UNTIL PLATELETS >100 X 109/L I : NEVER
DAYS UNTIL PLATELETS >100 X 109/L II;
LENGTH OF ADMISSION IN DAYS I : 49
LENGTH OF ADMISSION IN DAYS II;
NO. OF DAYS TEMP. >37.2°C I : 8
NO. OF DAYS TEMP. >37.2°C II:
NO. OF DAYS TEMP. >38.0°C I : 1
NO. OF DAYS TEMP. >38.0°C II;
NO. OF ANTIBIOTICS USED I : 7
NO. OF ANTIBIOTICS USED II;
NO. OF UNITS OF BLOOD I : 4
NO. OF UNITS OF BLOOD II;
NO. OF UNITS OF PLATELETS USED I ; 20
NO. OF UNITS OF PLATELETS USED II;
OTHER BLOOD PRODUCTS USED I : NONE
OTHER BLOOD PRODUCTS USED II;
WEIGHT LOSS IN KG 1:5
WEIGHT LOSS IN KG II;
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NO
TOTAL PARENTERAL NUTRITION ADMINISTERED II;
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COMPLICATIONS DURING ABMT I : NIL OF NOTE
COMPLICATIONS DURING ABMT II:
POSITIVE MICROBIOLOGY ISOLATES I : Coag -ve staph; H.
CI difficile Toxin
Faeces

















UNIQUE PATIENT NUMBER •• B1
PATIENT NAME •• B BAINS
HOSPITAL NUMBER •• QE HOSPITAL
DATE OF BIRTH •• 9.1.66
AGE IN YEARS • 1 8
SEX •• M
DIAGNOSIS • ALL
CLASSIFICATION •• CALL L1
DATE OF DIAGNOSIS •• 15.1.82
DATE OF 1ST CR •• 16.3.82
DATE OF CR PRE-ABMT • 16.3.82
STATUS AT TIME OF 1ST HARVEST : 1ST CR
DATE OF HARVEST I : 6.12.83
DATE OF HARVEST II: 26.3.84
STATUS AT TIME OF ABMT I : 1ST CR
DATE OF ABMT I : 13.12.83
DATE OF ABMT II: 9.4.84
NUCLEATED CELL COUNT X 108/KG I : 2.3
NUCLEATED CELL COUNT X 108/KG II: 1 .0
GM CFC X 104/KG I : 7.0
GM CFC X 104/KG II: 0.6
DAYS UNTIL WBC >1.0 X 109/L I : 28
DAYS UNTIL WBC >1.0 X 109/L II: NEVER
DAYS UNTIL NEUTS >0.5 X 109/L I : 24
DAYS UNTIL NEUTS >0.5 X 109/L II: NEVER
DAYS UNTIL PLATELETS >50 X 109/L I : 28
DAYS UNTIL PLATELETS >50 X 109/L II: NEVER
359
DAYS UNTIL PLATELETS >100 X 109/L I
DAYS UNTIL PLATELETS >100 X 109/L II
LENGTH OF ADMISSION IN DAYS I
LENGTH OF ADMISSION IN DAYS II
NO. OF DAYS TEMP. > 37.2°C I
NO. OF DAYS TEMP. > 37.2°C II
NO. OF DAYS TEMP. > 38.0°C I
NO. OF DAYS TEMP. > 38.0°C II
NO. OF ANTIBIOTICS USED I
NO. OF ANTIBIOTICS USED II
NO. OF UNITS OF BLOOD I
NO. OF UNITS OF BLOOD II
NO. OF UNITS OF PLATELETS USED I
NO. OF UNITS OF PLATELETS USED II
OTHER BLOOD PRODUCTS USED I
OTHER BLOOD PRODUCTS USED II
WEIGHT LOSS IN KG I
WEIGHT LOSS IN KG II
TOTAL PARENTERAL NUTRITION ADMINISTERED I


































I : NO MAJOR
COMPLICATION
II: LUNG INFECTION
I : Coag -ve staph; H.S./
Strep faecalis;
Faeces










UNIQUE PATIENT NUMBER B2
PATIENT NAME B MELLET
HOSPITAL NUMBER QE HOSPITAL
DATE OF BIRTH 2.11.33




DATE OF DIAGNOSIS 4.9.82
DATE OF 1 ST CR 9.11 .82
DATE OF CR PRE-ABMT 9.11.82
STATUS AT TIME OF 1ST HARVEST 1 ST CR
DATE OF HARVEST I : 30.10.83
DATE OF HARVEST II: 21.3.84
STATUS AT TIME OF ABMT I : 1 ST CR
DATE OF ABMT I : 16.2.84
DATE OF ABMT II: 18.3.85
NUCLEATED CELL COUNT X 108/KG I : 1 .3
NUCLEATED CELL COUNT X 108/KG II: 1 .6
GM CFC X 104/KG I : 1 .1
GM CFC X 104/KG II: 2.6
DAYS UNTIL WBC >1.0 X 109/L I : 1 1
DAYS UNTIL WBC >1.0 X 109/L II: 23
DAYS UNTIL NEUTS >0.5 X 109/L I : 1 2
DAYS UNTIL NEUTS >0.5 X 109/L II: 23
DAYS UNTIL PLATELETS >50 X 109/L I : 1 6
DAYS UNTIL PLATELETS >50 X 1 09/L II: 34
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DAYS UNTIL PLATELETS >100 X 109/L I
DAYS UNTIL PLATELETS >100 X 109/L II
LENGTH OF ADMISSION IN DAYS I
LENGTH OF ADMISSION IN DAYS II
NO. OF DAYS TEMP. > 37.2°C I
NO. OF DAYS TEMP. > 37.2°C II
NO. OF DAYS TEMP. > 38.0°C I
NO. OF DAYS TEMP. > 38.0°C II
NO. OF ANTIBIOTICS USED I
NO. OF ANTIBIOTICS USED II
NO. OF UNITS OF BLOOD I
NO. OF UNITS OF BLOOD II
NO. OF UNITS OF PLATELETS USED I
NO. OF UNITS OF PLATELETS USED II
OTHER BLOOD PRODUCTS USED I
OTHER BLOOD PRODUCTS USED II
WEIGHT LOSS IN KG I
WEIGHT LOSS IN KG II
TOTAL PARENTERAL NUTRITION ADMINISTERED I




I : NO MAJOR
COMPLICATIONS
II: ATRIAL TACHYCARDIA
POSITIVE MICROBIOLOGY ISOLATES I : Staph aureus; Blood
























DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L







































DAYS UNTIL PLATELETS >100 X 109/L I : 40
DAYS UNTIL PLATELETS >100 X 109/L II:
LENGTH OF ADMISSION IN DAYS I : NA
LENGTH OF ADMISSION IN DAYS II:
NO. OF DAYS TEMP. > 37.2°C I : NA
NO. OF DAYS TEMP. > 37.2°C II:
NO. OF DAYS TEMP. > 38.0°C I : NA
NO. OF DAYS TEMP. > 38.0°C II:
NO. OF ANTIBIOTICS USED I : NA
NO. OF ANTIBIOTICS USED II:
NO. OF UNITS OF BLOOD I : NA
NO. OF UNITS OF BLOOD II:
NO. OF UNITS OF PLATELETS USED I : NA
NO. OF UNITS OF PLATELETS USED II:
OTHER BLOOD PRODUCTS USED I : NA
OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG I : NA
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NA
TOTAL PARENTERAL NUTRITION ADMINISTERED II:
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COMPLICATIONS DURING ABMT I : SEPTICAEMIA
COMPLICATIONS DURING ABMT II:
POSITIVE MICROBIOLOGY ISOLATES I : a haem strep; Blood/
Coag -ve staph;
H.S., Nose
























DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L







































DAYS UNTIL PLATELETS >100 X 109/L I : 61
DAYS UNTIL PLATELETS >100 X 109/L II:
LENGTH OF ADMISSION IN DAYS I : NA
LENGTH OF ADMISSION IN DAYS II:
NO. OF DAYS TEMP. >37.2°C I : NA
NO. OF DAYS TEMP. >37.2°C II:
NO. OF DAYS TEMP. >38.0°C I : NA
NO. OF DAYS TEMP. >38.0°C II:
NO. OF ANTIBIOTICS USED I : NA
NO. OF ANTIBIOTICS USED II:
NO. OF UNITS OF BLOOD I : NA
NO. OF UNITS OF BLOOD II:
NO. OF UNITS OF PLATELETS USED I : NA
NO. OF UNITS OF PLATELETS USED II:
OTHER BLOOD PRODUCTS USED I : NA
OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG I : NA
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NA
TOTAL PARENTERAL NUTRITION ADMINISTERED II:
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COMPLICATIONS DURING ABMT HAEMORRHAGIC
CYSTITIS & LVF
COMPLICATIONS DURING ABMT II:




























DATE OF 1 ST CR
DATE OF CR PRE-ABMT
STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
DATE OF ABMT
NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
GM CFC X 104/KG
GM CFC X 104/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L







































DAYS UNTIL PLATELETS >100 X 109/L I : NEVER
DAYS UNTIL PLATELETS >100 X 109/L II:
LENGTH OF ADMISSION IN DAYS I : NA
LENGTH OF ADMISSION IN DAYS II:
NO. OF DAYS TEMP. > 37.2°C I : NA
NO. OF DAYS TEMP. > 37.2°C II:
NO. OF DAYS TEMP. > 38.0°C I : NA
NO. OF DAYS TEMP. > 38.0°C II:
NO. OF ANTIBIOTICS USED I : NA
NO. OF ANTIBIOTICS USED II:
NO. OF UNITS OF BLOOD I : NA
NO. OF UNITS OF BLOOD II:
NO. OF UNITS OF PLATELETS USED I : NA
NO. OF UNITS OF PLATELETS USED II:
OTHER BLOOD PRODUCTS USED I : NA
OTHER BLOOD PRODUCTS USED II:
WEIGHT LOSS IN KG I : NA
WEIGHT LOSS IN KG II:
TOTAL PARENTERAL NUTRITION ADMINISTERED I : NA






I : COLLAPSE DURING
MARROW INFUSION
II:
I : B haem Strep; Blood/

















CURRENT STATUS : DEAD
373
APPENDIX II
PATIENT DATA - LYMPHOMA
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ABBREVIATIONS
NA, Data not available.
PP, Private patient.
SEX:
M, male; F, female.
DIAGNOSIS:
NHL, non-Hodgkin1s lymphoma; HD, Hodgkin's disease.
STAGE AT DIAGNOSIS:
This refers to the Ann Arbor staging classification.
CLASSIFICATION:
INT GRADE, Intermediate grade diffuse; HIGH GRADE, High
grade diffuse; NS, Nodular sclerosing; MC, Mixed
cellularity.
TREATMENT PRE ABMT:
CHOP; Cyclophosphamide, Adriamycin, Vincristine,
Prednisolone.
M BACOD; Methotrexate, Bleomycin, Adriamycin,
Cyclophosphamide, Vincristine, Dexamethasone.
BACOP; Bleomycin, Adriamycin, Cyclophosphamide,
Vincristine, Prednisolone.
M BACOP; Methotrexate, Bleomycin, Adriamycin,
Cyclophosphamide, Vincristine, Prednisolone.
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HD MTX; High dose methotrexate.
DXT; Radiotherapy.
EVAP; VP1 6, Vinblastine, Adriamycin, Prednisolone.
Cyt/Thio/Cyclo, Cytosine Arabinoside, Thioguanine,
Cyclophosphamide.
IT MTX; Intrathecal methotrexate.
MOPP; Nitrogen Mustard, Vincristine, Procarbazine,
Prednisolone.
LOPP; Chlorambucil, Vincristine, Procarbazine,
Prednisolone.
Cis Plat; Cis Platinum.
VIND/VP16/CCNU/DEX Vindesine, VP16, Lomustine,
Dexamethasone.
ProMACE; Prednisolone, Methotrexate, Adriamycin,
Cyclophosphamide, VP16.
COP; Cyclophosphamide, Vincristine, Prednisolone.
CCNU/Bl/Vbl/P; Lomustine (CCNU), Bleomycin, Vinblastine,
Prednisolone.
ABVD; Adriamycin, Bleomycin, Vinblastine, Imidazole
Carboximide.
AVD; Adriamycin, Vinblastine, Imidazole Carboximide.
HD ARA C; High dose Cytosine Arabinoside.
OPEC; Vincristine, Prednisolone, VP16, Cyclophosphamide.
CCNU/Bleo/Vind; Lomustine, Bleomycin, Vindesine.
C/Vbl/Bl; Cyclophosphamide, Vinblastine, Bleomycin.
STATUS AT TIME OF ABMT:
RR, Resistant Relapse; NON RR, Non Resistant Relapse.
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ABMT PROTOCOL USED;
UCH I & II, BEAM, BNLI.
STATUS POST ABMT:
CR, Complete Remission; PR, Partial Remission; NE, Not
Evaluable; NR, No Response.
MICROBIOLOGY:
Coag -ve staph, Coagulase negative staphylococci
H.S., Hickman entry site.
Pseud, Pseudomonas
E coli, Escherichia coli
H tip, Hickman tip
a haem strep, a haemolytic streptococcus








Gp B, Group B
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UNIQUE PATIENT NUMBER : 34
PATIENT NAME : R TURNER
HOSPITAL NUMBER : EV0794
DATE OF BIRTH : 24.6.42
AGE IN YEARS : 38
SEX : M
DIAGNOSIS : NHL
STAGE AT DIAGNOSIS : III
CLASSIFICATION : INT GRADE
DATE OF DIAGNOSIS : 14.5.79
TREATMENT PRE ABMT : CHOP
M BACOD
PREVIOUS MARROW INFILTRATION
STATUS AT TIME OF 1ST HARVEST
DATE OF HARVEST
DATE OF HARVEST




NUCLEATED CELL COUNT X 108/KG
NUCLEATED CELL COUNT X 108/KG
DAYS UNTIL WBC >1.0 X 109/L















DAYS UNTIL NEUTS >0.5 X 10 /L I
DAYS UNTIL NEUTS >0.5 X 109/L II
DAYS UNTIL PLATELETS >50 X 109/L I
DAYS UNTIL PLATELETS >50 X 109/L II
DAYS UNTIL PLATELETS >100 X 109/L I
DAYS UNTIL PLATELETS >100 X 109/L II
COMPLICATIONS DURING ABMT I
































UNIQUE PATIENT NUMBER : 61
PATIENT NAME : R TIFFIN
HOSPITAL NUMBER : EL8793
DATE OF BIRTH : 21.4.27
AGE IN YEARS : 55
SEX : M
DIAGNOSIS : HD
STAGE AT DIAGNOSIS : III
CLASSIFICATION : NS
DATE OF DIAGNOSIS : APRIL 78
TREATMENT PRE ABMT : MOPP X 6
BACOP X 5
PREVIOUS MARROW INFILTRATION : NO
STATUS AT TIME OF HARVEST : RELAPSE
DATE OF HARVEST : 3.8.82
STATUS AT TIME OF ABMT I : RR
DATE OF ABMT I : 8.8.82
DATE OF ABMT II: 5.12.82
ABMT PROTOCOL USED : UCH I & II
NUCLEATED CELL COUNT X 108/KG : NA
DAYS UNTIL WBC >1.0 X 109/L I : 32
DAYS UNTIL WBC >1.0 X 109/L II: 23
DAYS UNTIL NEUTS >0.5 X 109/L I : 34
DAYS UNTIL NEUTS >0.5 X 109/L II: 25
DAYS UNTIL PLATELETS >50 X 109/L I : 46
DAYS UNTIL PLATELETS >50 X 109/L II: 38
DAYS UNTIL PLATELETS >100 X 109/L I : 60
DAYS UNTIL PLATELETS >100 X 109/L II: 73
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COMPLICATIONS DURING ABMT I :
COMPLICATIONS DURING ABMT II:
POSITIVE MICROBIOLOGY ISOLATES I :










































STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST I
DATE OF HARVEST II
STATUS AT TIME OF ABMT I
DATE OF ABMT I
DATE OF ABMT II
ABMT PROTOCOL USED
NUCLEATED CELL COUNT X 108/KG I
NUCLEATED CELL COUNT X 108/KG II
DAYS UNTIL WBC >1.0 X 109/L I
DAYS UNTIL WBC >1.0 X 109/L II
DAYS UNTIL NEUTS >0.5 X 109/L I





























DAYS UNTIL PLATELETS >50 X 109/L I :
DAYS UNTIL PLATELETS >50 X 109/L II:
DAYS UNTIL PLATELETS >100 X 109/L I :
DAYS UNTIL PLATELETS >100 X 109/L II:
COMPLICATIONS DURING ABMT I :
COMPLICATIONS DURING ABMT II:
POSITIVE MICROBIOLOGY ISOLATES I :











































STATUS AT TIME OF 1ST HARVEST
DATE OF HARVEST I :
DATE OF HARVEST II:
STATUS AT TIME OF ABMT I :
DATE OF ABMT I :
DATE OF ABMT II:
ABMT PROTOCOL USED :
NUCLEATED CELL COUNT X 108/KG I :
NUCLEATED CELL COUNT X 108/KG II:
DAYS UNTIL WBC >1.0 X 109/L I :
DAYS UNTIL WBC >1.0 X 109/L II:
DAYS UNTIL NEUTS >0.5 X 109/L I :


























DAYS UNTIL PLATELETS >50 X 109/L I
DAYS UNTIL PLATELETS >50 X 109/L II
DAYS UNTIL PLATELETS >100 X 109/L I
DAYS UNTIL PLATELETS >100 X 109/L II
COMPLICATIONS DURING ABMT I
COMPLICATIONS DURING ABMT II


































STATUS AT TIME OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT I
DATE OF ABMT I
DATE OF ABMT II
ABMT PROTOCOL USED
NUCLEATED CELL COUNT X 108/KG
DAYS UNTIL WBC >1.0 X 109/L I
DAYS UNTIL WBC >1.0 X 109/L II
DAYS UNTIL NEUTS >0.5 X 109/L I
DAYS UNTIL NEUTS >0.5 X 109/L II
DAYS UNTIL PLATELETS >50 X 109/L I





























DAYS UNTIL PLATELETS >100 X 1 0 /L I :
DAYS UNTIL PLATELETS >100 X 109/L II:
COMPLICATIONS DURING ABMT




































STATUS AT TIME OF 1ST HARVEST
DATE OF HARVEST I
DATE OF HARVEST II
STATUS AT TIME OF ABMT I
DATE OF ABMT I
DATE OF ABMT II
ABMT PROTOCOL USED
NUCLEATED CELL COUNT X 108/KG I
NUCLEATED CELL COUNT X 108/KG II
DAYS UNTIL WBC >1.0 X 109/L I
DAYS UNTIL WBC >1.0 X 109/L II
DAYS UNTIL NEUTS >0.5 X 109/L I


























DAYS UNTIL PLATELETS >50 X 10 /L I 1 5
DAYS UNTIL PLATELETS >50 X 1 0 /L II:
DAYS UNTIL PLATELETS >100 X 109/L I :
DAYS UNTIL PLATELETS >100 X 109/L II:
COMPLICATIONS DURING ABMT I :
COMPLICATIONS DURING ABMT II:




































STATUS AT TIME OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT I
DATE OF ABMT I
DATE OF ABMT II
ABMT PROTOCOL USED
NUCLEATED CELL COUNT X 108/KG
DAYS UNTIL WBC >1.0 X 109/L I
DAYS UNTIL WBC >1.0 X 109/L II
DAYS UNTIL NEUTS >0.5 X 109/L I
DAYS UNTIL NEUTS >0.5 X 109/L II
DAYS UNTIL PLATELETS >50 X 109/L I


























DAYS UNTIL PLATELETS >100 X 10 /L I NEVER
DAYS UNTIL PLATELETS >100 X 10/L II:
COMPLICATIONS DURING ABMT I :
COMPLICATIONS DURING ABMT II:






























STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST I :
DATE OF HARVEST II:
STATUS AT TIME OF ABMT I :
DATE OF ABMT I :
DATE OF ABMT II:
ABMT PROTOCOL USED :
NUCLEATED CELL COUNT X 108/KG I :
NUCLEATED CELL COUNT X 108/KG II:
DAYS UNTIL WBC >1.0 X 109/L I :
DAYS UNTIL WBC >1.0 X 109/L II:
DAYS UNTIL NEUTS >0.5 X 109/L I :





























DAYS UNTIL PLATELETS >50 X 109/L I :
DAYS UNTIL PLATELETS >50 X 109/L II:
DAYS UNTIL PLATELETS >100 X 109/L I :
DAYS UNTIL PLATELETS >100 X 109/L II:
COMPLICATIONS DURING ABMT I :
COMPLICATIONS DURING ABMT II:
POSITIVE MICROBIOLOGY ISOLATES I :









































STATUS AT TIME OF 1ST HARVEST
DATE OF HARVEST I
DATE OF HARVEST II
STATUS AT TIME OF ABMT I
DATE OF ABMT I
DATE OF ABMT II
ABMT PROTOCOL USED
NUCLEATED CELL COUNT X 108/KG I
NUCLEATED CELL COUNT X 108/KG II
DAYS UNTIL WBC >1.0 X 109/L I
DAYS UNTIL WBC >1.0 X 109/L II
DAYS UNTIL NEUTS >0.5 X 109/L I


























DAYS UNTIL PLATELETS >50 X 10 /L I 1 4
DAYS UNTIL PLATELETS >50 X 10 /L II:
DAYS UNTIL PLATELETS >100 X 109/L I :
DAYS UNTIL PLATELETS >100 X 109/L II:
COMPLICATIONS DURING ABMT I :
COMPLICATIONS DURING ABMT II:







































STATUS AT TIME OF HARVEST
DATE OF HARVEST




NUCLEATED CELL COUNT X 108/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 1 09/L
DAYS UNTIL NEUTS >0.5 X 1 09/L
DAYS UNTIL PLATELETS >50 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L
DAYS UNTIL PLATELETS >1 00 X 1 09/L





































COMPLICATIONS DURING ABMT I BREAKDOWN OF
PREVIOUS SKIN
GRAFT
COMPLICATIONS DURING ABMT II
POSITIVE MICROBIOLOGY ISOLATES I : Coag -ve staph
Blood
POSITIVE MICROBIOLOGY ISOLATES II
STATUS POST ABMT CR
TREATMENT POST ABMT NONE
COMPLICATIONS POST ABMT :
DATE OF RELAPSE :
SITE OF RELAPSE :
DATE OF DEATH :
CAUSE OF DEATH :














STATUS AT TIME OF 1 ST HARVEST
DATE OF HARVEST I
DATE OF HARVEST II
STATUS AT TIME OF ABMT I
DATE OF ABMT I
DATE OF ABMT II
ABMT PROTOCOL USED
NUCLEATED CELL COUNT X 108/KG I
NUCLEATED CELL COUNT X 108/KG II
DAYS UNTIL WBC >1.0 X 109/L I
DAYS UNTIL WBC >1.0 X 109/L II
DAYS UNTIL NEUTS >0.5 X 109/L I


























DAYS UNTIL PLATELETS >50 X 10 /L I :
DAYS UNTIL PLATELETS >50 X 109/L II:
DAYS UNTIL PLATELETS >100 X 109/L I :
DAYS UNTIL PLATELETS >100 X 109/L II:
COMPLICATIONS DURING ABMT I :
COMPLICATIONS DURING ABMT II:
































STATUS AT TIME OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT I
DATE OF ABMT I
DATE OF ABMT II
ABMT PROTOCOL USED
NUCLEATED CELL COUNT X 108/KG
DAYS UNTIL WBC >1.0 X 109/L I
DAYS UNTIL WBC >1.0 X 109/L II
DAYS UNTIL NEUTS >0.5 X 109/L I
DAYS UNTIL NEUTS >0.5 X 109/L II
DAYS UNTIL PLATELETS >50 X 109/L I
DAYS UNTIL PLATELETS >50 X 109/L II
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DAYS UNTIL PLATELETS >100 X 1 0 /L I


























COMPLICATIONS DURING ABMT I :
COMPLICATIONS DURING ABMT II:










































HD ARA C X 1
PREVIOUS MARROW INFILTRATION
STATUS AT TIME OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
ABMT PROTOCOL USED
NUCLEATED CELL COUNT X 108/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 1 09/L













































status at time of harvest
date of harvest
status at time of abmt
date of abmt
abmt protocol used
nucleated cell count x 108/kg
days until wbc >1.0 x 109/l
days until neuts >0.5 x 109/l
days until platelets >50 x 109/l
















































CURRENT STATUS ALIVE & WELL
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UNIQUE PATIENT NUMBER : 133
PATIENT NAME : T HAIGH
HOSPITAL NUMBER : GUY'S HOSPITAL
DATE OF BIRTH : 4.3.43
AGE IN YEARS : 41
SEX : M
DIAGNOSIS : NHL
STAGE AT DIAGNOSIS : II
CLASSIFICATION : INT GRADE
DATE OF DIAGNOSIS : NOVEMBER 83
TREATMENT PRE ABMT : CHOP X 2
PREVIOUS MARROW INFILTRATION : NO
STATUS AT TIME OF HARVEST : RELAPSE
DATE OF HARVEST : 10.2.84
STATUS AT TIME OF ABMT : NON RR
DATE OF ABMT : 22.2.84
ABMT PROTOCOL USED : BEAM
NUCLEATED CELL COUNT X 108/KG : 1.26
DAYS UNTIL WBC >1.0 X 109/L : 16
DAYS UNTIL NEUTS >0.5 X 109/L : 20
DAYS UNTIL PLATELETS >50 X 109/L : 34



















UNIQUE PATIENT NUMBER : 136
PATIENT NAME : C INGLE
HOSPITAL NUMBER : FB0573
DATE OF BIRTH : 2.12.65
AGE IN YEARS : 19
SEX : M
DIAGNOSIS : NHL
STAGE AT DIAGNOSIS : I
CLASSIFICATION : HIGH GRADE
DATE OF DIAGNOSIS : MAY 83
TREATMENT PRE ABMT : M BACOD X 4
DXT
PREVIOUS MARROW INFILTRATION : NO
STATUS AT TIME OF HARVEST : RELAPSE
DATE OF HARVEST : 2.3.84
STATUS AT TIME OF ABMT : RR
DATE OF ABMT : 13.3.84
ABMT PROTOCOL USED : BEAM
NUCLEATED CELL COUNT X 108/KG : 2.3
DAYS UNTIL WBC >1.0 X 109/L : 20
DAYS UNTIL NEUTS >0.5 X 109/L : 28
DAYS UNTIL PLATELETS >50 X 109/L : 36
DAYS UNTIL PLATELETS >100 X 109/L : 36
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COMPLICATIONS DURING ABMT : SEPTICAEMIA /
PERICARDIAL EFFUSION
POSITIVE MICROBIOLOGY ISOLATES : E coli; Blood/
Candida; Throat/

























STATUS AT TIME OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
ABMT PROTOCOL USED
NUCLEATED CELL COUNT X 108/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L













































UNIQUE PATIENT NUMBER : 146
PATIENT NAME : D GOODMAN
HOSPITAL NUMBER : FD1621
DATE OF BIRTH : 12.2.59
AGE IN YEARS : 25
SEX : F
DIAGNOSIS : HD
STAGE AT DIAGNOSIS : IIA
CLASSIFICATION : NS
DATE OF DIAGNOSIS : APRIL 82
TREATMENT PRE ABMT : LOPP X 6
EVAP X 7
DXT
PREVIOUS MARROW INFILTRATION : NO
STATUS AT TIME OF HARVEST : DIAGNOSIS
DATE OF HARVEST : 13.5.82
STATUS AT TIME OF ABMT : RR
DATE OF ABMT : 1.6.84
ABMT PROTOCOL USED : TBI 875
NUCLEATED CELL COUNT X 108/KG : 0.85
DAYS UNTIL WBC >1.0 X 109/L : 26
DAYS UNTIL NEUTS >0.5 X 109/L : 28
DAYS UNTIL PLATELETS >50 X 109/L : 26

























UNIQUE PATIENT NUMBER : 153
PATIENT NAME : J HINCHLIFFE
HOSPITAL NUMBER : FD1622
DATE OF BIRTH : 28.3.50
AGE IN YEARS : 33
SEX : F
DIAGNOSIS : NHL
STAGE AT DIAGNOSIS : IV
CLASSIFICATION : HIGH GRADE
DATE OF DIAGNOSIS : 4.7.83
TREATMENT PRE ABMT : CHOP X 6
CIS PLAT X 1
PREVIOUS MARROW INFILTRATION : NO
STATUS AT TIME OF HARVEST : 2ND CR
DATE OF HARVEST : 20.7.84
STATUS AT TIME OF ABMT : NON RR
DATE OF ABMT : 28.7.84
ABMT PROTOCOL USED : BEAM
NUCLEATED CELL COUNT X 108/KG : 2.04
DAYS UNTIL WBC >1.0 X 109/L : 12
DAYS UNTIL NEUTS >0.5 X 109/L : 18
DAYS UNTIL PLATELETS >50 X 109/L : 24
























UNIQUE PATIENT NUMBER : 155
PATIENT NAME : S PANATTI
HOSPITAL NUMBER : EY2746
DATE OF BIRTH : 14.4.54
AGE IN YEARS : 30
SEX : M
DIAGNOSIS : HD
STAGE AT DIAGNOSIS : IIA
CLASSIFICATION : NS
DATE OF DIAGNOSIS : 9.12.81
TREATMENT PRE ABMT : BACOP/OPEC X 3
DXT
PREVIOUS MARROW INFILTRATION : NO
STATUS AT TIME OF HARVEST : RELAPSE
DATE OF HARVEST : 17.8.84
STATUS AT TIME OF ABMT : RR
DATE OF ABMT : 26.8.84
ABMT PROTOCOL USED : BEAM
NUCLEATED CELL COUNT X 108/KG : 3.3
DAYS UNTIL WBC >1.0 X 109/L : 11
DAYS UNTIL NEUTS >0.5 X 109/L : 15
DAYS UNTIL PLATELETS >50 X 109/L : 13
DAYS UNTIL PLATELETS >100 X 109/L : 24
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COMPLICATIONS DURING ABMT : NO MAJOR
COMPLICATIONS
POSITIVE MICROBIOLOGY ISOLATES : Candida; Faeces/
Coag -ve staph,
diphtheroids; H.S.
STATUS POST ABMT : CR
TREATMENT POST ABMT :
COMPLICATIONS POST ABMT : HERPES ZOSTER
DECEMBER 1985
DATE OF RELAPSE :
SITE OF RELAPSE :
DATE OF DEATH :
CAUSE OF DEATH
























PREVIOUS MARROW INFILTRATION : NO
STATUS AT TIME OF HARVEST : RELAPSE
DATE OF HARVEST : 30.8.84
STATUS AT TIME OF ABMT : NON RR
DATE OF ABMT : 10.9.84
ABMT PROTOCOL USED : BNLI
NUCLEATED CELL COUNT X 108/KG : 1.78
DAYS UNTIL WBC >1.0 X 109/L : 16
DAYS UNTIL NEUTS >0.5 X 109/L : 16
DAYS UNTIL PLATELETS >50 X 109/L : 38


















































STATUS AT TIME OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
ABMT PROTOCOL USED
NUCLEATED CELL COUNT X 108/KG
DAYS UNTIL WBC >1.0 X 1 09/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 1 09/L















































STATUS AT TIME OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
ABMT PROTOCOL USED
NUCLEATED CELL COUNT X 108/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 1 09/L






































































STATUS AT TIME OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
ABMT PROTOCOL USED
NUCLEATED CELL COUNT X 108/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 1 09/L





















































PREVIOUS MARROW INFILTRATION : NO
STATUS AT TIME OF HARVEST : RELAPSE
DATE OF HARVEST : 6.12.84
STATUS AT TIME OF ABMT : RR
DATE OF ABMT : 14.12.84
ABMT PROTOCOL USED : BEAM
NUCLEATED CELL COUNT X 108/KG : 1.34
DAYS UNTIL WBC >1.0 X 109/L : 31
DAYS UNTIL NEUTS >0.5 X 109/L : 31
DAYS UNTIL PLATELETS >50 X 109/L : 42






















































PREVIOUS MARROW INFILTRATION : NO
STATUS AT TIME OF HARVEST : RELAPSE
DATE OF HARVEST : AUGUST 84
STATUS AT TIME OF ABMT : RR
DATE OF ABMT : 18.12.84
ABMT PROTOCOL USED : BEAM
NUCLEATED CELL COUNT X 108/KG : 1.78
DAYS UNTIL WBC >1.0 X 1 09/L : 17
DAYS UNTIL NEUTS >0.5 X 109/L : 23
DAYS UNTIL PLATELETS >50 X 109/L : 31

































STATUS AT TIME OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
ABMT PROTOCOL USED
NUCLEATED CELL COUNT X 108/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L




































































STATUS AT TIME OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
ABMT PROTOCOL USED
NUCLEATED CELL COUNT X 108/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L





















































UNIQUE PATIENT NUMBER : 183
PATIENT NAME : J CAPON
HOSPITAL NUMBER : FH5335
DATE OF BIRTH : 7.5.46
AGE IN YEARS : 39
SEX : F
DIAGNOSIS : NHL
STAGE AT DIAGNOSIS : IV
CLASSIFICATION : HIGH GRADE
DATE OF DIAGNOSIS : JULY 84
TREATMENT PRE ABMT : CHOP X 6
DXT
PREVIOUS MARROW INFILTRATION : YES
STATUS AT TIME OF HARVEST : RELAPSE
DATE OF HARVEST : 26.4.85
STATUS AT TIME OF ABMT : NON RR
DATE OF ABMT : 7.5.85
ABMT PROTOCOL USED : BNLI
NUCLEATED CELL COUNT X 108/KG : NA
DAYS UNTIL WBC >1.0 X 109/L : 26
DAYS UNTIL NEUTS >0.5 X 109/L : 29
DAYS UNTIL PLATELETS >50 X 109/L : 28
DAYS UNTIL PLATELETS >100 X 109/L : 30
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COMPLICATIONS DURING ABMT


























UNIQUE PATIENT NUMBER : 185
PATIENT NAME : G MANSER
HOSPITAL NUMBER : FC7326
DATE OF BIRTH : 11.10.71
AGE IN YEARS : 1 3
SEX : M
DIAGNOSIS : HD
STAGE AT DIAGNOSIS : IVB
CLASSIFICATION : MC
DATE OF DIAGNOSIS : 4.2.84
TREATMENT PRE ABMT : BACOP/OPEC X 4
PREVIOUS MARROW INFILTRATION : NO
STATUS AT TIME OF HARVEST : RELAPSE
DATE OF HARVEST : 1.6.85
STATUS AT TIME OF ABMT : NON RR
DATE OF ABMT : 14.6.85
ABMT PROTOCOL USED : TBI & CYCLO
NUCLEATED CELL COUNT X 108/KG : 14.6/wt
DAYS UNTIL WBC >1.0 X 109/L : 13
DAYS UNTIL NEUTS >0.5 X 109/L : 13
DAYS UNTIL PLATELETS >50 X 109/L : 18






































STATUS AT TIME OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
ABMT PROTOCOL USED
NUCLEATED CELL COUNT X 108/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L
















































CURRENT STATUS ALIVE & WELL
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UNIQUE PATIENT NUMBER : 187
PATIENT NAME : A PAVLOU
HOSPITAL NUMBER : PP
DATE OF BIRTH : 23.7.35
AGE IN YEARS : 50
SEX : M
DIAGNOSIS : NHL
STAGE AT DIAGNOSIS : III
CLASSIFICATION : HIGH GRADE
DATE OF DIAGNOSIS : OCTOBER 83
TREATMENT PRE ABMT : ProMACE/MOPP
PREVIOUS MARROW INFILTRATION : NO
STATUS AT TIME OF HARVEST : RELAPSE
DATE OF HARVEST : 9.6.85
STATUS AT TIME OF ABMT : NON RR
DATE OF ABMT : 20.6.85
ABMT PROTOCOL USED : BEAM
NUCLEATED CELL COUNT X 108/KG : 2.73
DAYS UNTIL WBC >1.0 X 109/L : 12
DAYS UNTIL NEUTS >0.5 X 109/L : 21
DAYS UNTIL PLATELETS >50 X 109/L : 16




















: ALIVE & WELL
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UNIQUE PATIENT NUMBER : 1 88
PATIENT NAME : R MARSH
HOSPITAL NUMBER : 320623
DATE OF BIRTH : 27.10.55
AGE IN YEARS : 30
SEX : M
DIAGNOSIS : HD
STAGE AT DIAGNOSIS : IVB
CLASSIFICATION : NS
DATE OF DIAGNOSIS : JANUARY
TREATMENT PRE ABMT , : LOPP X 9
DXT
PREVIOUS MARROW INFILTRATION : NO
STATUS AT TIME OF HARVEST : RELAPSE
DATE OF HARVEST : 28.6.85
STATUS AT TIME OF ABMT : NON RR
DATE OF ABMT : 5.7.85
ABMT PROTOCOL USED : BEAM
NUCLEATED CELL COUNT X 108/KG : 1.48
DAYS UNTIL WBC >1.0 X 109/L : 22
DAYS UNTIL NEUTS >0.5 X 109/L : 24
DAYS UNTIL PLATELETS >50 X 109/L : 28














Coag -ve staph; Blood
/Herpes simplex;Mouth
/ ? Fungi x 3; Sputum
CR
NIL
CURRENT STATUS ALIVE & WELL
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UNIQUE PATIENT NUMBER : 191
PATIENT NAME : M DEBLANK
HOSPITAL NUMBER : 336160
DATE OF BIRTH : 16.3.55
AGE IN YEARS : 30
SEX : F
DIAGNOSIS : NHL
STAGE AT DIAGNOSIS : IV
CLASSIFICATION : HIGH GRADE
DATE OF DIAGNOSIS : NOVEMBER 84
TREATMENT PRE ABMT : CHOP X 6
DXT
PREVIOUS MARROW INFILTRATION : NO
STATUS AT TIME OF HARVEST : RELAPSE
DATE OF HARVEST : 11.7.85
STATUS AT TIME OF ABMT : NON RR
DATE OF ABMT : 20.7.85
ABMT PROTOCOL USED : BNLI
NUCLEATED CELL COUNT X 108/KG : 1.125
DAYS UNTIL WBC >1.0 X 109/L : 13
DAYS UNTIL NEUTS >0.5 X 109/L : 16
DAYS UNTIL PLATELETS >50 X 109/L : 16
DAYS UNTIL PLATELETS >100 X 109/L : 17
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COMPLICATIONS DURING ABMT : NO MAJOR
COMPLICATIONS





STATUS POST ABMT : CR
TREATMENT POST ABMT :
COMPLICATIONS POST ABMT :
DATE OF RELAPSE :
SITE OF RELAPSE :
DATE OF DEATH :
CAUSE OF DEATH :














STATUS AT TIME OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
ABMT PROTOCOL USED
NUCLEATED CELL COUNT X 108/KG
DAYS UNTIL WBC >1.0 X 1 09/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L


























COMPLICATIONS DURING ABMT : SEVERE MUCOSITIS
POSITIVE MICROBIOLOGY ISOLATES : Candida; Throat,
faeces/Coag -ve
staph; H.S.
STATUS POST ABMT : CR
TREATMENT POST ABMT :
COMPLICATIONS POST ABMT :
DATE OF RELAPSE :
SITE OF RELAPSE :
DATE OF DEATH :
CAUSE OF DEATH :















STATUS AT TIME OF HARVEST
DATE OF HARVEST
STATUS AT TIME OF ABMT
DATE OF ABMT
ABMT PROTOCOL USED
NUCLEATED CELL COUNT X 108/KG
DAYS UNTIL WBC >1.0 X 109/L
DAYS UNTIL NEUTS >0.5 X 109/L
DAYS UNTIL PLATELETS >50 X 109/L
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DOUBLE AUTOGRAFTING: A POTENTIAL CURATIVE REGIMEN FOR
ACUTE LEUKAEMIA?
C.C. Anderson, D.C. Linch & A.H. Goldstone, for the Blooms-
bury Transplant Team.
INTRODUCTION
The conditioning regime used for allogeneic bone marrow
transplantation in acute leukaemia has two functions:
firstly to serve as immunosuppressive therapy to prevent
rejection of the allogeneic marrow and secondly to eradicate
host disease. The conditioning regimen most commonly
used is TBI given as a single dose or in fractions to
a total dose of 9-12 Grays together with cyclophosphamide
60mg/kg on two consecutive days as pioneered by the Seattle
transplant unit, (Thomas et al, 1975).
Rejection of a marrow graft following this regimen
in patients allografted for acute leukaemia is rare.
Relapse however, still remains a problem. In patients
with acute myeloid leukaemia, (AML), treated by allografting
in first remission the incidence of relapse is reported
to be between 10 and 25%, (O'Reilly RJ, 1983 ; Deeg et
al, 1984). The majority of relapses occurring in the
first two years post graft, although relapse has been
reported even six years later, (Deeg et al, 1984). Fewer
patients with acute lymphoblastic leukaemia,(ALL), have
been allografted in first remission but there is the
suggestion that relapse is more frequent than in AML.
In patients with AML and ALL allografted after first
remission the relapse rate is higher, (Appelbaum et al,
1983 ; Deeg et al, 1984 ), with five year survival of less
than 27% in ALL with leukaemic relapse being the commonest
cause of death, (Thomas et al, 1983).
In the first 100 patients transplanted in Seattle
for acute leukaemia in relapse, a time at which the
leukaemic burden would be high, and the disease is more
likely to be resistant than early in first remission,
the majority of patients surviving the procedure relapsed.
Twelve patients, not only achieved a CR but remain
in remission many years later, (Thomas ED, 1983). This
approach is therefore capable of eradicating disease in
a small proportion of patients with relapse but there
is no way of determining which patients will be cured
and which will relapse.
Autologous bone marrow grafting has the advantage
that immune mediated graft rejection does not occur.
There are therefore two main problems to consider
when deciding on a suitable conditioning regimen for ABMT:
the eradication of disease in the patient as in the
allograft situation and the eradication of residual disease
in the marrow. The absence of a graft-versus-leukaemia,
(GVL), effect, (Weiden et al, 1981), in autografting may
&
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mean that an even stronger ablative regimen is required
than cyclophosphamide and TBI.
The same pre-graft conditioning as for allografts
has been used for autologous bone marrow transplantation,
(ABMT), (Burnett et al, 1984). Alternatively a combination
chemotherapy regimen has been used. The autologous marrow
has been used unpurged, (Gorin et al, 1985; Burnett et
al, 1984 ), or has been purged, 'in vitro", in an attempt
to remove the presumed residual disease, (Ritz & Schlossman,
1982 ; Laporte et al, 1984 ), although the need for purging
has not yet been proven.
There is as yet no convincing evidence of benefit
from, 'purging' the autologous marrow in any situation,
(Gorin et al, 1985 ), and for AML in particular .there is
no evidence of altered sensitivity of leukaemic cells
from normal progenitor cells when treated with cytotoxic
drugs, 'in vitro', (Douay et al, 1984), nor is there a
suitable monoclonal antibody available which can distinguish
between these cell types.
We have chosen a double autograft technique as a means
of addressing both leukaemic eradication in the host and
purging of the marrow.
Eradication "of residual leukaemia in the host: If
a single dose of massive chemo/radiotherapy may eradicate
disease in some but not all patients, then to repeat the
procedure should produce a greater tumour kill. TBI cannot
be repeated a second time and is therefore an unsuitable
modality for a double protocol.. We therefore decided
on a sequential combination chemotherapy protocol using
the same drug regimen for the first and second ABMT.
Eradication of residual leukaemia in the marrow:
We argued that a double protocol would effect a form of
'in vitro' purging. For example if the marrow at the
time of first harvest contained x tumour cells then post
harvest the cryopreserved marrow would contain only 2%
x assuming a harvest of 2% of the total marrow content
and no differential loss of disease and normal stem cells
during cryopreservation. The repopulated marrow would
contain only 2% of x if the regrowth of leukaemic and
normal cells was the same, so at the second harvest if
a further 2% of the marrow were harvested, then the second
marrow innoculum would contain only 0.04% of the original
leukaemic mass. However, the success of induction regimes
which render the patients marrow severely hypoplastic
suggests that normal haemopoietic tissue has a regenerative
advantage to the leukaemic population. This would make
the residual proportion of leukameic cells post double
ABMT considerably less than the hypothetical 0.04%
postulated above. This might fall below the critical
level at which the body's own defences might be able to




A total of 42 patients with acute leukaemia have been
223
treated; 41 adults and one child of six years old. The
median age was 35 years. There were 23 males and 18
females. Further details are given in Table I and II.
Twenty-four patients were treated in first remission,
16 with AML and 8 with ALL. The remaining 18 patients
w°re treated during relapse or in a later remission with
marrow harvested and stored either in first or subsequent
remissions. Eight of these patients had AML and ten had
ALL.
Treatment Protocol
The chemotherapy used for both ABMT I and II was the
same and is as follows: cyclophosphamide 1.5 G/m2/day,
days -5, -4 and -3, adriamycin 50 mg/m2 day -5, BCNU 3 00
mg/m2 day -5, cytosine arabinoside and thioguanine both
200 mg/m2 given in two divided dosed day -5 to -2 inclusive.
The autologous bone marrow was returned on day 0.
Figure 1 shows details of the treatment plan. The
first bone marrow harvest was performed, where possible,
following recovery from consolidation therapy in first
remission patients and as . soon as possible following
reinduction therapy in the 9 patients harvested and treated
in second remission.
Twenty-two of the twenty-four first remission patients
were treated within 12 months of their diagnosis with
a mean of 8 months, (range 3-23).
Nineteen patients have completed the second part.
All had their marrow reharvested as soon as possible after
full haematological recovery and proceeded directly to
the second treatment, except for one patient who was delayed
after harvesting because hospital facilities were
temporarily unavailable.
In every case marrow was judged clear of disease by
morphological examination of aspirates taken within the
five days preceeding the harvest.
The harvested marrow was processed and cryopreserved
in liquid nitrogen as previously described, (Linch et
al, 1982 ), and when thawed was reinfused into a central
line. The mean number of nucleated cells frozen was 1.89
x 1C)8 cells/kg.
All patients had Hickman central venous catheters
inserted prior to starting chemotherapy. All patients
receiving very high dose chemotherapy were nursed in single
rooms without filtered air precautions. Routine antifungal
prophylaxis with oral nystatin or amphotiracin was given.
Some . patients also received antibacterial prophylaxis
with cotrimoxazole, but this was abandoned in December,
1983 because of increasing bacterial resistance of
intestinal flora.
First remission ALL patients had both intrathecal
methotrexate and cranial irradiation as CNS prophylaxis
prior to ABMT.
Patients with AML received no maintenance therapy
post ABMT but patients with ALL were maintained on a regime
using methotrexate, mercaptopurine and cytosine arabinoside










(as soon as possible after full
haematological reconstitution)
HIGH DOSE CHEMOTHERAPY II
ABMT II
NO FURTHER TREATMENT MAINTENANCE CHEMOTHERAPY
A All patients
B 33 patients harvested in 1st remission
C 8 patients harvested in 2nd remission
D 9 patients harvested in 1st remission but not treated
E 5 patients treated in relapse
F 4 patients reinduced before treatment








and prednisolone for at least two years in view of the
evidence that remission is prolonged by continuing
maintenance chemotherapy in childhood ALL, (The MRC Trials,
1982), or until relapse, whichever was the sooner.
RESULTS
Response to therapy
First remission AML: 16 patients have so far been
treated. Eleven, (69%), continue in unmaintained remission
day 1705, 1508 , 802, 770, 607, 573 , 458 , 426, 368 , 317,
with no procedular deaths. Five have relapsed day 35,
68, 191, 229, 322.
First remission ALL: Three of eight patients, (37.5%),
remain in remission on maintenance chemotherapy day 816,
562, 292. Three patients, (37.5%), died of infection,
one during ABMT I, and two during ABMT II. One patient
with T-ALL had a CNS relapse before the second harvest
and has since died day 138. The longest survivor, to
date, had an extramedullary relapse day 983 and died in
relapse in spite of further chemotherapy day 1093.
Others: Four of five patients treated with this regime
as reinduction therapy following relapse acheived a complete
remission, (CR), the fifth patient died during aplasia
of a cerebral haemorrhage. Two patients, (both ALL),
went on to receive ABMT II. The other two patients, (both
AML), had delayed haematological recovery and did not
receive ABMT II. All have relapsed and died except for
one patient with ALL who received both ABMT I and II and
is still in second remission day 1239.
Eleven patients treated in second remission have died,
ten in relapse (day 126, 197 , 240, 245, 257, 263 , 352 ,
436, 515), one died of aspergillus pneumonia day 124 during
the aplasia induced by ABMT II. The remaining patient
with ALL continues in second remission, (day 507).
The one patient treated in third remission relapsed,
(day 144), and died.
Haematological recovery
Details of recovery are given in Table III.
Assays of GM-CFC on the harvested marrow were unhelpful
in predicting the speed of engraftment, (Anderson et al,
1985 ) .
Morbidity
One death from a cerebro-vascular accident day 12
post ABMT I before platelet recovery.
Four deaths were attributed clinically to rapidly
progressive pneumonias, although Aspergillus fumigatus
was the only organism isolated and this from only one
of them.
Non-fatal infections were the commonest complications,
with a pyrexia of >38 °C in forty patients, (95%), receiving
ABMT I, and in all patients during ABMT II.
Cytotoxic induced nausea and vomiting occurred in
all patients but was not usually severe.
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Two patients were thought to have cardiotox.icity:
one patient, (UPN 164), who developed pericarditis post
chemotherapy, and one other, (UPN B4) , who developed left
ventricular failure necessitating omission of the final
dose of cyclophosphamide.
One patient suffered a grand mal convulsion which
was never fully explained. Greater details of these compli¬
cations are to be published elsewhere, (Anderson et al,
1985 ) .
DISCUSSION
Eleven, (69%), of our patients with AML who were treated
with the ABMT protocol in first remission as intensive
consolidation therapy remain in unmaintained remission
with a median follow up of eighteen months, (range 11-
56 months), post ABMT. These results are as good as or
better than most reported results of conventional
chemotherapy protocols in adult patients, (Weinstein et
al, 1983).
The five relapses have occurred in patients who had
only ABMT I, none as yet occurring in the group who had
both ABMT I and II. Numbers are small and a longer follow
up period is required to draw any conclusions.
Maraninchi et al, 1984, have also advocated a double
protocol. Four of their five long term survivors had
ABMT I and II, (11+, 11+, 28 + , 29+), and of ten relapses
eight patients received only ABMT I.
The collective EBMT date, (Gorin et al, 1985), which
includes patients from both our own group and those reported
by Maraninchi et al, 1984, showed a trend in favour of
double autografting when compared to single autografts
when comparing disease free survival: 79% versus 48%
at 640 days, (p<0.1). Numbers are small and the differences
do not acheive statistical significance. If encouraging
results are maintaned it will not be possible to determine
if this is due to improved leukaemia eradication or 'in
vivo' purging. This will depend on the development of
sensitive assays for minimal residual disease.
Studies from our own institution, (Souhami et al,
1985), have attempted to assess the increase in tumour
kill in a solid tumour - small cell carcinoma of the lung
when treated with a double ABMT protocol. Tumour volumes
were measured by thoracic computed tomographic, (CT) ,
scan before and after each cycle of high dose
cyclophosphamide. The average decrease in tumour volume
was from 99.2 cc to 21 cc post ABMT I and reduced further
to only 14.1 cc post ABMT II. When compared to an earlier
study using ABMT I only, the double procedure did not
increase the response rate or prolong the survival. The
results were assumed to imply rapid emergence of drug
resistance after a single cycle of high dose chemotherapy.
In acute leukaemia we hope the malignant cells may be
different, or that a combination chemotherapy protocol
will result in a smaller chance of producing a drug
resistant clone.
The small number of patients with ALL treated in first
CR are inadequate to draw any conclusions in this disease.
Sixteen of our patients treated beyond first CR have
relapsed within 13 months of ABMT. Only eight of these
patients received ABMT I and II. Only two remain in CR,
one who was treated with ABMT I only, (day 507), and one
who received both ABMT I and II, (day 1239). It seems
likely this represents failure to eradicate host disease
as has been found following allografting, (Thomas et al,
1983 ) .
The relapse of five, (50%), of patients with AML treated
in first CR who did not have ABMT II whilst there are
no relapses in the six patients who had ABMT I and II
could mean that the second ABMT has resulted in a greater
reduction of host disease. It could also mean that delay
in haematological recovery after ABMT I which was the
main reason for failing to preceed to ABMT II may be a
characteristic of more aggressive or resistant disease
and such patients may be a poor prognosis group,
irrespective of whether they receive ABMT II or not.
We are encouraged by our data in first remission AML
to hope there may be an 'in vivo' purging effect and to
employ ABMT II whenever possible.
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TABLE III
KAEMATOLOGICAL RECOVERY IN DAYS. (Day 0=ABMT).
ABMT I ONLY - ALL PATIENTS (n=42)
RANGE
Total WBC >1000 x 10/1 19 12 - 40
Neutrophils >500 x 10/1 23 14 - 52
Platelets >50 x 10/1 36 13 -228
Nucleated cells x 10/kg 1.9 0.6 - 3.1
1 patient died before recovery - his results are therefore not
included.
1 patient died before platelet recovery - his WBC results only
are included.
COMPARISON OF ABMT I VS II (n=19)
ABMT I RANGE ABMT II RANGE
Total WBC >1000 x' 10/1 17 11 -28 23 13 -41
Neutrophils >500 x 10/1 21 12 -39 27 14 -45
Platelets >50 x 10/1 24 13 -39 38 00IT)1oCN
Nucleated cells x 10/kg 1.8 0 .6- 3.2 1.9 Oloi—i
GM-CFC x 10/kg 5.8 0 .7-13.6 5.3 0.9-15.0
3 patients died before recovery in ABMT II - their results are
not included.
Clin. lab. Haemat. 1986, 8, 1-8
A rise in the percentage of large unstained
cells in the peripheral blood determined by
the Hemalog D90 automated differential
counter is a feature of impending myeloid
engraftment following bone marrow
transplantation
P.J. MARTIN, FIMLS, C.C. ANDERSON, MRCP,
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Summary The early phase of bone marrow regeneration has been monitored by
automated differential counts on the peripheral blood using a Hemalog D90,
following 107 transplant procedures. An elevated percentage of large unstained
cells (LUCs) was detected in over 98% of cases and in 72% of cases the rise in
percentage LUCs preceded the rise of the total leucocyte count into the
detectable range on a Coulter counter (> 0.3 x 109/1) by an average of 4 days.
These LUCs are shown to be CD8 + T lymphocytes. The ability to detect the
earliest signs of regeneration is particularly useful when regeneration is delayed
and repeat marrow infusion is considered.
Keywords: automated differential counts, large unstained cells, bone marrow
transplantation
Previous investigations of marrow regeneration following bone marrow
transplantation have focused on the time of neutrophil and platelet recovery to a
fixed value, (Goldstone et al. 1983) or on the lymphocyte subpopulation
imbalances that arise (De Bruin et al. 1981, Bacigalupo et al. 1981, Linch et al.
1983, Ansley & Orstein 1970). In this report the very earliest phases of
regeneration detected in the peripheral blood have been studied. Automated cell
counters such as the Coulter S and the Hemalog D90 only give a reliable white
cell count above 0.3 x 109/1 but the Hemalog D90 will produce a very accurate
and reproducible differential count at white cell counts below this value (Ansley
& Ornstein 1970). The automated Hemalog D90 differential count was therefore
Correspondence: Dr A.H. Goldstone, Consultant Haematologist, University College Hospital,
University Street, London, Wl, UK.
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determined serially in a large number of autologous and allogeneic bone marrow




Mononuclear cells were prepared from heparinized peripheral blood by density
separation on ficoll hypaque (SG = 1.077).
Cell morphology
This was assessed on standard blood films and cytospin preparations of
mononuclear cells using May Grunwald Giemsa stain.
Immunological phenotyping
Mononuclear cell aliquots were stained with mouse monoclonal antibodies and
fluorescent conjugated goat antimouse immunoglobulin (Nordisc Ltd.) as
previously described (Linch et al. 1982). Stained cells were analysed on a
fluorescent activated cell sorter (FACS IV). The leucocyte phenotype was also
assessed on air dried films or cytospin preparations using the alkaline
phosphatase—anti-alkaline phosphatase technique (Cordell et al. 1984).
Adequate controls were always used to exclude endogenous alkaline phosphatase
activity and non-specific binding of antibody. Alkaline phosphatase cyto¬
chemistry was finally performed with naphthol AS-B1 phosphoric acid as
substrate (pH 9.2), fast red TR as the capture agent and haematoxylin as the
counter stain.
Monoclonal antibodies
UCHT1 was used as an anti-CD3 reagent and was kindly provided by PCL
Beverley. Anti-CD4 (Leu 3a) and anti-CD8 (Leu 2a) antibodies were obtained
from Becton Dickinson. UCHM1 stains 80% of normal monocytes and 'pro¬
monocytes' as determined by analysis of monocytic leukaemias (Linch et al.
1984), and was provided by PCL Beverley. Leu M3 (Becton Dickinson) was used
as a further monocyte specific reagent. DA2 was used to detect non-polymorphic
determinants of HLADR (Brodsky et al. 1979). Monoclonal anti alkaline
phosphatase was provided by PCL Beverley.
Patients
Eighty patients received 107 transplant procedures with survival to a stage at
which evidence of haemopoietic regeneration was detectable. Of these patients 76
LUCs in the blood following marrow transplantation 3
were adults and 48 were male. Eleven patients received allogeneic marrow from
an HLA-matched sibling for acute leukaemia (9 cases) aplastic anaemia (1 case)
and congenital mucopolysacharridosis (1 case). Patients with acute leukaemia
were conditioned with cyclophosphamide and single fraction total body
irradiation (1000 cGys) and the patients with aplastic anaemia and mucopoly¬
sacharridosis with cyclophosphamide and cyclophosphamide plus busulphan
respectively. Sixty-nine patients received high dose chemotherapy and cryopre-
served autologous bone marrow rescue as treatment for acute leukaemia (25
patients) small cell carcinoma of the lung (32 patients) carcinoma of the ovary (8
cases) and lymphoma (4 cases). Twenty-seven patients received two high dose
chemotherapy and autologous bone marrow transplant procedures. The details of
the different protocols have been published elsewhere (Souhami et al. 1983,
Goldstone et al. 1984a, b).
Assessment of haemopoietic recovery
Blood samples from all patients were evaluated for haematological recovery by
daily cell counts on a Coulter Counter S Plus. Automated cytochemistry was also
performed on a Hemalog D90. Patients included early in the study had fewer
Hemalog D counts, but efforts were made to obtain daily counts in the later
patients during the early regenerative period. The principles of the Hemalog D90
automated cytochemistry system have been previously described (Ansley &
Orstein 1970, Mansberg et al. 1974). White cells are differentiated by their light
scattering and light absorption characteristics against preset electronic thresholds
on three separate channels (peroxidase, non-specific esterase and Astra Blue). The
non-specific esterase and the Astra Blue stain count monocytes and basophils
respectively. The peroxidase channel is more complex, not only counting
peroxidase positive cells, neutrophils, eosinophils, monocytes and basophils, but
also the non-staining cells of the lymphocyte and primitive myeloid lineage. The
light scatter patterns recognize cell size and the specific staining reaction of cells is
interpreted by light absorption.
One component of this automated differential white cell count is an electronic
threshold area into which large cells having no cytochemical staining are counted
(LUCs). This group of large unstained cells is usually considered to be part of the
lymphocyte population if it falls within the normal range (0.8-3.1%). However,
when this cell component is elevated immature cell types and atypical lymphoid
cells must be considered and a May-Grunwald Giemsa stained blood film
examined.
The high level of precision of the differential white cell count in leucopenic
patients using this technique has previously been reported (Ross & Bardwell
1982). In leucopenic patients with an absolute neutrophil count of 0.5 x 109/1 the
coefficient of variation is 8% compared to a 20% coefficient of variation using
manual methods of differential white cell count.
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Results
Detection of LUCs following transplantation
An elevated percentage LUC count was detected following 105 transplant
procedures. In only two cases was a rise in the percentage of LUCs not detected.
Serial counts were available in 78 cases and in these cases the mean peak LUC
count was 19.3% ±(SE) with a range of 3.2-56.8%.
The relationship of the rise in total white cell count to the rise in percentage of
LUCs is shown for all 105 cases in which a rise occurred (Figure 1). In 72% of
the 78 cases in which serial data was available, the rise in LUCs preceded the rise
in WBC by an average of 4 days. In 23 further cases in which the serial data is
incomplete but evaluable in this respect, 20 also showed a rise in the percentage
of LUCs predating the rise in WBC. In 17% the rise in LUCs and WBC were
simultaneous and only in 8% of cases did the rise in WBC predate the rise in
LUC percentage. The relationship between the rise in percentage of LUCs and
rise in total WBC was similar for both allografts and autografts (Table 1). The
autologous transplants were performed in cases of acute leukaemia, resistant
lymphoma and solid tumours (small cell cancer of the lung and ovarian
carcinoma). Regeneration was more delayed in the cases autografted for acute
leukaemia; the time to reach a leukocyte count >0.5xl09/l was 24.3 days
compared to 11.4 days in the remainder. Patients with solid tumours were
autografted as first line treatment and received the lowest levels of ablative
chemotherapy; regeneration was invariably rapid in this group. Nonetheless,
despite these differences the rise in percentage of LUCs still predated the rise in
WBC by a similar time, being 4.0, days in acute leukaemia, 3.0, days in patients
with lymphoma and 4.1 days in patients with solid tumours. This time interval in
the allografts was an average of 3.9 days.
g Figure 1. Appearance of total
^ leukocytes and LUCs in the
o blood following allogeneic and
autologous bone marrow
transplantation. #, Total
leucocytes; □, % LUCs.
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Allogeneic 11 8 0 2 1
Autologous 67 48 13 5 1
Totals 78 56 13 7 2
Two patients showed regeneration of leucocytes without a rise in percentage
of LUCs. Both of these patients had ALL and suffered from opportunistic lung
infections. The significance of this is not clear.
In only two cases in which a rise in LUC was noted was there failure of the
WBC to rise. In one case this was due to death from an intracerebral
haemorrhage on day 12 at a time when the percentage of LUCs was rising but the
WBC had not risen above 0.3 x 109/1. In the other case the percentage of LUCs
rose to a peak of 22% on day 19 and then fell back to the normal range by 28
days. This patient developed an Aspergillus pneumonia during the regeneration
period and died on day 33 without a leucocyte count ever rising above
0.3 x 109/1.
Six patients received repeated granulocyte infusions for uncontrolled sepsis
early after transplantation before evidence of regeneration. In no instance was
there a rise in the percentage of LUCs detected.
The nature of LUCs
Careful inspection of blood films with very high percentage LUC counts, during
the early regeneration period, reveals that these cells are large mononuclear cells,
often with indented nuclei showing some chromatin condensation but no
nucleoli. They have moderate quantities of faintly basophilic cytoplasm which
contain no obvious granules. These cells most commonly resemble monocytes,
but LUCs are by definition non-specific esterase (NSE) and peroxidase negative.
This NSE negativity has been confirmed by manual techniques. Furthermore,
adherence for 1 h to plastic of ficoll hypaque separated mononuclear cells did not
reduce the percentage of LUCs as determined by re-analysis on the Haemalog
D90 in two cases tested.
In four further cases, adherent cell depleted mononuclear cells containing
more than 10% LUC were phenotyped with a range of monoclonal antibodies.
The predominant cell type present was a CD8 + T cell (Mean CD3%, 47%; mean
CD8%, 42%). B cells as detected by anti-Bl represented only 3.5% of cells. There
were no monocytic cells detected by staining with UCHM1 or Leu M3.
In one case over 20% of all leucocytes before separation were LUCs.
Mononuclear cells from this patient were analysed on a FACS IV and 34% of
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Control anti CD3
anti CD8 anti HLA-DR
Light Scatter (Size)
Figure 2. Size and fluorescence profiles of peripheral blood mononuclear cells in the early stages of
engraftment.
cells were found to be large cells distinct in size from a typical lymphocyte
(Figure 2, control). Analysis of the fluorescence profiles revealed that virtually all
the large cells were CD3+ CD8 + T cells (Figure 2, anti CD3 and anti CD8).
Approximately half the large cells expressed HLA-DR antigens (Figure 2, anti
HLA-DR). This CD3+ CD8+ phenotype of the large mononuclear cells in the
early regenerative period was confirmed in five further cases by immuno-
histological staining of blood smears.
Discussion
A rise in the percentage of LUCs counted on the Haemalog D is indicative of
successful engraftment following bone marrow transplantation. In 72% of cases
this rise can be detected before the rise in total leucocyte count (> 0.3 x 109/1)
can be reliably measured on the Coulter counter. In these cases the rise in
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percentage of LUCs is detected an average of 4 days before the leucocyte rise. In
only one case surviving long enough for evaluation was a rise in the percentage of
LUCs not followed by subsequent engraftment. This patient had developed a
fungal pneumonia and it is likely that this caused toxic suppression of the graft
after early engraftment had already commenced. Serial marrow biopsies were not
performed and firm support for this hypothesis that the percentage rise in LUC
predicted impeding myeloid engraftment is lacking. This information is
frequently of value to the clinician, particularly when engraftment is slow, the
patient is sick and re-infusion of further marrow is being considered. This applies
to allografts and autografts in which only half the harvested marrow was
reinfused (lymphoma protocol in this study). It is in this context worthy of note
that granulocyte transfusions did not cause a rise in the percentage of LUCs
which might falsely have been interpreted as evidence of engraftment. The
kinetics of early engraftment were similar in autografts and allografts regardless
of the underlying disease, although the time to reach 0.5 x 109/1 neutrophils in
the peripheral blood was delayed in the patients with acute leukaemia receiving
autografts.
Regeneration was generally rapid in the patients treated for small cell
carcinoma of the lung and it appears that the marrow reinfusion did not lessen
the period of aplasia. It is probable that regeneration came from stem cells
surviving chemotherapy rather than from the infused autologous marrow and
that the initial rise in the percentage of LUCs is a feature of recovery from severe
myelosuppression rather than a feature of transplantation per se. In support of
this view, we have also noted an initial rise in the percentage of LUCs in the
regenerative phase of patients receiving heavy leukaemia induction therapy
without marrow support.
The LUCs, although of monocytoid appearance, are shown to be T
lymphocytes of the CD8 + subset. We have previously shown that CD8 +
lymphocytes predominate in the peripheral blood after both autologous and
allogeneic marrow transplants (Linch et al. 1983) and it is now apparent that in
the majority of cases this type of lymphocyte is among the first to appear in the
blood. It is possible that this initial T cell expansion may facilitate myeloid
engraftment. There is some evidence that extensive T cell depletion of donor
marrow for the prevention of graft versus host disease may lead to delayed
engraftment and even graft failure in some cases (Waldmann et al. 1984). It will
be of considerable interest to study the kinetics of early engraftment using the
Hemalog D after such T cell depletion procedures.
Note added in proof. The possibility that these CD8 + cells are NU cells remains to be explored.
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Summary. 24 adult patients with acute myeloid leukaemia (AML) were treated
with intensive chemotherapy followed by autologous marrow rescue. The
procedure was repeated twice in eight patients. 11 of 1 6 patients treated in first
remission continue in first unmaintained remission (9-54 months, median 17
months). Eight patients treated at relapse or second remission have relapsed
again and died within 14 months of their first autologous bone marrow
transplant (ABMT). This form of intensification therapy would appear valuable
for adult AML patients in first remission.
The prognosis for adult patients with acutemyeloid leukaemia in first remission remains poor
on conventional chemotherapy protocols (Lister & Rohatiner, 1982) and once relapse has
occurred few patients have extended survival. Allografting is a feasible proposition for only a
small proportion of patients (i.e. those of young age with HLA-matched donor). Autologous
bone marrow transplantation (ABMT) is in contrast available to all patients in remission less
than 55 years of age. The mortality from such an approach may be no greater than recent
intensive consolidation/late intensification regimes and morbidity may be less due to the
shorter treatment period (Weinstein et al, 1983). A potential complication of ABMT in
leukaemia is ofminimal residual leukaemia remaining in the harvested autologous marrow.
In this study we have attempted to reduce residual leukaemia and prolong remission by a
double grafting procedure using two sequential courses of high dose chemotherapy with
autologous marrow rescue.
PATIENTS AND METHODS
Patient characteristics. A total of 24 adult patients with AML have been treated; median
age 40 years; 13 males, 11 females. 16 patients had AML treated in first remission, eight
Correspondence: Dr A. H. Goldstone, Department of Haematology. University College Hospital. Gower
Street, London, W.C.I.
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patients were treated during relapse or second remission with marrow harvested and stored
in either first or second remission. Further details are given in Table I.
Treatment protocol (see Fig 1). Patients were referred from several centres and although
initial therapy was not standardized induction had been achieved with regimes containing a
Table I. Patient characteristics
Diag. Cr> Diag. > Status DFS
Age FAB No. of >CR ABMT ABMT post post Total Current
UPN Sex (yr) class. grafts (mth) (mth) (mth) ABMT ABMT surv. status
Patients treated with ABMT during first remission
19 M 25 Ml 2 2 2 4 CR 54 + 58 + A & W
30 M 38 M3 1 1 7 8 CR 48 + 56 + A & W
103 F 43 M4 2 2 5 7 CR 24 + 31 + A & W
108 F 39 Ml 2 2 7 9 CR 24 + 33 + A & W
128 F 32 M2 1 1 5 6 CR 18 + 24 + A & W
131 F 45 M4 1 3 5 8 CR 17+ 25 + A & W
132 M 47 Ml 1 2 4 6 CR 11 23 + Relapse
B3 M 42 M4 1 3 1 4 CR 2 7 Dead
B4 F 55 M2 1 3 10 13 CR 6 21 Dead
143 M 49 Ml 2 1 3 4 CR 13 + 17 + A&W
147 M 35 M5 2 2 4 6 CR 12 + 18 + A & W
148 M 26 Ml 2 1 6 7 CR 12 + 19 + A&W
156 F 19 M2 1 3 9 12 CR 11 + 23 + A&W
161 M 36 Ml 1 2 7 9 CR 9 + 18 + A&W
163 F 36 M4 1 4 2 6 CR 7 14 + Relapse
174 F 40 M2 1 3 4 7 Rel.** 0 13 + Relapse
Patients treated with ABMT as reinduction therapy or in second remission
41*/t F 57 M2 1 2 20 22 CR 7 32 Dead
55 F 31 Ml 1 2 5 7 CR 2 15 Dead
92*/t M 49 Ml 1 3 22 25 NE, died 25 Dead
Day 12
98 M 44 Ml 2 6 4 10 CR 8 19 Dead
1007t M 51 M5 1 2 6 8 CR 3 11 Dead
122 F 34 M5 1 1 6 7 CR 2 14 Dead
125* M 21 Ml 2 2 35 37 CR 5 43 Dead
129 M 51 M6 1 1 35 36 CR 13 50 Dead
UPN: Unique Patient Number. All patients grafted in the Bloomsbury Transplant Unit have
been given consecutive numbers dependent only on the date ofABMT. Where the UPN has been
prefixed with a 'B' the patients were grafted at the Queen Elizabeth Hospital, Birmingham. FAB
class.: French, American. British classification. CR: Complete remission. DFS: Disease free
survival. + indicates continuing survival.
* Patients who were harvested in first remission.
t Patients who were treated in first relapse.
** Although performed in apparent remission this patient regenerated with disease.
BM Transplantation in AMI 531
central core of daunorubicin, cytosine arabinoside and thioguanine and when these agents
had failed other therapy includingM-AMSA, VP16 and adriamycin had been introduced. The
first bone marrow harvest was performed as soon as possible after consolidation therapy in
first remission patients (range 1-9 months) and as soon as possible following reinduction
therapy in the four patients harvested and treated in second remission (range 2 d to 4
months). The four patients who were harvested at some stage during first remission and then
treated during relapse or second remission had their marrow stored for a median of 223 d
(range 201-730 d). The 16 first remission patients had theirmarrow stored for a mean of 23
d (median 10 d, range 5-107 d) the five second remission patients for a mean of 1 5 d (range
7-24 d).
All first remission patients were treated with AMBTI within 13 months of their diagnosis
(mean 7 months, range 4-13 months) and within 9 months of achieving CR (mean 4
months, range 1-9 months).
In every case, marrow was judged clear of disease by morphological examination of
aspirates taken within 5 d of the harvest.
The marrow was harvested, processed and cryopreserved in liquid nitrogen as previously
described (Linch et al, 1982). The marrow was thawed rapidly and reinfused into a Hickman







REINDUCTION HIGH DOSE CHEMOTHERAPY
ABMT I
HARVEST II
(as soon as possible after full
haematological reconstitution)
HIGH DOSE CHEMOTHERAPY II
ABMT II
A All patients
B 20 patients harvested in 1st remission
C 4 patients harvested in 2nd remission
D 4 patients harvested in 1st remission but not treated
E 3 patients treated in relapse
F 1 patient reinduced before treatment
G 8 patients who had part II
Fig 1. Treatment plan.
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High dose chemotherapy regime. The ablative chemotherapy used for both ABMT I and II
was the same and is as follows: cyclophosphamide 1-5 g/m2/d, days —5, —4, —3,
adriamycin 50 mg/m2 day —5, BCNU 300 mg/m2 day —5, cytosine arabinoside and
thioguanine both 200 mg/m2/d given in two equal doses day —5 to —2 inclusive. The
autologous bone marrow was returned on day 0. ABMT II was attempted as soon as full
regeneration had occurred from ABMT I but was performed in only six first remission patients
and two others grafted at a later stage. The reasons for not performing ABMT II are shown in
Table II.
All patients receiving very high dose chemotherapy were nursed in ordinary single rooms
without filtered air precautions. Routine antifungal prophylaxis with oral nystatin or
amphotericin was given. All had Hickman central catheters inserted prior to starting
chemotherapy.
Some patients also received antibacterial prophylaxis with cotrimoxazole, but this was
abandoned in December 1983 because of increasing resistance of bacteria on in vitro tests of
stool cultures and inadequate proof of benefit (Henry et al. 1984).
Response to therapy
First remission AML. 16 patients have so far been treated. 11/16 continue in
unmaintained remission 54, 48, 24, 24, 18, 17, 13, 12, 12, 11 and 9 months post ABMT,
with no procedural deaths. 5/16 have relapsed at 1, 2, 6, 7 and 11 months post ABMT (see
Fig 2).
Others. Two of three patients treated with this regime as reinduction therapy following
relapse achieved a complete remission (CR), neither went on to receive part II because of
delayed haematological recovery. Both have relapsed and died (at 4 and 10 months). One
patient died during aplasia of a cerebral haemorrhage on day 12.
RESULTS
Table II. Reasons for not proceeding to ABMT II










* One patient was not reconsidered because of
very slow physical recovery after part I. One patient
has been delayed because of the finding of a reduced
left ventricular ejection fraction on MUGA scan.
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Fig 2. Disease free survival, first remission AML ( ) versus others ( ) post ABMT.
The five patients treated in second remission have all relapsed and died (6, 7, 8, 9 and 14
months).
Haematological recovery
The mean dose of nucleated cells was 1-85 x 108/kg (ABMT I and II included); range 0-6-
3-1 x 107kg.
Regeneration time after all ABMTs compared to contemporary patients allografted in our
institution is shown in Table III.
Haematological recovery was delayed in the second ABMT (see Table IV) even though the
mean dose of nucleated cells infused for each procedure was comparable.
Morbidity
Infective complications. There were 10 episodes of gram — ve septicaemia; four Pseudomo-
nas aeruginosa, four Escherichia coli, one Klebsiella aerogenes and one Flavobacterium species.
Seven patients had gram +ve organisms isolated from the blood, four of which were of
doubtful significance.
14/24 had Candida species isolated from one or more sites. 21/24 patients with Hickman
lines in situ had coagulase — ve staphylococci isolated from the entry site, 11/24 had
diphtheroids isolated and only 3/24 had a Staphylococcus aureus isolated. However, only one
patient was thought to have a septicaemia originating from the Hickman line (caused by a
coagulase — ve staphylococcus).
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Table III. Comparison of haematological recovery following
ABMT I with contemporary allograft patients
Recovery in days following:
Autograft
Allograft A B
(n=10) ("= 21) (n = 24)
Total WBC > 1000 x 109/1 15 21 21
Neutrophils >500xl09/l 16 25 26
Platelets >50x 109/1 19 40 44
Day 0 =Day of AMBT. A = A11 patients autografted during
remission. B = A11 patients whether autografted during remis¬
sion or at relapse. Comparison of the difference between the
means ofeach sample (for a small sample) showed no statistical
difference.
Table IV. Comparison of haematological recovery in patients who
received both ABMT I and II
Recovery in days following:
ABMT I ABMT II
TotalWBC >1000 x 109/l 18 26 P<0-05
Neutrophils > 500 x 109/1 21 30 P>0 05, <0-1 NS
Platelets > 50 x 109/1 27 42 PcO-01
n = 8. Statistics are by Student t test for paired samples.
Non-infective complications. One early death was from an intra-cerebral haemorrhage on
day 12, before regeneration had occurred.
One patient with no past history of epilepsy had a grand mal convulsion for which there
was no obvious explanation, on day 98 (day 24 post ABMT II) when the platelet count was
36 x 109/1, unsupported, and the total WBC and neutrophil count were 2-6 and 1 • 1 x 109/1
respectively. When the anti-convulsants were withdrawn 1 month later he suffered a further
fit and has had to remain on medication.
All patients suffered from some degree of nausea and vomiting. The oldest patient in the
series (57 years) failed to recover from this and at the time of relapse 7 months later had lost
22 kg.
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DISCUSSION
The first prerequisite for long survival in AML is the achievement of remission. Once this has
been attained, treatment must be directed to maintaining this remission, although the
optimal treatment modality to achieve this has not been defined. Conventional chemo¬
therapy often given for extended periods of time only results in long-term survival rates of
approximately 25% (Lister & Rohatiner, 1982). The option of an allogeneic graft is restricted
to those young patients with a suitable HLA-matched donor, and the problems of GVHD,
interstitial pneumonitis and immunosuppression cause considerable morbidity and mor¬
tality. The advent of T-cell depletion of donor marrow (Reisner et al, 1983; Prentice et al,
1982) may significantly reduce some of these difficulties, but there is little evidence as yet that
it will enable allogeneic transplantation to be extended to the use of mis-matched family
donors.
ABMT as rescue from high dose chemotherapy merits serious consideration as intensive
consolidation therapy in first remission of adult patients with AML. The attractions of this
approach are evident. Every patient has a donor; the immediate morbidity and mortality is
very low compared to allogeneic transplantation and patients aged up to 57 years (UPN 41)
have received this treatment. There is no GVHD and in our experience no interstitial
pneumonitis.
The main disadvantage of using ABMT in leukaemia is the possibility that the graft is
contaminated with leukaemia. Attempts are being made to 'purge' this residual leukaemia by
drugs such as cyclophosphamide derivatives (Kaizer et al, 1981; Laporte et al, 1984)
although the scientific basis for this is questionable. Furthermore, there is no proof that any
sort of purging is required in this situation (Gorin et al, 1985). None the less, the basic idea
behind our double autograft procedure is to both increase the cytoreductive effect and to
effect an 'in vivo purging'. This is based on the assumption that following marrow ablation
normal cells regenerate more quickly than leukaemic cells and shortly after the first ABMT
the ratio of normal to malignant cells will be greatest. Many patients cannot, however,
tolerate two autografts.
This autograft series ofABMT in first remission differs from that ofBurnett et al (1984), in
that ablative chemotherapy rather than irradiation was used in an attempt to reduce
morbidity and to allow two grafts to be carried out. There is no proven advantage yet to
chemotherapy or TBI in this situation (Gorin etal, 1985). 11/16 (68-75%) ofpatients treated
as consolidation therapy in first remission remain disease free with a median follow up of
more than 16 months post ABMT (range 6-54 months). This is a small series of patients but
these results are clearly encouraging. To date, all five relapses in first remission patients have
occurred in patients who have received only one autograft, with a median disease free
survival of 17 months, which is as good as other treatment regimens. None of the six patients
who received both ABMT I and II have relapsed. This difference is not yet statistically
significant but may mean that the second ABMT has resulted in a greater reduction of host
disease. It could also mean that delay in haematological recovery after ABMT I which was the
main reason for failing to proceed to ABMT II may be a characteristic ofmore aggressive or
resistant disease and such patients may be a poor prognosis group, irrespective of whether
they receive ABMT II or not.
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Massive chemotherapy with ABMT rescue is also effective in inducing a CR in relapsed
patients, but all eight of our relapsed and second remission patients have relapsed again
within 13 months (2, 2, 3, 5, 7, 8 and 13 months) except for one patient who died on day 12
of an intra-cerebral haemorrhage. It is likely that this represents failure to eradicate disease in
the patient rather than contamination of the cryopreservedmarrow, although proof of this is
still lacking.
The major practical difficulty of our double ABMT approach to treatment of patients with
AML in first remission is the prolonged cytopenia which may follow particularly thrombocy¬
topenia which has been the major cause of failure to proceed to ABMT II (see Table II),
although no patient has required platelet support after discharge except for operative
intervention. Autoantibodies have been identified in some patients following both autografts
and allografts (Minchinton et al, 1984). We have identified a granulocyte autoantibody in
one of our patients (UPN 128) who took 52 d to achieve a neutrophil count of 500 x 109/1;
however, she was too thrombocytopenic to test for platelet autoantibodies. She achieved a
platelet count ofmore than 100 x 109/l, day 494. Prolonged thrombocytopenia has also been
reported post allograft (First et al, 1985), although the more prolonged and severe
thrombocytopenia appears to be associated with the more severe grades of acute and chronic
GVHD. The difference in incidence post allograft and autograft may also reflect previous
chemotherapy damage to the infused autologous marrow.
In this series there has been no ABMT procedural deaths in first remission patients and
this is of vital importance in the overall context of this therapy. However, most patients
become pyrexial and septicaemia was documented in 41% of ABMT procedures.
The results ofABMT in first remission AML are encouraging andmerit formal comparison
with conventional therapy and allogeneic grafting in a large series of patients. In second
remission results are disappointing and offer no advantage over conventional therapy.
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